Development and application of monoclonal antibodies to Chikungunya virus proteins by Goh, Lucas Yuan Hao
  
 
 
Development and Application of Monoclonal Antibodies to Chikungunya 
Virus Proteins  
Lucas Yuan Hao Goh 
Bachelor of Biotechnology (Class I Honours) 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2015 
School of Chemistry and Molecular Biosciences 
 
 
 
 
2 
 
ABSTRACT 
Chikungunya virus (CHIKV) is a mosquito-borne pathogen that causes arthritic disease in 
humans and is considered a serious health threat in regions where competent mosquito vectors 
are prevalent. The recent CHIKV epidemic (2004-2014) has resulted in an estimated 1.4-6.5 
million cases, involving more than 40 countries. There are no commercially licensed human 
vaccines available against infection with this re-emerging alphavirus. Treatment of CHIKV 
rheumatic disease usually involves the use of analgesics and/or non-steroidal anti-
inflammatory drugs, with relief often inadequate. Furthermore, the number of monoclonal 
antibodies (mAbs) specific for CHIKV is limited. 
This thesis describes the generation and characterisation of a suite of mAbs that are specific to 
the E2 or capsid protein (CP) of CHIKV. These mAbs were shown to be reactive in a range of 
assays including ELISA, Western blot, immunofluorescence and immunohistochemistry. 
Eleven CP-specific mAbs were capable of recognising isolates that represent the major 
genotypes of CHIKV, as well as several other alphaviruses. In contrast, five mAbs specific for 
the E2 glycoprotein were able to distinguish CHIKV from all other alphaviruses tested. Two 
of these E2-specific mAbs have the ability to provide complete protection against arthritis in a 
CHIKV mouse model when administered prior to infection. The anti-E2 mAbs have also been 
used successfully in a sensitive epitope-blocking ELISA to detect anti-CHIKV antibodies in 
clinical samples. Moreover, we have identified CHIKV in a serum sample from a patient using 
an antigen-capture ELISA. 
The recent re-emergence of CHIKV and its potential threat to human health has called for a 
better understanding of the virus for improved treatment, prevention and control measures. To 
do so, we have mapped the binding sites of the anti-CP mAbs with the help of N- and C-
terminally truncated versions of the CHIKV CP. Two putative binding regions, residues 1 to 
35 and 105-210 of CP, were identified. Competitive binding studies also revealed that five of 
the CP-specific mAbs recognised a series of overlapping epitopes that are likely to be the 
nuclear export signal of CHIKV CP. Furthermore, we have confirmed the presence of a smaller, 
truncated product of CP that may have structural and/or functional significance during viral 
replication. Evidence was also provided to show that the C-terminus of CP is required for 
antibody binding. 
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Several ELISA-based diagnostic tests have been developed for the detection anti-CHIKV 
antibodies. However, international standardization and validation of these assay are currently 
limited. The use of human sera collected from infected or uninfected individuals is required for 
the validation of diagnostic assays, as well as to determine cut-off values. Numerous drawbacks 
associated with the routine usage of pooled reference sera from CHIKV-infected patients 
include obtaining sufficient quantities to meet demands, stringent safety procedures and ethical 
concerns to be taken into account, and the requirement of standardization for each batch of 
control material. Therefore, a recombinant, chimeric version of a selected anti-CP mAb was 
created as an alternative positive control in diagnostic kits. The chimeric 5.2H7 mAb was 
assessed in ELISA and Western blot, and was found to have specificity and sensitivity levels 
comparable to that of the original mAb. In addition, we have derived a novel method to 
specifically amplify the variable chain sequences of antibody genes that could be applied 
towards the generation of any other chimeric mAbs, while avoiding the notoriously 
troublesome aberrant heavy or light chain genes. 
Given the current shortage of widely-available reagents for CHIKV, these specific antibodies 
present not only useful tools for further investigations on the structure and function of the virus, 
but may also provide the basis for new diagnostics and treatment of the disease. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 INTRODUCTION TO ALPHAVIRUSES 
Alphaviruses are small, enveloped, positive-sense single-stranded RNA viruses that are 
recognised as the etiological agents of severe polyarthritis/polyarthralgia and encephalitis. 
These viruses are the cause of some of the worlds’ most important emerging infectious diseases 
and are responsible for significant global health issues. Belonging to the Togaviridae family, 
the genus Alphavirus comprises more than 40 recognised members that have been categorised 
into at least seven antigenic complexes based on serological cross-reactivity against other 
viruses of the same genus (Table 1.1). Four of these serogroups – represented by Semliki 
Forest, eastern equine encephalitis, western equine encephalitis and Venezuelan equine 
encephalitis – encompass most of the medically significant alphaviruses. Alphaviruses cause a 
variety of human diseases, ranging from mild febrile illness to severe polyarthritis and 
encephalitis, with the former generally associated with ‘Old World’ viruses and the latter with 
‘New World’ viruses (i.e. eastern, western and Venezuelan encephalitis viruses) (Powers and 
Logue, 2007; Suhrbier et al., 2012). These viruses are transmitted by blood-sucking arthropods, 
typically the mosquito, and can replicate in both arthropod and vertebrate hosts. 
The Semliki Forest group consists of Old World viruses that are associated with rheumatic 
diseases. This includes chikungunya virus (CHIKV), Ross River virus (RRV), o’nyong-nyong 
virus (ONNV) and Semliki Forest virus (SFV). Co-infections of viruses from this serogroup 
have been reported, notably with other mosquito-borne viruses such as dengue virus (DENV) 
(Khai Ming et al., 1974; Mitchell et al., 1987; Kumar et al., 2012). 
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Table 1.1. Alphavirus species and antigenic relationships (L'Vov D et al., 1979; Olaleye et al., 1988; Weaver 
et al., 1993; Weaver et al., 1997; Hommel et al., 2000; Powers et al., 2001). 
Antigenic complex Species 
 
Barmah Forest Barmah Forest virus (BFV) 
Eastern equine encephalitis Eastern equine encephalitis virus (EEEV) 
Middelburg Middelburg virus (MIDV) 
Ndumu Ndumu virus (NDUV) 
Semliki Forest Chikungunya virus (CHIKV) 
 Mayaro virus (MAYV) 
 O'nyong nyong virus (ONNV) 
  Subtype: Igbo-Ora virus 
 Ross River virus (RRV) 
  Subtype: Bebaru virus (BEBV) 
  Subtype: Getah virus (GETV) 
  Subtype: Sagiyama virus (SAGV) 
 Semliki Forest virus (SFV) 
  Subtype: Me Tri virus (MTV) 
 Una virus (UNAV) 
Venezuelan equine encephalitis Cabassou virus (CABV) 
 Everglades virus (EVEV) 
 Mosso das Pedras virus (MDPV) 
 Mucambo virus (MUCV) 
 Paramana virus (PARAV) 
 Pixuna virus (PIXV) 
 Rio Negro virus (RNV) 
 Tonate virus (TONV) 
 Trocara virus (TROCV) 
  Subtype: Bijou Bridge virus (BBV) 
 Venezuelan equine encephalitis virus (VEEV) 
Western equine encephalitis Aura virus (AURAV) 
 Buggy Creek virus (BCRV) 
 Babanki virus (BBKV) 
 Fort Morgan virus (FMV) 
 Highlands J virus (HJV) 
 Kyzylagach virus 
 Sindbis virus (SINV) 
 Ockelbo virus 
 Western equine encephalitis virus (WEEV) 
 Whataroa virus (WHAV) 
Unclassified Salmon pancreas disease virus (SPDV) 
 Sleeping disease virus (SDV) 
 Southern elephant seal virus (SESV) 
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1.2 CHIKUNGUNYA VIRUS 
CHIKV was first isolated in 1952 in Tanzania from human serum, Aedes spp. and Culex spp. 
mosquitoes (Robinson, 1955; Ross, 1956). However, the first descriptive characterisation (i.e. 
clinical symptoms) of the disease was recorded by David Bylon in 1779 during an epidemic in 
Batavia, now known as Jakarta (Carey, 1971). The word chikungunya, derived from African 
dialect, Makonde, means “that which bends up”, referring to the cramped posture resulting 
from the debilitating arthralgic condition of diseased individuals (Enserink, 2006; Sourisseau 
et al., 2007). 
 
1.3 EPIDEMIOLOGY, TRANSMISSION & PATHOGENESIS 
Since its discovery, CHIKV has been responsible for regular epidemics primarily in Africa, 
Asia and most recently, Europe and the Americas (Figure 1.1). Sporadic cases were reported 
in West Africa, from Senegal to Cameroun, and in multiple other African countries where 
CHIKV is endemic. In the 1960s and 1990s, many epidemics occurred in Asia (Pialoux et al., 
2007; Jain et al., 2008). Major epidemics appear and disappear cyclically, usually ranging from 
7-20 years (Caglioti et al., 2013). In 2004-2007, the largest epidemic of CHIKV disease was 
recorded, beginning with an outbreak in Kenya that spread across the Indian Ocean Islands to 
India, where an estimated 1.4 to 6.5 million cases of infections occurred. During 2005-2006, 
approximately 255,000 cases of CHIKV disease were reported in the Reunion Island (French 
Indian Ocean), amounting to an unprecedented 33% of the total population (Ravi, 2006; 
Schuffenecker et al., 2006; Simon et al., 2006). The virus caused the first autochthonous 
epidemic outbreak in the north-east of Italy in 2007, with >200 human infections traced back 
to the same index case (Rezza et al., 2007; Watson, 2007; Angelini et al., 2008). CHIKV has 
since then been detected in numerous other European countries including France, Germany and 
the Netherlands (Chretien and Linthicum, 2007; Hassing et al., 2008; Queyriaux et al., 2008; 
Frank et al., 2011; Grandadam et al., 2011). By 2010-2011, CHIKV infections were being 
reported in South Asia and New Caledonia in the Pacific Ocean (Ng and Hapuarachchi, 2010; 
Powers, 2011). Since then, large CHIKV outbreaks were recorded in the Republic of Congo, 
Cambodia, Indonesia, the Philippines and even the main island of Papua New Guinea (Caglioti 
et al., 2013). 
Due to the increase in international travel, CHIK fever has been identified in nearly 40 countries 
including Japan and the USA (Schwartz and Albert, 2010; Gibney et al., 2011; Mizuno et al., 
2011; Miner et al., 2015), and is listed as a category C priority pathogen by the US National 
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Institute of Allergy and Infectious Diseases (2011). Between December 2013 and March 2015, 
the Pan American Health Organisation/World Health Organisation has reported more than 1.2 
million suspected and almost 5,000 confirmed cases of indigenously-acquired CHIK fever 
throughout the Americas involving 44 countries or territories 
(http://www.cdc.gov/chikungunya/geo/index.html). Furthermore, the Centers for Disease 
Control and Prevention (CDC) has reported 2,344 cases of infections in 47 states of the USA, 
as of 10th March 2015 (http://www.cdc.gov/chikungunya/geo/united-states-2015.html). The 
CHIKV epidemic appears to be continuing with outbreaks recently reported in Australasia and 
the Caribbean (Horwood et al., 2013; Viennet et al., 2013; Van Bortel et al., 2014). 
 
Figure 1.1. Geographical distribution of CHIKV. Data according to the latest update (10th March 2015) of the 
Centers for Disease Control and Prevention (CDC) website. Map does not include countries of territories where 
only imported cases have been documented. 
CHIKV is believed to be maintained in the wild by sylvatic cycles of transmission between 
forest-dwelling Aedes spp. mosquitoes and non-human primates (Singh and Unni, 2011). 
Although varying geographically and with ecological conditions, Ae. furcifer, Ae. africanus, 
Ae. neoafricanus, Ae. taylori and Ae. luteocephalus are the major species of mosquitoes 
involved in the maintenance of CHIKV in rural sylvatic cycles (McIntosh and Jupp, 1970; Jupp 
and McIntosh, 1990; Diallo et al., 1999; Thonnon et al., 1999). Meanwhile, the urban mosquito 
Ae. aegypti has been found to be the most significant vector in urban areas of Africa and in 
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virtually all of Asia, with humans being the key and most efficient reservoir identified (Powers 
and Logue, 2007). 
Three lineages of CHIKV, namely Asian, West African, and East/Central/South African 
(ECSA), with distinct genotypic and antigenic characteristics, have been identified 
(Schuffenecker et al., 2006). The divergence of each distinct lineage reflects, to some extent, 
the path of global transmission and occasional outbreaks (Caglioti et al., 2013). Phylogenetic 
analysis showed that the CHIKV strains circulating currently share a common ancestor that 
existed within the last five centuries (Volk et al., 2010). Despite their proximal geographical 
distance, the West and ECSA African lineages did not cluster together, indicating limited 
genetic exchange between the two lineages on the continent. There is, however, evidence that 
the West African and ECSA lineages may co-circulate in enzootic cycles (Volk et al., 2010). 
The acquisition of an A226V mutation in the E1 glycoprotein of ECSA CHIKV isolates, as 
observed in the La Reunion outbreak starting in 2005, has been suggested to be responsible for 
the increased transmissibility of the virus by the widely-distributed Ae. albopictus mosquito 
(Vazeille et al., 2007). In addition to the lack of herd immunity in the region, the A226V 
mutation was thought to be a significant contributing factor to the abrupt and escalating nature 
of the outbreak. This was mainly due an altered vector specificity, allowing the mutated virus 
to adapt well to replicating in Ae. albopictus (Tsetsarkin et al., 2007). The mutated strain spread 
from the Indian Ocean to East Africa and Asia, and eventually caused the CHIKV outbreak in 
Italy (Angelini et al., 2007). 
Virus strains responsible for the outbreaks in the Caribbean belongs to the Asian genotype, 
possibly introduced by travellers from Asia where epidemics have been occurring since the 
1960s (Lanciotti and Valadere, 2014; Halstead, 2015). While Ae. aegypti mosquitoes are 
widespread in the Caribbean region, Ae. albopictus mosquitoes also found in the Americas and 
on a number of Caribbean islands (Van Bortel et al., 2014). The presence of both Ae. aegypti 
and Ae. albopictus mosquitoes, susceptible human amplifying hosts and the ability of CHIKV 
to transmit in temperate climates has since resulted in comparisons of its potential spread in 
the US to that of the West Nile virus (WNV) epidemic in the early 2000s (Higgs, 2014). Ae. 
albopictus mosquitoes have also established themselves in most European countries, possibly 
due to a warmer climate in the past decade, and is known to be highly-active especially during 
the summer (Chretien and Linthicum, 2007; Queyriaux et al., 2008). Currently, CHIKV’s 
urban transmission cycle relies primarily on Ae. aegypti and/or Ae. albopictus mosquitoes to 
initiate human-mosquito-human transmission, utilising humans as reservoirs/amplifying hosts. 
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The primary mode of CHIKV’s urban transmission to vertebrates is through the bite of an 
infected mosquito. However, in the recent Indian Ocean epidemics, numerous cases of 
infection were the result of mother-to-child transmission, with a high neonate morbidity rate 
of up to 100%, and majority (50-90%) presenting with severe illness (Ramful et al., 2007; 
Gerardin et al., 2008). Following transmission, CHIK replicates in the skin prior to 
dissemination into the bloodstream, eventually infecting the liver and joints (Talarmin et al., 
2007). Infection with CHIKV results in a brief viraemia, usually 5-7 days, followed by an acute 
onset of disease 2-4 days after infection (Schwartz and Albert, 2010). A wide range of cell 
types and tissues have been shown to be infected by arthritogenic alphaviruses, including 
monocytes and/or macrophages, dendritic cells, muscle cells, periosteum and possibly 
keratinocytes. Widespread infection of these cells and the associated inflammatory immune 
responses probably account for the acute symptoms caused by CHIKV and other closely-
related viruses (Suhrbier et al., 2012, and references therein). The rise in viral titre coincides 
with disease onset, triggering the activation of an innate immune response, the hallmark of 
which is represented by the production of type I interferons. Patients typically clear the virus 
approximately one week post-infection, at which time there is evidence of CHIKV-specific 
adaptive T cell and antibody-mediated responses. Virus-specific IgM, and sometimes IgG, can 
be detected as early as 3-4 days after symptom onset (Blacksell et al., 2011; Gibney et al., 
2011). An estimated 30-40% of infected adults experience chronic or recurrent arthralgia 
and/or arthritis (Schwartz and Albert, 2010). 
 
1.4 CLINICAL FEATURES 
CHIKV causes a DENV-like illness in humans, characterised by fever, myalgia, a rash which 
is usually maculopapular in appearance, followed by acute and chronic 
polyarthralgia/polyarthritis that primarily affects the peripheral small joints (Robinson, 1955; 
Tesh, 1982). The incapacitating arthralgic syndrome typically resolves within weeks to months, 
but can be protracted (Borgherini et al., 2008; Hoarau et al., 2010; Suhrbier et al., 2012). 
The disease has a sudden onset, with an incubation period between 3-12 days (Mohan, 2006). 
During the initial viraemic phase, body temperature rises rapidly to around 40 °C and may be 
accompanied by a rigor. Chikungunya (CHIK) fever corresponds to the period of viraemia and 
is thought to be related to the ability of the virus to induce large amounts of interferon (IFN) 
(Carey et al., 1969). Headaches are very common, and non-pruritic maculopapular rashes are 
often seen appearing on the face, limbs and trunk of the body in 80% of cases, 4-8 days after 
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the initial illness (Griffin, 2007). The most significant manifestation of CHIKV, allowing a 
differential diagnosis from DENV, is the excruciating joint pain that occurs with virtually every 
adult clinical case (Fourie and Morrison, 1979; Economopoulou et al., 2009). The arthralgia is 
usually symmetrical and peripheral, noted mainly in the fingers, wrists, elbows, knees, ankles 
and toes. Affected joints exhibit tremendous sensitivity and swelling typically lasting for weeks 
or months. Paraesthesia of the skin over these joints is common, suggesting neurological 
involvement (Powers and Logue, 2007). Normally, the acute febrile illness resolves within a 
few days, whereas the morbidity associated with prolonged joint pain persists typically from 
weeks to months, thus, resulting in serious economic and social implications for both the 
infected individuals and their communities. There have also been documented cases of 
CHIKV-induced arthralgia lasting for several years, with up to 12% of patients developing 
chronic joint problems (Brighton et al., 1983; McGill, 1995). Symptoms in children described 
in a 2008 study included fever, rashes, headache, gastrointestinal disorders, and arthralgia 
and/or diffuse pain, with neurological symptoms (up to 73%) often starting less than 24 hours 
after the onset of fever, 40% of which led to encephalitis (Robin et al., 2008). Other common 
manifestations in children include lymphadenopathy, conjunctival injection, swelling of 
eyelids and pharyngitis (Jadhav et al., 1965). Hemorrhagic fever was also observed in nearly 
8% of infected patients in a study involving 639 children in Bangkok (Nimmannitya et al., 
1969). 
Although CHIKV disease is usually self-limiting, recent epidemics has seen the virus 
associated with some severe disease manifestations and mortality, primarily amongst elderly 
patients with co-morbidities, and the very young through mother-to-child transmissions 
(Robillard et al., 2006; Mavalankar et al., 2008; Economopoulou et al., 2009; Tandale et al., 
2009; Jaffar-Bandjee et al., 2010). In the 2005-2006 Reunion Island CHIKV outbreak, babies 
of 38 mothers who showed symptoms during delivery, or if the new-borns became ill in the 
first days of life, were found to be infected with CHIKV by detection of viral RNA via RT-
PCR and/or presence of specific anti-CHIKV IgM. All neonates were found to be symptomatic 
and presented with clinical symptoms 3-7 days post-infection (Ramful et al., 2007). In two 
other studies relating to the same outbreak, vertical transmission was confirmed with nearly 
half of the infected new-borns presenting neonatal CHIK disease symptoms such as fever, pain, 
rashes and peripheral edema. About half of the infected neonates developed serious 
haemorrhage, disseminated intravascular coagulation, and/or cardiac and neurological 
manifestations; the latter often leading to permanent neurological, visual and/or movement-
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based disabilities. Fetal transmission during pregnancy also led to abortion (Lenglet et al., 
2006; Gerardin et al., 2008). Three cases of epidermolysis bullosa were also described for the 
first time following CHIKV infection (Ernould et al., 2008). 
Rare symptoms such as lymphopenia, severe dermatological lesions, lethal hepatitis and 
encephalitis in both adults and new-borns have also been described recently during the Reunion 
outbreak (Lenglet et al., 2006; Pialoux et al., 2007; Sourisseau et al., 2007). In April 2006, 213 
deaths were reported to be directly or indirectly caused by CHIKV during the Reunion 
outbreak, leading to a case fatality rate of approximately 1 in 1000 (Josseran et al., 2006). 
 
1.5 VACCINES, TREATMENT & PREVENTION 
CHIKV infections have been shown to elicit long-lasting immunity in patients, while infection 
studies with animal models have demonstrated cross-protection against other alphaviruses 
(Hearn and Rainey, 1963; Nitatpattana et al., 2014; Gasque et al., 2015). There are no licensed 
human vaccines available for any alphavirus, although vaccines for CHIKV are in development 
(Akahata et al., 2010; Wang et al., 2011; Brandler et al., 2013; Metz et al., 2013). Furthermore, 
no curative or prophylactic treatments are available to combat infection with this re-emerging 
virus, though development of monoclonal antibody therapy are in progress (Pal et al., 2013). 
Treatment of CHIKV rheumatic disease is symptom-oriented and usually involves the use of 
salicylate analgesics and/or non-steroidal anti-inflammatory drugs, with relief often inadequate 
(Suhrbier et al., 2012). 
Neutralizing antibodies are believed to be crucial for providing protection, with recent studies 
illustrating that polyvalent CHIKV-specific antibodies are able to prevent CHIKV infection 
and disease in mouse models (Couderc et al., 2009; Gardner et al., 2010). 
Means of prevention relies on personal protection against mosquito bites and vector control. 
The use of insect repellent and wearing bite-proof, protective clothing reduces the chances of 
individuals getting bitten by mosquitoes. However, the most efficient strategy for controlling 
viral transmission is based on vector control, especially on interventions that aim to reduce the 
human-vector contact. The three types of interventions that can be implemented are: (i) the 
increase of population awareness about the risks of arboviral transmission, (ii) the reduction of 
larval breeding sites by eliminating water-holding containers and/or by using larvicides, and 
(iii) the control of local adult mosquitoes by spraying insecticides (Doucoure et al., 2014). 
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1.6 VIRAL MORPHOLOGY, GENOMIC STRUCTURE & LIFE CYCLE 
The CHIKV genomic RNA encodes four non-structural proteins involved in virus replication 
and pathogenesis, and five structural proteins. Recent in vitro and in vivo biochemical and 
functional studies have allowed additional elucidation of the virus life-cycle and pathogenesis. 
Furthermore, the efficiency with which many of these viruses replicate, coupled with the broad 
range of susceptible and permissive hosts, has allowed them to be used as tools in heterologous 
gene expression and gene therapy delivery vectors. Taken together, recent discoveries within 
the alphavirus field have provided a broader perspective of the virus lifecycle and may allow 
for additional control as well as further exploitation of these important viruses. 
As with other alphaviruses, the CHIKV virion contains a  nucleocapsid consisting of a linear, 
positive-sense single-stranded RNA genome of approximately 11.7 kb complexed with 
multiple copies of the capsid protein (CP) and surrounded by a host-derived lipid envelope  
(Strauss and Strauss, 1994a). The virion is spherical with a diameter of ~70 nm and contains a 
~40 nm nucleocapsid particle (Simizu et al., 1984) (Figure 1.2). Supported by a lipid envelope, 
the viral E1 and E2 glycoproteins are arranged in an icosahedral lattice with T = 4 symmetry. 
The glycoproteins assemble as heterodimers that are then grouped as trimers to form 80 knobs 
on the virion surface (Kielian and Rey, 2006). These glycoprotein spikes are involved in cell 
receptor recognition, and are essential for cell entry via endocytosis and low pH-dependent 
membrane fusion. 
 
Figure 1.2. Structure of CHIKV. Model of a CHIKV virion (left) generated from information gathered from the 
Protein Data Bank based on EM density of SINV (PDB ID: 2XFB) and schematic representation of a cross-section 
of CHIKV particle showing a nucleocapsid core enveloped by a lipid bilayer of trimeric spikes of the E1-E2 
glycoproteins. 
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The CHIKV RNA genome has a 7-methlyguanosine cap at its 5ʹ end, while the 3ʹ end is 
covalently-linked to a poly-A tail (Figure 1.3). Containing two open reading frames (ORFs), 
the genome encodes for a non-structural polyprotein at its 5ʹ end and a structural polyprotein 
at the 3ʹ end (Strauss and Strauss, 1994a). 
 
Figure 1.3. Schematic representation of the CHIKV RNA genome. Encoded in the genomic RNA are four 
non-structural proteins and five structural proteins. 
Alphaviruses enter their target host cells by endocytosis in a clathrin-dependent manner via a 
range of receptors, such as dentritic cell/liver/lymph node-specific ICAM 3-grabbing non-
integrins, heparin sulphate, laminin and integrins. However, the precise roles of these receptors 
have not been established (Griffin, 2007). Upon entry into the cell, the acidic environment of 
the endosome triggers conformational changes within the viral envelope that causes the E1 
fusion peptide to be exposed, mediating virus-host cell membrane fusion (Figure 1.4) (Kielian 
et al., 2010). This enables cytoplasmic delivery of the nucleocapsid core and release of the viral 
genome (Marsh and Helenius, 2006; Jose et al., 2009). 
Non-structural proteins are required for viral replication and are directly translated from the 5ʹ 
end of the genomic RNA into two polyproteins - P123 or the larger P1234 (Jose et al., 2009; 
Sreejith et al., 2012). The latter occurs due to a translational read-through of on opal 
termination codon at the end of nsP3 (Shin et al., 2012). This is estimated to occur with 10-
20% efficiency, as illustrated in Sindbis virus (SINV) (Li and Rice, 1993). Both polyproteins 
will then undergo processing by the virus-encoded protease located within non-structural 
protein 2 (nsP2) into their respective intermediate and final component proteins (Strauss et al., 
1992). These nsPs assemble to form the viral replication complex, which synthesizes a full-
length negative-strand RNA intermediate that serves as a template for the synthesis of both the 
subgenomic (26S) and genomic (46S) RNAs (Figure 1.4). 
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Figure 1.4. CHIKV life cycle, adapted from Schwartz and Albert (2010). 
Meanwhile, at the 3ʹ one-third end of the RNA, downstream of the non-structural protein ORF, 
a polyprotein precursor (C-pE2-6K-E1) is generated by the translation of a subgenomic 26S 
mRNA, which is processed by an autoproteolytic serine protease. The capsid protein (CP) is 
then released from the remaining polyprotein while the pE2 and E1 glycoproteins are generated 
by undergoing further processing (Figure 1.4). pE2 and E1 proteins associate with one another 
in the Golgi and are exported to the plasma membrane, where pE2 is cleaved into E2 and E3. 
Viral assembly is promoted by the binding of viral genomic RNA to CP, and the recruitment 
of the membrane-associated envelope glycoproteins. The assembled CHIKV particle then buds 
at the host cell membrane, forming a matured virion (Simizu et al., 1984; Schwartz and Albert, 
2010). 
1.7 CHIKV NON-STRUCTURAL PROTEINS 
Alphaviruses encode four nsPs that are processed from a single non-structural polyprotein. 
Apart from the formation of the viral replication complex, each nsP has been shown to have its 
own function. nsP1 is involved in the synthesis of the negative strand viral RNA and has both 
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guanine-7-methyltransferase and guanyltransferase enzymatic activities (Salonen et al., 2005; 
Griffin, 2007). nsP2 displays helicase activity required for the unwinding of dsRNA replicative 
intermediates, harbours an RNA triphosphatase and proteinase for the cleavage of the non-
structural polyprotein. It is also known that nsP2 plays a role in shutting-off host cell 
transcription (Garmashova et al., 2007). nsP3 is part of the replicase unit required for both the 
minus-strand and subgenomic RNA synthesis, and possesses ADP-ribose 1”-phosphate 
phosphatase and RNA-binding activity (Jose et al., 2009). Similarly, nsP4 harbours the RNA-
dependent RNA polymerase that is also required for RNA replication (Griffin, 2007; Schwartz 
and Albert, 2010). 
 
1.8 CHIKV STRUCTURAL PROTEINS 
The genomic RNA of CHIKV encodes five structural proteins that are processed from a single 
structural polyprotein. These structural proteins form an integral part in the formation of the 
virion particle, while possessing specific functions of their own.  
1.8.1 Capsid protein 
The multifunctional CP plays an important role in the assembly and budding of alphaviruses. 
The viral genomic RNA is enclosed in a nucleocapsid core (NC) composed of 240 copies of 
CP in a T = 4 arrangement, leading to an ordered array of projections that are seen as 
capsomeres on the core (Strauss and Strauss, 1994b). Being the first structural polyprotein 
synthesized, CP functions as a serine protease to cleave itself from the nascent viral polyprotein 
precursor (Melancon and Garoff, 1987; Choi et al., 1991). CP then recognises and binds onto 
the genomic RNA before associating itself with other CP molecules,  assembling into an 
ordered protein to form the NC, encapsidating the viral RNA in the process (Soderlund and 
Ulmanen, 1977; Ulmanen, 1978; Owen and Kuhn, 1996; Jose et al., 2009). Each CP monomer 
interacts in a one-to-one ratio with the cytoplasmic domain of the E2 transmembrane spike 
glycoprotein, thereby driving envelopment and budding of new virions at the plasma membrane 
of the infected cell (Suomalainen et al., 1992; Zhao et al., 1994; Owen and Kuhn, 1997; Jose 
et al., 2013). During entry of the virus into a new host cell, each CP on the NC interacts with 
ribosomes resulting in disassembly of the NC and release of genomic RNA into the cytoplasm 
(Singh et al., 1997). Apart from its structural significance, studies have also shown that the CP 
plays a role in the inhibition of host cell protein synthesis (Elgizoli et al., 1989). 
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The alphavirus CP is organized into three separate regions – I, II and III – each with their 
distinct functions (Hong et al., 2006). The unconserved N-terminal domain of the alphavirus 
CP has a large number of positively-charged amino acid residues implicated in non-specific 
RNA binding (Garmashova et al., 2007). The highly-conserved C-terminal region harbours a 
globular chemotrypsin-like serine protease and contains the binding site for the cytoplasmic 
tail of the spike protein (Griffin, 2007). Furthermore, it has been shown that CP contains two 
nuclear localization signals (NLS) responsible for the karyophilic properties of the protein 
(Nigg et al., 1991; Favre et al., 1994; Jakob, 1994). Synthetic peptides derived from alphavirus 
NLS sequences have been used to demonstrate efficient transport of the CP into the nucleolus 
of both higher and lower eukaryotic target cells (Favre et al., 1994). However, to date, reasons 
for this import/export of CP to/from the nucleus are still unknown. 
1.8.2 Envelope glycoproteins & their signal peptides 
The virion envelope of CHIKV consists of a host-derived lipid bilayer in which 240 copies of 
the E1 and E2 glycoprotein are embedded as 80 trimeric spikes on the virus surface. After the 
self-cleavage of CP from the structural polyprotein, the remaining envelope cassette is 
translocated to the endoplasmic reticulum (ER) by signal sequences E3 and 6K (Firth et al., 
2008; Snyder and Mukhopadhyay, 2012). E1 and pE2 (precursor to the E3 and E2) are then 
assembled as heterodimers in the ER. Thereafter, E3 is cleaved from pE2 by furin and 
glycosylated in the trans-Golgi compartment, and the resultant E1-E2 heterodimers are then 
transported to the plasma membrane. 
The E1 glycoprotein is responsible for fusion of the viral membrane with the endosomal 
membrane upon entry into host cells. The CHIKV E1 protein has a single N-linked 
glycosylation site, a short intracytoplasmic tail and a positionally-conserved internal 
hydrophobic stretch of amino acids in the N-terminal portion that serves as a fusion peptide for 
virion entry into the cell (Pletnev et al., 2001). The E1 ecto-domain comprises three β-barrel 
domains – I, II and III. Domain I harbours the amino terminus and is spatially located between 
the other two domains. The C-terminus of E1 lies within domain III, and the fusion peptide is 
at the distal end of domain II (Jose et al., 2009).  
The E2 protein is involved in host-cell receptor binding and the subsequent clathrin-mediated 
endocytosis. The E2 glycoprotein is a transmembrane protein that has two N-linked 
glycosylation sites and contains the most important epitopes for neutralizing antibodies (Davis 
et al., 1987; Vrati et al., 1988; Metz et al., 2011; Warter et al., 2011). Unlike the E1 protein, 
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E2 is a thin, long molecule, with a narrow stem that twists around the E1 molecule. The E2 
protein also has an exposed leaf-like structure that sits at the top of the spike protein, concealing 
the distal fusion tip of the E1 glycoprotein domain II (Jose et al., 2009). The carboxy-terminal 
domain of E2 consists of ~30 amino acids that interact with the NC core (Mukhopadhyay et 
al., 2006). 
The E3 protein serves as a signal sequence for the translocation of the pE2-6K-E1 polyprotein 
into the ER. An essential step for virus maturation, E3 is then cleaved from E2 by furin in the 
trans-Golgi complex (Strauss and Strauss, 1994a). The small, 64-amino-acid E3 also mediates 
proper folding of pE2 and controls the spike functions by interacting with the fusion protein 
E1. E3 is known to be required for efficient particle assembly, mediating both spike folding 
and spike activation for viral entry (Snyder and Mukhopadhyay, 2012). The small 6K protein 
is an acylated protein that is cysteine-rich and hydrophobic in nature. Although only small 
amounts are incorporated into virions, the 6 kDa protein has numerous functions. It acts as a 
signalling peptide for E1, is involved in envelope protein processing, membrane 
permeabilisation, virion assembly, as well as virus budding (Firth et al., 2008). 
1.9 CURRENT DIAGNOSTIC METHODS 
The advancement in technology and travel has seen mosquito vectors expand to new areas, and 
diseases spread to previously inaccessible regions. The unprecedented CHIKV epidemic in 
2004-2007 underlined the fact that CHIKV is no longer simply a developing world problem. 
Factors such as increased international travel and the enhanced fitness of Aedes albopictus 
mosquitoes to transmit CHIKV, due to the A226V mutation in the E1 glycoprotein, has seen 
the virus spread to continents outside of Africa or Asia. Furthermore, in the recent outbreaks, 
CHIKV infections have been associated with neurological complications, such as encephalitis, 
which were previously limited only to New World alphaviruses (Rampal et al., 2007; Chandak 
et al., 2009). 
The most suitable test for diagnosing CHIKV is dependent on the phase of disease (Figure 
1.5). Acute symptoms generally last for approximately five days, during which viraemia is 
present and can be confirmed by virus isolation, RT-PCR or antigen detection from the blood 
of viraemic patients or infected tissues. RNA and antigen from non-viable virus can also be 
detectable for a few days after this (Sam et al., 2011). CHIKV-specific IgM can be detected 3-
8 days after onset of symptoms and can persist for several months (Yap et al., 2010). On the 
other hand, virus-specific IgG can reach detectable levels 4-10 days after onset of symptoms, 
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often lasting for years after infection (Kam et al., 2012). Complement fixation and 
neutralization of viral infectivity are other tests that have been employed to detect CHIKV 
infection (Olaleye et al., 1989; Warter et al., 2011). 
 
 
Figure 1.5. Typical course of CHIKV disease in adults (Suhrbier et al., 2012). A schematic representation of 
the typical course of CHIKV disease, illustrating the time points of typical symptoms (pink) and biomarkers (blue) 
in boxes. Viraemia is usually followed by fever, myalgia, polyarthralgia and/or polyarthritis. A rash, usually 
maculopapular in appearance, can appear 2-4 days post-symptom onset. Polyarthralgia and/or polyarthritis and 
IgG levels in blood can persist for months to years. Virus-specific IgM and IgG can be detected as early as three 
or four days after symptom onset, respectively. 
The gold standards of CHIKV diagnosis are detection of virus or viral RNA. However, virus 
isolation is time consuming and requires specialised facilities and skills, which are very limited 
especially in developing countries. Highly-specific and sensitive RT-PCR techniques for 
CHIKV have been described, but reagents and equipment required to perform these assays are 
too costly for widespread use (Laurent et al., 2007; Santhosh et al., 2007; Naze et al., 2009; 
Reddy et al., 2012). Furthermore, detection of RNA is restricted to acute phase samples (day 
0-7) (Figure 1.5), and inappropriate storage methods of samples may lead to degradation of 
virus and RNA. 
CHIKV antigen detection can be a good alternative due to the fact that it makes use of simpler, 
more accessible and established serological platforms such as ELISA, as demonstrated by the 
diagnosis of DENV using NS1 antigen detection kits (Anderson et al., 2014; da Costa et al., 
2014). Although more sensitive results are obtained by gene detection methods such as PCR, 
viral antigen detection tests are increasingly being used because of their low demand on 
laboratory equipment and relatively low cost (Grandien, 1996). The use of virus-specific mAbs 
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in turn provides an increased specificity for disease diagnosis. Antigen detection can be applied 
to several detection techniques with involving mAbs. The identification of viral proteins in 
tissue sections via immunohistochemistry and in vitro cell or tissue culture-isolated viruses by 
immunofluorescence are two such examples. Significantly shorter performance times have 
since been reported with the use of mAbs for the rapid detection of numerous infectious 
diseases, including dengue, malaria, hepatitis and respiratory viruses (Grandien, 1996; Attallah 
et al., 2003; Majumdar et al., 2013; Ahmed and Broor, 2014; Maltha et al., 2014). 
Unfortunately, there are currently no widely-available CHIKV-specific reagents that can be 
used in a sensitive antigen detection assay, while in-house CHIKV antigen detection ELISAs 
described to date do not have their performance characteristics clearly defined (Shukla et al., 
2009; Kashyap et al., 2010). In the meantime, serological diagnosis of CHIKV via IgM or IgG 
capture is more broadly used as it is relatively inexpensive and easier to perform. Nevertheless, 
the sensitivity of most existing serological diagnostic tests are poorly established, and lack 
credibility, in terms of specificity, due to the high possibility of false-positive results from 
cross-reactivity with other closely-related alphaviruses such as RRV, ONNV, Sindbis virus and 
Barmah Forest virus (Niedrig et al., 2009; Blacksell et al., 2011). 
1.9.1 Importance/Principles of a diagnostic assay for CHIKV 
Infectious diseases account for approximately a third of deaths worldwide and is the leading 
cause of death in children below the age of five at almost 70% in 2008 (Black et al., 2010). 
Numerous common tropical infections, such as dengue, malaria, typhus and leptospirosis, 
cause non-specific fever similar to chikungunya (Ezzedine et al., 2008; Schilling et al., 2009; 
Sam et al., 2011; Kumar et al., 2012). Without specific diagnosis, it will be difficult to tell 
these diseases apart based on clinical symptoms. A study by Baba and colleagues (2013), which 
included malaria, typhoid, CHIKV, DENV, WNV and yellow fever virus, showed that 
approximately 40% of patients were infected with a combination of one or more of these 
pathogens; half of the patients also tested positive with anti-CHIKV antibodies via plaque 
reduction neutralisation tests. This suggests that the misdiagnosis of arboviral co-infections, 
combined with the under-reporting and/or lack of disease surveillance can increase the 
potential for unnoticed and uncontrolled spread of medically-important vector-borne diseases, 
which may result in underlying public health concerns. 
Although no specific vaccines or antivirals are available for CHIKV, there are several 
advantages for the diagnosis of the infection. It is not uncommon that patients presenting with 
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undiagnosed fever are empirically and unnecessarily given antibiotics, which is a waste of 
resources and may contribute to antimicrobial resistance (Sam et al., 2011). Early detection of 
CHIKV can result in prompt interventions for vector control to contain potential outbreaks. In 
addition, effective surveillance of the emerging disease, especially in developing countries, can 
alert the local and global community to impending threats, which is crucial for prevention of 
large epidemics or further spread. 
According to the WHO, the ideal test for any infectious disease should have the following 
characteristics, labelled “ASSURED”: affordable, sensitive, specific, user-friendly, rapid and 
robust in if different climates, equipment-free, and be delivered to those who need it (Urdea et 
al., 2006). Furthermore, by combining the detection of both pathogen-specific antigen and 
serum antibodies, the sensitivity of the test(s) can be greatly increased. The development of a 
robust, yet reliable point-of-care assay that is rigorously evaluated with well-characterised 
samples collected from a variety of clinical settings, including infections caused by different 
CHIKV isolates, will have the potential to be an ideal test. Additionally, if possible, an antigen-
detecting kit should be validated for use on mosquitoes, which could greatly benefit vector 
surveillance programs. 
 
1.9.2 Positive controls for an ELISA-based antibody detection assay 
In a diagnostic kit, reference material or positive controls must be included for use with each 
assay run to confirm the integrity of all test reagents and components. Moreover, to determine 
if a result is considered positive or negative, the inclusion of a cut-off calibrator at a pre-
determined concentration would be required for comparison with sample results. The 
standardisation and quality of control reagents are integral parts of the optimisation process by 
which the physical, chemical and biological parameters of an assay are evaluated to ensure that 
the performance characteristics of the assay are best suited to its intended application. The 
labour intensive process of optimising controls for an assay is a fundamental and critical step 
to achieving a reliable and predictable assay performance. These control samples should ideally 
represent known infected animals (i.e. humans) from the population that will become the target 
of the assay. Obtaining such reference samples, however, is not always possible (OIE 
Terrestrial Manual 2014, http://www.oie.int/international-standard-setting/terrestrial-
manual/access-online/). Kits used for the detection of serum antibodies against infectious 
agents commonly utilise human reference sera to establish cut-off values and verify the 
performance of these tests (Jacobson, 1998). These preparations usually consist of pooled sera 
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from virus-immune individuals. However, this approach has several disadvantages when used 
for routine diagnostics. A constant supply of high-titred serum from confirmed cases of CHIKV 
infections can be challenging to obtain, particularly if CHIKV is rare or exotic in the region. 
The collection of blood from individuals who are ill, from the young and elderly, or in societies 
where acquiring blood is forbidden, has caused various human ethical issues as well. Moreover, 
there are safety concerns of disease contraction, at both the manufacturer and consumer ends, 
when dealing with potentially infectious human sera. Finally, continuous standardization will 
be required for each finite batch of material collected due to variable antibody titres and 
sensitivity or specificity (Hackett et al., 1998). With every varying batch of reference material 
collected, assays will then be re-calibrated against an international, national or in-house 
standard prior to aliqouting and storage for routine use (OIE Terrestrial Manual 2014, 
http://www.oie.int/international-standard-setting/terrestrial-manual/access-online/). Thus, the 
development of a more consistent, readily available control reagent alternative would help 
provide serodiagnostic assays with greater reliability and reproducibility in terms of standards. 
1.9.3 Chimeric antibodies as alternatives 
Chimeric mouse-human mAbs are antibodies that retain their antigen-recognising variable 
chain regions, but have been engineered to have human constant regions that contain epitopes 
required for recognition by enzyme-conjugated signal antibodies (Morrison et al., 1984). The 
creation of humanised chimeric mAbs that bind viral antigen from all genotypes of CHIKV 
would be a superior alternative to pooled immune human sera as a reference reagent in 
diagnostic tests. Apart from their capacity to be continuously expressed in stable cell lines, 
purified chimeric mAbs can offer greater consistency compared to their human-derived serum 
counterparts. Naturally, with the use of chimeric mAbs as alternative controls, ethical problems 
regarding the collection of human blood will therefore be no cause for concern. The successful 
use of chimeric mAbs as positive controls in an ELISA-based diagnostic was first described 
for the detection of the parasitic protozoan Toxoplasma gondii (Hackett et al., 1998). There 
have since been several other published uses of protein-specific chimeric mAbs as diagnostic 
control reagents (Schuurman et al., 1997; Ichikawa et al., 1999; Simon et al., 2001; Jones and 
Barnard, 2007). 
1.10 HYBRIDOMA TECHNOLOGY AND THE GENERATION OF MONOCLONAL ANTIBODIES 
In 1975, hybridoma technology was invented by Kohler and Milstein (1975). The remarkable 
and indispensable platform for generating unlimited quantities of pure, mono-specific 
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antibodies directed against virtually any antigen of interest was seen as a significant milestone 
in biomedicine and immunology. Monoclonal antibodies (mAbs) are highly-specific and 
homogeneous species of immunoglobulin molecules produced in vitro by a single hybridoma 
clone generated by the fusion of a myeloma cell with a B lymphocyte from a donor or 
immunised animal (Zhang, 2012). Hybridoma-derived mAbs have since served as invaluable 
tools in revolutionising discovery research and therapeutic development in fields such as 
biology, immunology, oncology and infectious diseases (Little et al., 2000; Weiner, 2007; An, 
2010). Furthermore, with the establishment of mAb chimerisation and humanisation, along 
with the development of transgenic-humanised mice, hybridoma technology has opened up 
new possibilities for effectively engineering and generating recombinant forms of these mAbs 
as therapeutics and/or diagnostics. In recent years, mAbs have emerged as the most rapidly 
expanding class of biopharmaceuticals for a large variety of clinical settings, with 26 out of the 
currently 28 FDA-approved therapeutic mAbs originating from hybridomas (Reichert, 2011; 
Zhang, 2012). 
MAbs generated from immune hosts by the hybridoma approach often exhibit good binding 
affinity due to in vivo secondary immune responses, and are thus very useful as diagnostic 
reagents (Nossal, 1992). Detection of viruses via immunoassays with the use of mAbs are 
generally much faster and/or simpler to perform as compared to other commonly used methods 
such as virus isolation or detection of viral nucleic acid. Immunoassays also provide greater 
flexibility and variety (e.g. capture of both viral antigens and/or antibodies) compared to using 
molecular methods. Examples of mAb-utilising detection techniques include ELISAs, Western 
blotting, dipsticks, dot blot tests, immunofluorescence assays and immunohistochemistry. 
Aside from their use in therapeutics and diagnostics, mAbs are also important research tools to 
assist investigators in gaining a better understanding of viruses, with emphasis on the structure 
and function of specific viral proteins. Although alphaviruses have been well-studied, SINV 
and SFV have been used as the main investigation models for the genus. Given the shortage of 
widely available reagents for CHIKV, the re-emergence of the virus and its potential threat to 
human health has intensified the need for new research reagents, and improved diagnostics and 
treatments. CHIKV-specific mAbs can therefore be tools capable of providing a practical 
resolution to these demands. 
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1.11 RESEARCH PROJECT AIMS AND DESIGN 
The primary objective of this project was to develop, characterise and evaluate a set of reagents, 
in the form of mAbs, for chikungunya virus. These mAbs will be useful tools for CHIKV 
research, diagnostics and potentially disease therapeutics. Additionally, the creation of 
recombinant CHIKV structural proteins - rE1, rE2 and rCap - will assist in the assessment of 
mAb production and/or be used as safe diagnostic antigen alternatives. Specific aims of the 
project were: 
i) To generate and characterize a suite of mAbs to CHIKV proteins for use in virus 
detection and/or immunotherapy; 
ii) Express recombinant CHIKV structural proteins to characterise the epitopes 
recognised by mAbs and assess their use in diagnostic tests; 
iii) Genetically engineer and express CHIKV-specific chimeric mouse-human mAbs 
for use as reference controls in diagnostics; and 
iv) Evaluate the use of these mAbs and recombinant antigens for use as diagnostics for 
CHIKV. 
The lack of virus-specific mAbs has resulted in poor serodiagnosis accuracy of CHIKV via 
commercially diagnostic test kits such as ELISAs and immuno-chromatographic tests (Niedrig 
et al., 2009; Blacksell et al., 2011). This is mainly due to insufficient affinity of existing 
antibodies towards CHIKV, as well as the inability to accurately distinguish between CHIKV 
and other closely-related alphaviruses, resulting in false-positive results from cross-reactivity. 
It is therefore imperative that CHIKV-specific reagents such as mAbs and antigens, are 
developed for serodiagnostic assays that boast high sensitivity and specificity. Successful 
chimerisation of CHIKV-specific mAbs can also be useful as positive controls in place of 
human reference sera for diagnostic kits. As compared to obtaining potentially infectious 
human blood, such recombinant alternatives will provide added consistency, supply and safety 
to existing and future serodiagnostic assays. Furthermore, should the anti-CHIKV mAbs 
generated in this project provide evidence of protection against disease in animal models before 
and/or after viral inoculation, they may have potential as therapeutic agents. Finally, these 
CHIKV-reactive mAbs will undoubtedly be valuable tools for CHIKV and alphavirus research. 
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CHAPTER 2: GENERAL MATERIALS AND METHODS 
2.1. CELL CULTURE 
Maintenance of eukaryotic cell or tissue cultures were performed under sterile conditions in a 
laminar flow cabinet within a physical containment level 2 (PC2) laboratory, unless otherwise 
stated. Cells were cultured as monolayers, unless otherwise stated, in sterile culture flasks 
(Greiner Bio-One) of varying sizes in their respective medium containing sterile-filtered and 
heat inactivated fetal bovine serum (FBS, Gibco, Life Technologies). All cell cultures were 
supplemented with 50 U penicillin mL-1, 50 μg streptomycin mL-1 and 2 mM L-Glutamine 
(Gibco, Life Technologies), unless otherwise stated. The choice/use of each particular cell line 
are presented and/or described in detail in their respective material and methods sections of 
each chapter/paper article. 
2.1.1. Mammalian cell lines  
COS-7L and Vero cells were propagated in Roswell Park Memorial Institute medium 1640 
(RPMI 1640, Lonza) and Dulbecco’s Modified Eagle medium (DMEM, Lonza), respectively, 
supplemented with 2% FBS during maintenance, or 5% FBS for growth. Hybridoma cells were 
expanded in Hybridoma serum-free medium (HSFM, Gibco, Life Technologies) with 20% 
FBS, before being weaned off all FBS for harvesting. All mammalian cell lines were incubated 
in vented-flasks (Greiner Bio-One) at 37 °C with 5% CO2 in a humidified cell culture incubator 
(Sanyo Electric). Cells were passaged by removal of supernatant prior to rinsing twice with 
sterile PBS. Following the wash step, 1 mL of Trypsin-EDTA (Invitrogen, Life Techonologies) 
was added and cells were allowed to incubate at 37 °C for 5 min. Firm tapping of flasks was 
performed to detach the monolayer before the cells were thoroughly resuspended in 10 mL of 
PBS and diluted accordingly, as required, with fresh growth/maintenance media. In the case of 
hybridoma cells, supernatants were gently removed and stored, leaving behind an appropriate 
amount for resuspension of cells via gentle agitation. Fresh HSFM was then used to top up to 
the required volume for further harvesting, or counted (see section 2.1.3.) and expanded in a 
larger-sized flask. 
2.1.2. Insect cell lines  
C6/36 (Aedes albopictus mosquito) cells were propagated in RPMI 1640 containing 2% FBS 
or 5% FBS for maintenance or growth, respectively. C6/36 cell lines were incubated at 28 °C 
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in sealed flasks (Greiner Bio-One) as described above. Passaging of the insect cells are as 
described previously for mammalian cells, except that Trypsin-PBS (Invitrogen, Life 
Techonologies) was used instead of Trypsin-EDTA. 
2.1.3. Cell counting  
When necessary, 10 μL of resuspended cells were diluted 1:1 with trypan-blue dye and loaded 
onto a haemocytometer with a glass coverslip. The average cell count per chamber grid was 
doubled and then multiplied by 104 to determine the number of cells per millilitre. Cells were 
then placed back into their respective vessel or appropriately seeded. 
2.1.4. Cryopreservation and resuscitation of cell lines 
Cell cultures were allowed to expand to logarithmic-phase, typically 70-80% confluency, 
before being rinsed twice with sterile PBS and trypsinised. In the case of hybridoma cells, cells 
were simply detached via gentle agitation in their own culture supernatants. Detached cells 
were then resuspended in fresh media and pelleted for 5-10 min, depending on cell type and 
amount, at 1,000 rpm on a bench-top centrifuge. Supernatants were removed and the resulting 
cell pellets were gently resuspended in ice-cold freezing media containing 10% DMSO and 
20% FBS in the appropriate growth medium. Cells were then aliquoted into 1 mL cryo-vials 
(Nunc) and immediately frozen to -80 °C, at approximately 1 °C/min, in a cryo-freeze container 
(Nalgene). 
Cell line resuscitations were initiated by rapidly thawing cells in a 37 °C water bath, followed 
by the addition of 9 mL of fresh growth media into a 15 mL tube (BD Falcon). Cells were 
pelleted by centrifugation for 5-10 min at 1,000 rpm. Supernatants were discarded and cells 
were resuspended in the appropriate amount of fresh growth media. Cells were allowed to 
expand to at least 60% confluency in their respective flasks, at the appropriate conditions, 
before replacing with maintenance media containing a lower concentration of FBS. 
2.2. STANDARD PROCEDURES INVOLVING THE HANDLING OF VIRUSES 
Specific components, including virus isolates, are presented and/or described in detail in their 
respective material and methods sections of each chapter/paper article. All virus manipulations 
were performed under sterile conditions in a Class II biosafety cabinet. All CHIKV-related 
work were executed within a PC3 laboratory, while other viruses were handled in a PC2-
approved laboratory. 
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2.2.1. VIRUS STOCKS  
Virus stocks used in this project included CHIKV Mauritius strain (CHIKVMAU) (GenBank ID: 
EU404186), CHIKV Asian, Thailand strain (CHIKVTHAI) (GenBank ID: FJ457921), CHIKV 
Asian, East Timor strain (CHIKVET) (GenBank ID: GQ433359), CHIKV La Reunion strain 
(CHIKVIMT), RRV T48 strain (RRVT48) (GenBank ID: GQ433359), Sindbis virus MRE16 
strain (SINVMRE16) (GenBank ID: AF492770), BFV BH2193 strain (BFVBH2193) (GenBank ID: 
U73745) and Semliki Forest virus (SFV) (GenBank ID: NC_003215). Viral stocks were stored 
at either -80 °C or in liquid nitrogen, unless otherwise stated. See specific material and methods 
sections for more detailed information. 
2.2.2. Infection of cells  
Viruses were allowed to infect cells in serum-free media for 1 h at a multiplicity of infection 
(M.O.I.) of 0.1, in the appropriately-sized flask (Greiner Bio-One), under the appropriate 
incubation conditions for the respective cell lines. Following incubation, infectious media were 
removed and cell monolayers were washed thrice with PBS. Fresh growth media were added 
and cells were incubated for a further 48-72 h, or until desired cytopathic effects (CPE) were 
observed, before culture supernatants were clarified by centrifugation at 12,000 x g for 10 min 
at 4 °C and stored at -80 °C in 0.5 mL aliquots, or used immediately for downstream purposes. 
2.2.3. Determination of viral titres using TCID50 assay 
To perform a 50% tissue culture infectious dose (TCID50), Vero cells were seeded into 96-well 
plates (BD Falcon) at 30-40% confluency and allowed to multiply. Once cells reached 
logarithmic-phase (70-80% confluency), 50 uL of diluted virus (10-3 to 10-8) in complete 
growth media (DMEM supplemented with 2% FBS and antibiotics) was added to each well, 
with desired replicates. Plates were then incubated for 3-5 days at 37 °C with 5% CO2. TCID50 
was determined by the Reed and Muench method, utilising the number of wells showing CPE. 
2.2.4. Determination of viral titres using plaque assay  
Virus titres could also be determined through their ability to form plaques on Vero cell 
monolayers in 6-well plates (BD Falcon). Following an hour of incubation with serially-diluted 
virus (10-3 to 10-8), inoculums were removed and cell monolayers were overlaid with 1% low-
melting-point agarose in complete growth media (DMEM supplemented with 2% FBS and 
antibiotics). Infected cells were allowed to incubate for 3-5 days at 37 °C with 5% CO2. After 
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incubation, the agarose overlay was removed prior to the fixing of cells with 10% formalin or 
4% para-formaldehyde for 1 hr at room temperature. Monolayers were then stained with 0.5% 
crystal violet solution for 30 min. Viral titres were obtained by counting the number of plaques 
per dilution. For greater consistency and accuracy, dilutions exhibiting 20-200 plaques per well 
were used for calculation. 
2.3. STANDARD PROCEDURES INVOLVING THE HANDLING OF DNA  
Specific components, including DNA templates, plasmids/constructs, primers and PCR 
conditions, are presented and/or described in detail in their respective material and methods 
sections of each chapter/paper article. DNA material were stored at either -20 °C or in a -80 °C 
freezer, unless otherwise specified. 
2.3.1. Quantification of DNA 
DNA concentrations were determined by obtaining the ratio of absorbance at 260 nm (A260) 
and 280 nm (A280) of a sample, using the Nanodrop 1000 UV Spectrophotometer (Thermo 
Fisher Scientific). A ratio of ~1.8 (± 0.1) is generally accepted as pure DNA. 
2.3.2. Polymerase chain reaction 
Standard and high-fidelity polymerase chain reaction (PCR) reactions were performed using 
Taq DNA polymerase (New England Biolabs, NEB) and Phusion DNA Polymerase (NEB), 
respectively, with compatible buffers provided by the manufacturer. PCR mixes were prepared 
under sterile conditions in a Class II biosafety cabinet, with all reagents diluted/reconstituted 
in sterile, nuclease-free or diethylpyrocarbonate-treated water. Deoxynucleotide triphosphate 
(dNTP) solution mixes (2.5 mM each in water diluted in Tris-HCl to pH 7.0) were obtained 
from NEB, while primers were custom-made by Integrated DNA Technologies or Sigma-
Aldrich. PCR runs were performed using either the Mastercycler EP-S thermo-module 
(Eppendorf), PCR Express thermal cycler (Thermo Electron Hybaid) or the PCR Sprint thermal 
cycler (Thermo Electron Hybaid). 
2.3.3. DNA Cloning 
Directional cloning with restriction enzymes (REs) were performed by incorporating RE 
sequences into gene-specific primers (GSPs) flanking the genes of interest. DNA fragments 
were then digested with the appropriate REs and purified using the NucleoSpin Gel and PCR 
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Clean-up kit (Macherey-Nagel). The receiving vector was digested with the same pair of REs 
with the inclusion of calf-intestinal alkaline phosphatase (NEB) to avoid self-ligation. Ligation 
of insert to vector was performed at a 1:3 molar ratio using 3 Weiss units of T4 DNA ligase 
(NEB) and 1x rapid ligation buffer. Reactions were allowed to incubate at 4 °C overnight prior 
to bacterial transformation. 
For non-directional TA cloning, 3ʹ A-overhangs were created on PCR products not amplified 
with Taq DNA polymerase. PCR products were incubated with 0.2 mM of dNTPs, 1U of Taq 
DNA polymerase and 1x Thermopol buffer (NEB) at 72 °C for 15 min, prior to ligation into 
the pGEM-T Easy vector (Promega), according to the manufacturer’s instructions. 
2.3.4. Bacterial transformation  
Following ligation, 1-2 μL of the reaction was added to 50 μL DH5α competent cells and 
incubated on ice for at least 30 min. Cells were then heat shocked for exactly 45 sec at 42 °C 
and placed immediately on ice for a further 2 min. The cells were recovered by adding 150 uL 
of sterile SOC media (2% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) and incubation at 37 °C with 
shaking for an hour. After recovery, 100 μL of the transformants - and further 10-fold dilutions 
if required - were plated onto sterile LB-ampicillin plates (15 g/L bacteriological-grade agar in 
Luria-Bertani medium, supplemented with 20 μg/mL ampicillin) and incubated in a 37 °C 
incubator for 16-20 hr. 
2.3.5. Colony PCR  
The colony PCR screening technique was employed to identify successfully transformed 
bacteria colonies containing the desired ligated plasmid construct(s). Using Taq DNA 
polymerase (NEB), a standard PCR was performed using post-transformation bacteria samples 
as templates. Two types of template material could be used for colony PCRs: i) transformed 
bacteria colonies picked off LB-ampicillin plates using a sterile pipette tip; or ii) culture 
supernatant of picked colonies that were sub-cultured overnight in LB broth containing 
ampicillin. 
2.4. STANDARD PROCEDURES INVOLVING THE HANDLING OF RNA 
Specific components, including RNA templates and primers, are presented and/or described in 
detail in their respective material and methods sections of each chapter/paper article. All RNA 
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manipulations, where end product(s) were to be used in further downstream work, were 
performed under sterile conditions in a Class II biosafety cabinet. Equipment/non-disposable 
components used for handling RNA were treated with RNase Away (Thermo Scientific), 
whenever possible. 
2.4.1. Quantification of RNA 
RNA concentrations were determined by obtaining the ratio of absorbance at 260 nm (A260) 
and 280 nm (A280) of a sample, using the Nanodrop 1000 UV Spectrophotometer (Thermo 
Fisher Scientific). A ratio of ~2.0 (± 0.1) is generally accepted as pure RNA. RNA material 
were stored at -80 °C, unless otherwise specified. 
2.4.2. Reverse transcription 
Following the extraction of total RNA using TRIzol reagent (Life Technologies) or TRI reagent 
(Sigma-Aldrich), according to their respective manufacturer’s instructions, first-strand 
synthesis was performed to obtain cDNA for downstream manipulation or PCR. The RNA 
template was allowed to denature and anneal with the appropriate reverse-GSP in a reaction 
containing 0.5-2 μg of RNA template, 0.4 μM GSP, 0.4 mM dNTP mix and nuclease-free water 
to a final volume of 16 μL. Reaction mix was heated to 65-80 °C, depending on annealing 
temperature of GSPs, for 3-5 min, and placed promptly onto ice. Following that, 1 μL of RNAse 
inhibitors, 1x reverse transcriptase (RT) buffer (NEB) and 200 U M-MuLV RT (NEB) were 
added to the initial reaction mix. cDNA synthesis was carried out at 42 °C for 1 hr prior to the 
inactivation of the RT enzyme at 90 °C for 10 min. cDNA products were stored at -20 °C until 
required, or used immediately. 
2.5. STANDARD PROCEDURES INVOLVING THE HANDLING OF PROTEINS 
Specific components and conditions involving protein work are presented and/or described in 
detail in their respective material and methods sections of each chapter/paper article. Protein 
material were stored at -20 °C, unless otherwise specified. 
2.5.1. Quantification of proteins 
A bicinchoninic acid assay (Pierce, Thermo Scientific) was utilised, according to the 
manufacturer’s instructions, to measure total protein concentration at an absorbance of 562 nm.  
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CHAPTER 3: NEUTRALIZING MONOCLONAL ANTIBODIES TO THE E2 PROTEIN OF 
CHIKUNGUNYA VIRUS PROTECT AGAINST DISEASE IN A MOUSE MODEL 
 
This chapter has been published as Goh, L. Y., Hobson-Peters, J., Prow, N. A., Gardner, J., 
Bielefeldt-Ohmann, H., Pyke, A. T., Suhrbier, A. and Hall, R. A. (2013). Neutralizing 
monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a 
mouse model. Clin Immunol 149(3): 487-497. 
 
3.1. ABSTRACT 
Chikungunya virus (CHIKV) recently caused the largest epidemic ever recorded for this virus 
involving an estimated 1.4-6.5 million cases, with imported cased reported in over 40 countries.  
The number of monoclonal antibodies specific for this re-emerging alphavirus is currently 
limited.  Herein we describe the generation and characterization of five monoclonal antibodies 
specific for the E2 glycoprotein of CHIKV. The antibodies detected a range of CHIKV isolates 
in several assays including ELISA, Western blot, immunofluorescence assay (IFA) and 
immunohistochemistry (IHC) without evidence of cross-reactivity with other alphaviruses. 
Four antibodies also neutralized CHIKV in vitro, two of which provided complete protection 
against arthritis in a CHIKV mouse model when administered prior to infection. Given the 
current shortage of widely available reagents for CHIKV, these specific antibodies will be 
useful not only in research, but may also provide the basis for new diagnostics and treatments. 
3.2. INTRODUCTION 
Chikungunya virus (CHIKV) belongs to a group of mosquito-transmitted arthritogenic 
alphaviruses that include the Australian Ross River virus (RRV) and Barmah Forest virus 
(BFV), the African o’nyong-nyong virus, the South American Mayaro virus, and the globally 
distributed Sindbis viruses (Suhrbier et al., 2012).  Alphaviruses are enveloped, single-stranded 
positive-sense RNA viruses whose 11.5 kb genomes encode four non-structural proteins (nsP 
1-4) and five structural proteins; capsid, E3, E2, 6K and E1 (Strauss and Strauss, 1994b). 
CHIKV was first isolated in 1952 in Tanzania and has caused sporadic epidemics of primarily 
rheumatic disease every 2-50 years mainly in Africa and Asia (Suhrbier et al., 2012).  Since 
2004, CHIKV has been responsible for a series of unprecedented outbreaks with an estimated 
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1.4-6.5 million human infections, with imported cases reported in over 40 countries (Suhrbier 
et al., 2012).  Although typically transmitted by Aedes aegypti mosquito vectors in urbanized 
areas, the recent epidemic was associated with the emergence of a new clade of chikungunya 
viruses, characterized by an amino acid substitution in the CHIKV E1 glycoprotein (A226V), 
that allowed efficient transmission by Aedes albopictus mosquitoes (Kumar et al., 2008). In 
the past 30 years, Aedes albopictus has experienced a dramatic global expansion in its 
geographic distribution (Lambrechts et al., 2010), and its presence in southern Europe allowed 
the first autochthonous (endogenously transmitted) CHIKV infections in Italy in 2007 (>200 
cases) and in France in 2010 (Suhrbier et al., 2012).   
CHIKV disease in humans is characterized by acute and chronic polyarthralgia/polyarthritis, 
which usually resolves within weeks to months, but can be protracted (Hoarau et al., 2010; 
Suhrbier et al., 2012). The acute phase of disease is often also associated with an abrupt onset 
of fever, myalgia, and a rash (usually maculopapular) (Robinson, 1955; Tesh, 1982; Borgherini 
et al., 2007; Staples et al., 2009; Suhrbier et al., 2012). Although CHIKV disease is usually 
self-limiting, the recent epidemic has been associated with some severe disease manifestations 
and mortality, primarily amongst elderly patients with co-morbidities and the very young 
(Mavalankar et al., 2008; Economopoulou et al., 2009; Tandale et al., 2009; Jaffar-Bandjee et 
al., 2010).  During the recent epidemic, mother-to-child transmission was also observed and 
about half the neonates born to viraemic mothers became infected.  About half the infected 
neonates developed serious forms of CHIKV disease characterized by hemorrhage, 
disseminated intravascular coagulation, and/or cardiac and neurological manifestations; the 
latter often leading to permanent disabilities (Suhrbier et al., 2012 and refs therein). 
Serodiagnosis by IgM and IgG ELISA tests are used as standards for laboratory-based 
diagnoses of arthritogenic alphavirus diseases, and in-house CHIKV ELISAs have been 
developed in a number of countries (Suhrbier et al., 2012). Detection of the mosquito-borne 
virus has also been achieved using PCR-based methods; however, blood samples must be taken 
during the viraemic period (Edwards et al., 2007; Laurent et al., 2007; Santhosh et al., 2007). 
Treatment of CHIKV rheumatic disease usually involves the use of analgesics and/or non 
steroidal anti-inflammatory drugs, with relief often inadequate. There is currently no licensed 
human vaccine available for any alphavirus, although CHIKV vaccines are in development 
(e.g. Bharat Biotech) (Akahata et al., 2010). Neutralizing antibodies are believed to be crucial 
for providing protection, with polyvalent CHIKV-specific antibodies able to prevent CHIKV 
infection and disease in mouse models (Couderc et al., 2009; Gardner et al., 2010). 
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CHIKV is a biosafety level 3 pathogen in most countries and is listed as a US National Institute 
of Allergy and Infectious Diseases category C priority pathogen (Diseases, 2011). The US 
Army has long recognized CHIKV as a potential biological weapon, and CHIKV is considered 
a possible agent for bioterrorism (Studies, 2011). Centers for Disease Control and Prevention 
(CDC), and the Pan-American Health Organization recently completed a preparedness plan for 
the spread of CHIKV to the Americas due to the fact that all the conditions and vectors exist 
for such an event (Organization, 2011). 
Due to the re-emergence of CHIKV and the potential threat to human health there has been a 
quest for new research reagents, and improved diagnostics and treatments.  Herein we report 
the generation and characterization of a panel of monoclonal antibodies (mAbs) to the E2 
glycoprotein of CHIKV. These antibodies recognized multiple isolates of CHIKV and did not 
cross-react with other arthritogenic alphaviruses. We illustrate the use of these monoclonal 
antibodies in Western blot, IFA, IHC, capture ELISA diagnostic assays and as potential 
prophylactic biological drugs in a mouse model of CHIKV viraemia and arthritic disease.  
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3.3. MATERIAL AND METHODS 
3.3.1. Cell and virus culture 
Mosquito cells (C6/36 - Aedes albopictus) were propagated in RPMI 1640 supplemented with 
2% fetal bovine serum. Cultures were passaged by dissociating the cell monolayer from the 
flask with trypsin/PBS and were incubated at 28 °C. Vero and COS-7L (African green monkey 
kidney) cell lines were cultured in DMEM and RPMI 1640, respectively, supplemented with 
2% fetal bovine serum. Mammalian cells were passaged by dissociating the surface monolayer 
from the flask with trypsin/EDTA and were cultured at 37 °C with 5% CO2. Hybridoma cells 
were expanded in Hybridoma SFM (Gibco, Life Technologies) with 20% fetal bovine serum 
at 37 °C with 5% CO2. All cell cultures were supplemented with 50 U penicillin mL
-1, 50 μg 
streptomycin mL-1 and 2 mM L-Glutamine (Gibco, Life Technologies). 
 
Viruses used to infect C6/36 cells for fixed-cell ELISA (Clark et al., 2007) included CHIKV 
Mauritius strain (CHIKVMAU) (GenBank ID: EU404186); CHIKV Asian strain (CHIKVASIAN) 
(GenBank ID: FJ457921); CHIKV Asian, East Timor strain (CHIKVET) (provided by Dr. 
Alyssa Pyke, Queensland Health Forensic and Scientific Services); RRV T48 strain (RRVT48) 
(GenBank ID: GQ433359); Semliki Forest virus (SFV) (GenBank ID: NC_003215); Sindbis 
virus MRE16 strain (SINVMRE16) (GenBank ID: AF492770) and BFV BH2193 strain 
(BFVBH2193) (GenBank ID: U73745). Briefly, cells seeded in 96-well plates were infected at an 
M.O.I. of 0.1 and incubated for 3-4 days before the culture supernatant was removed and cells 
were fixed overnight in 20% acetone, 0.2% bovine serum albumin in phosphate-buffered saline 
(PBS) at 4 °C. Plates were then air-dried and stored at -20 °C until use. 
 
Mock and virus-infected C6/36 cell monolayers were incubated in a similar manner before 
cells were rinsed in PBS and disrupted by sonication in the presence of BS9 lysis buffer (120 
mM NaCl, 50 mM H3BO3, 1% Triton X-100 and 0.1% SDS, pH 9.0). The lysate was clarified 
by centrifugation at 12,000 x g for 10 min at 4 °C and stored at -20 °C (Clark et al., 2007). 
3.3.2. Mouse immunization 
Groups of three to five female BALB/c mice 6-8 weeks of age were immunized subcutaneously 
(s.c.) onto the ventral side of the ear using a dry-coated nanopatch as described previously 
(Prow et al., 2010). Briefly, mice were given 0.5 μg or 5.0 μg of sucrose gradient-purified γ-
irradiated CHIKVMAU antigen (strain 06113879 – 2006 Mauritius, provided by Dr. Julian 
Druce, VIDRL, Australia) with Quil-A saponin (Brenntag Biosector) as adjuvant. An identical 
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immunization was performed three weeks later with a final boost of 5.0 μg CHIKVMAU antigen 
given four weeks after the second application. Mice were then challenged with live virus as 
described previously (Gardner et al., 2010; Prow et al., 2010). Finally, 20 months later, mice 
were boosted with 10 μg of binary-ethyleneimine inactivated CHIKVASIAN (Gardner et al., 
2010) via subcutaneous injection at the base of the tail four days prior to hybridoma production. 
 
3.3.3. Hybridoma production 
Mouse spleens were harvested for hybridoma production by fusion of spleen B cells with 
MRX63 myeloma cells as previously described (Clark et al., 2007). Hybridomas secreting 
CHIKV-reactive mAbs were identified by fixed-cell ELISA as described below (section 
3.3.4.). Isotype determination of selected monoclonal antibodies was performed using the 
Mouse Typer isotyping kit (Bio-Rad) according to the manufacturer’s instructions. 
 
3.3.4. Fixed-cell ELISA 
Fixed-cell ELISAs were performed as described previously (Hall et al., 1988; Clark et al., 
2007). Briefly, acetone-fixed plates of infected C6/36 cells were blocked with TENTC 
blocking buffer (0.05 M Tris-HCl pH 8.0, 1 mM EDTA, 0.15 M NaCl, 0.05% (v/v) Tween 20, 
0.2% (w/v) casein) for 1 h at 28 °C prior to probing of fixed antigen with hybridoma culture 
fluid at starting dilution of 1/10, and then serially diluted 2-fold across the plate. After 
incubation for 1 h at 28 °C, wells were washed four times with PBS with 0.1% Tween-20 
(PBS/T) wash buffer and bound antibodies were detected with a HRP-conjugated goat anti-
mouse IgG (DAKO) diluted 1:4,000 in blocking buffer. Following a 1 h incubation, the plates 
were washed six times prior to the addition of 2, 2’-azino-bis-3-ethylbenzthiazoline-6-
sulphonic acid (ABTS) substrate solution (0.02% (w/v) ABTS, 0.06% (w/v) H2O2 in 200 mM 
Na2HPO4 and 100 mM citric acid solution) for 30 min at 28 °C in the dark. Absorbance was 
measured at 405 nm using a Labsystems Multiscan EX Type 355 UV plate reader (Pathtec). 
The criterion for specific recognition of antigen was defined as an OD405mn value of at least 
0.25 and at least 2-fold greater than that generated by probing uninfected C6/36 cells with the 
corresponding antibody dilutions. Control monoclonal antibodies G8, 2F2 and 9E8 specific for 
RRV, SINV and BFV, respectively, were used in the comparative ELISAs described below 
(Clancy, 1991; Oliveira et al., 2006). 
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3.3.5. Recombinant CHIKV glycoprotein expression 
CHIKV E2 and E1 constructs were generated by amplifying the respective glycoprotein genes, 
from cDNA synthesized by reverse-transcription PCR of genomic RNA of CHIKVMAU, with 
primer sets CHIKV E3_E2 Forward 5ʹ- 
ATATAATAGCTAGCATGAGTCTTGCCATCCCAGTTATG-3ʹ, CHIKV E3_E2 Reverse 
5ʹ-TTATAATAGGATCCTGTTCTGATGCAGCATA-3ʹ, CHIKV 6K_E1 Forward 5ʹ-
AATTAATTGCTAGCATGGCCACATACCAAGAGG-3ʹ, CHIKV 6K_E1 Reverse 5ʹ-
ATATATATGGATCCGTGCCTGCTGAACGACACG-3ʹ, followed by ligation into a 
pcDNA3.1 (+) vector (Invitrogen) modified to express V5 and histidine tags at the C-terminus 
of the recombinant proteins. COS-7L cell transfection was performed using Lipofectamine 
2000 (Invitrogen) according to manufacturer’s instructions. Cells were harvested 24 h post-
transfection by addition of BS9 lysis buffer and clarified by centrifugation (Hobson-Peters et 
al., 2008). PNGase F enzyme (Sigma-Aldrich) was used, according to manufacturer’s 
instructions, to cleave N-linked oligosaccharide chains for verification of glycosylation (Setoh 
et al., 2011). 
 
3.3.6. Immunofluorescence assay (IFA) 
Transfected COS-7L cells were fixed onto glass coverslips with 100% ice-cold acetone and 
incubated with selected mAbs in hybridoma culture fluid for 1 h at 37 °C. In the case of live 
virus infection, Vero cells were allowed to grow overnight on glass coverslips before being 
infected with CHIKV at an M.O.I. of 0.1 for 1 h. Cells were then washed twice with PBS and 
incubated at 37 °C in complete growth medium. At 72 h post-infection, Vero cells were fixed 
and incubated with anti-CHIKV mAbs at a 1/20 dilution as described above. Coverslips were 
then washed and stained with Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen) 
diluted 1:500 in blocking buffer for 1 h at 37 °C, followed by Hoechst 33342 stain (Invitrogen; 
1:1,000 in PBS) for 5 min.  Coverslips were mounted with ProLong Gold Anti-Fade reagent 
(Invitrogen) and imaged using a Zeiss LSM 510 META confocal microscope. 
 
3.3.7. Western blot 
CHIKV antigens were prepared as crude, CHIKV-infected cell lysate or transfected COS-7L 
cell lysates as previously described (Setoh et al., 2011). For reduction and carboxymethylation 
of antigens, lysates were reconstituted in 0.1 M Tris-HCl and reduced with 1 M dithiothreitol 
(DTT). Samples were then gently treated with streaming nitrogen for 30 seconds before being 
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heated at 95 °C for 5 min. Reduced lysates were cooled at 4 °C for 5 min prior to the addition 
of iodoacetic acid to a final concentration of 1 M. Samples were gassed as described above and 
incubated at 37 °C in the dark for 1 h (Clark et al., 2007). All CHIKV antigens were prepared 
in 4 X NuPAGE LDS sample buffer (Invitrogen) and heated at 95 °C for 5 min. The proteins 
were resolved on 4-12% Bis-Tris precast SDS-PAGE gels (Invitrogen), transferred onto 
Hybond C nitrocellulose membranes (Amersham) and immune-stained as previously described 
(Clark et al., 2007). Briefly, membranes were blocked with TENTC blocking buffer for 1 h at 
room temperature prior to the addition of CHIKV-specific mAbs or anti-CHIKV polyclonal 
mouse sera diluted 1/20, unless otherwise stated, in blocking buffer. After incubation for 
another hour, membranes were washed thrice with PBS/T wash buffer and bound antibodies 
were detected with a HRP-conjugated goat anti-mouse IgG diluted 1:4,000 in blocking buffer. 
The blots were incubated for a further 1 h before being washed three times with PBS/T wash 
buffer. Finally, blots were developed in DAB substrate solution (1.5 mM 3,3ʹ-
diaminobenzidine, 0.06% (v/v) H2O2 in PBS, pH 7.2) for 15 min before reactions were 
terminated by rinsing with PBS or ddH2O. 
 
3.3.8. Competitive binding assays 
Competitive binding between CHIKV E2 mAbs was assessed as described previously (Hall et 
al., 2009). Briefly, purified mAbs were biotinylated using the BiotinTag kit (Sigma), according 
to the manufacturer’s instructions. The competitive binding ELISAs were performed in 96 well 
plates coated with a lysate of CHIKVMAU-infected C6/36 cells diluted 1/500 in coating buffer 
(0.05M sodium carbonate/bicarbonate, pH 9.6). After washing, a pre-defined optimal 
saturating concentration of each of the unlabelled mAbs (1.3A2 - 1.25 µg/mL; 4.6F5 - 0.078 
µg/mL; 4.10C12 - 1.25 µg/mL; 5.2B2 - 20 µg/mL; 5.2H8 - 0.156 µg/mL; and 4G2 - 0.4 µg/mL) 
was added for 1 h at 28 °C. Without washing, a pre-defined optimal non-saturating dilution of 
each biotin-labelled ‘competitor’ mAb (1.3A2 - 1.25 µg/mL; 4.6F5 - 1.25 µg/mL; 4.10C12 – 
2.5 µg/mL; 5.2B2 - 20 µg/mL; and 5.2H8 - 5 µg/mL) was added for 1 h at 28 °C. After washing 
six times with PBS/T, horseradish peroxidase (HRP)-conjugated streptavidin (Invitrogen) was 
added and incubated for 30 min. The wells were washed prior to incubation with ABTS 
substrate solution. 
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3.3.9. Antigen-capture ELISA 
U-bottom PVC 96-well plates (BD Falcon) were coated with 1 μg of purified anti-E2 mAb at 
4 °C overnight in coating buffer (50 mM Na2CO3, 50 mM NaHCO3, pH 9.6). Purified soluble 
E2 (sE2) antigen, kindly provided by Stefan Metz (Laboratory of Virology, Wageningen 
University, The Netherlands), was captured by incubation for 1 h at 28 °C, prior to another 
hour of blocking as described previously. A second biotinylated anti-E2 mAb that binds a 
different epitope from the capturing mAb was used as a detecting antibody. After incubation 
for 1 h at 28 °C, enzyme activity was visualized by the addition of ABTS substrate solution as 
described previously (Clark et al., 2007). Concentrations of purified sE2 protein were initially 
determined using a BCA Protein Assay kit (Pierce) by the provider (Stefan Metz, personal 
communications) and confirmed in our laboratory using a Nanodrop 1000 Spectrophotometer 
(Thermo Fisher Scientific). 
 
3.3.10. Microneutralization assay 
Virus neutralization tests were performed on Vero cells as described previously (Hall et al., 
1995) with minor modifications. Antibodies tested were subjected to heat inactivation at 56 °C 
for 30 min before being diluted with DMEM supplemented with 2% FBS. Polyclonal mouse 
serum was used at an initial dilution of 1:20, while purified CHIKV-specific mAbs were used 
at a starting concentration of 5 μg per well. Each well was then examined microscopically for 
cytopathic effect (CPE) and fixed with 4% paraformaldehyde in PBS for 1 h at room 
temperature before staining with 0.05% crystal violet for validation of cell viability. 
Neutralization titers were expressed as the reciprocal of the highest serum dilution where CPE 
did not occur. 
 
3.3.11. Passive immunization with mAb and virus challenge 
Six-week old C57BL/6 mice were subcutaneously inoculated with 400 μg (~15 mg/kg) of 
monoclonal antibody in 100 μL PBS one day prior to challenge with CHIKV (LR2006-OPY1), 
and viraemia and foot swelling (arthritis) monitored as described previously (Gardner et al., 
2010). Viral titres were calculated as log10 50% cell culture infectious dose per mL of serum 
(log10 CCID50/ml) using 10-fold serial dilutions on C6/36 cells and detection of infection in 
individual wells using Vero cell cytopathic effects as described (Rudd et al., 2012). The 
detection cut off is 2 log10 CCID50. Foot swelling over time was determined blinded and as a 
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group average of the percentage increase in foot height x width (in the metatarsal region) for 
each foot compared with the same foot on day 0 (Rudd et al., 2012). 
 
3.3.12. Immunohistochemical staining of CHIKV-infected mouse tissue 
Tissue samples from control and CHIKV-infected mouse foot pads were fixed in 10% neutral 
buffered formalin for 24 h at room temperature and decalcified with 15% EDTA in 0.1% 
phosphate buffer over 10 days before being embedded in paraffin wax. Tissue sections, 5 µm 
thick, from uninfected and CHIKVREUNION-infected mice were collected onto charged slides 
and deparaffinised with three changes of xylene (2 min each), followed by rehydration through 
a series of graded ethanol concentrations and finally water. Sections were subjected to antigen 
retrieval by heating at 95 °C in a citrate-buffer, pH 6 (Target Retrieval Solution, DAKO) for 
25 min followed by a 20 min cooling period at room temperature, or by incubation with 
Proteinase K (DAKO) at room temperature for 10 min. A series of blocking steps were 
performed at room temperature incubation with (i) Peroxidase Block (DAKO) for 10 min, (ii) 
0.15 M glycine in PBS for 15 min, (iii) Antibody Diluent with Background-Reducing 
Components (DAKO) for 30 min, with a brief rinse in Tris-buffered saline with 0.1% Tween-
20 (TBS/T) between each step. The tissue samples were then incubated in 1 µg/mL of purified 
4.10C12 mAb at 4 °C overnight, prior to 15 min washing with TBS/T. Antibody binding was 
visualized using the anti-mouse IgG Envision kit (DAKO) according to the manufacturer’s 
instruction. Sections were counterstained with Meyer’s hematoxylin, mounted with Glycergel 
Mounting Medium (DAKO) and examined under a Nikon Eclipse 51E microscope. Digital 
micro-photographs were captured using a Nikon DS-Fi1 camera with a DS-U2 unit and 
processed with the NIS-Elements F software. 
 
3.3.13. Statistical analysis 
Statistical analysis was performed using SPSS for Windows (version 19; SPSS, Chicago, IL, 
USA). For comparison of two samples, the t-test was used when the difference in the variances 
was less than four and skewness was greater than minus two and kurtosis was less than two. 
Otherwise, non-parametric tests were used; the Mann-Whitney U test if the difference in the 
variances was less than four and the Kolmogorov-Smirnov test if the difference in the variances 
was greater than 4.  
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3.4. RESULTS 
 
3.4.1. Production of CHIKV-specific monoclonal antibodies 
Five hybridomas secreting antibodies reactive to CHIKV proteins were cloned by limit dilution 
and mAbs were harvested as clarified culture supernatant. The reactivity of these mAbs (1.3A2, 
4.6F5, 4.10C12, 5.2B2 and 5.2H8) towards CHIKV and related alphaviruses were determined 
by fixed-cell ELISA (Table 3.1). While all five mAbs recognized CHIKVMAU, CHIKVASIAN 
and CHIKVET strains by ELISA, none were able to detect proteins from fixed cells infected 
with the related viruses RRV, SFV, SINV or BFV, suggesting that all mAbs produced were 
specific to CHIKV. All five mAbs were of the IgG2A isotype. 
 
Table 3.1. Reactivity of CHIKV E2-specific mAbs towards various CHIKV strains and other alphaviruses 
in ELISA. 
Monoclonal 
Antibody 
Reactivity in fixed-cell ELISA 
CHIKV 
(Mau) 
CHIKV 
(Asian) 
CHIKV 
(ET) 
RRV 
(T48) 
SFV 
 
SINV 
(MRE16) 
BFV 
(BH2193) 
1.3 A2 IgG2a + + + + + + + + + + + + + + - - - - 
4.6 F5 IgG2a + + + + + + + + + + + + + + - - - - 
4.10 C12 IgG2a + + + + + + + + + + + + + + + - - - - 
5.2 B2 IgG2a + + + + + + + + + + + + + + - - - - 
5.2 H8 IgG2a + + + + + + + + + + + + + + - - - - 
G8 IgG2a + + + + + + + + + + + + + - + + + 
2F2 IgG1 - - - - - + + + + - 
9E8 - - N.D. N.D. - - + + + + + 
2B2 IgG2a - - - - - - - 
 
The dilution producing the maximum mean absorbance reading was scored as: +++++, OD > 1.0; ++++, OD = 0.75 
to 1.0; +++, OD = 0.5 to 0.75; ++, OD = 0.3 to 0.5; +, OD = 0.25 to 0.3. 
 
3.4.2. CHIKV-specific mAbs recognize epitopes on the E2 glycoprotein 
To determine the protein specificity of these mAbs, recombinant full-length CHIKV E1 (rE1) 
and E2 (rE2) glycoproteins were expressed in COS-7L cells. Successful expression of the 
glycoproteins, along with their C-terminus V5-His epitope tag, was confirmed with the use of 
anti-V5 mAbs (Figure 3.1). 
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Figure 3.1. Monoclonal antibody reactivity by IFA with acetone-fixed monolayers of COS-7L cells 
transfected with rE2 and rE1 constructs. Cells were probed with respective mAbs before incubation with an 
anti-mouse Alexa Fluro 488 conjugate (green) and Hoechst 33342 (blue) for nuclear staining. B10/G8 mAbs were 
generated to the E1 protein of RRV and are cross-reactive with the E1 protein of CHIKV. Successful expression 
of rE2 and rE1 was demonstrated using anti-V5 mAb. CHIKV mAbs produced in this study reacted with rE2 in 
IFA, while rE1 was detected using E1-specific cross-reactive RRV mAbs (B10 and G8) produced previously 
(Broom et al., 1998). 
 
Alphavirus E1 and E2 proteins have asparagine (N) linked glycosylation sites; however, the 
number of glycosylation sites vary between different species of viruses (Burke and Keegstra, 
1979; Rice and Strauss, 1981; Knight et al., 2009). CHIKV-E1 is predicted to be glycosylated 
at N141, while CHIKV-E2 was expected to have two glycosylation sites at N263 and N273 
(Blom et al., 2004). Undigested rE1 and rE2 were shown to be ~51 kDa and ~56 kDa, 
respectively, while their PNGase F-digested counterparts were ~48 kDa and ~50 kDa in size 
(Figure 3.2A). This difference in mass is consistent with the single N-linked glycosylation site 
in E1 and two sites within E2 as elaborated in a previous study (Metz et al., 2011). Further 
analysis also revealed that the binding of all five anti-E2 mAbs was not dependent on the 
glycosylation status of the protein as they were capable of detecting the E2 protein in both its 
original and deglycosylated forms (Figure 3.2B). 
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Figure 3.2. Western blot analyses of full-length recombinant E1 and E2 proteins expressed in COS-7L cells 
with or without PNGaseF treatment. (A) Boiled, unreduced lysates of transfected COS-7L cells expressing rE1 
and rE2 were digested with PNGase F (+) or undigested (-); recombinant CHIKV proteins detected using anti-V5 
mAb. (B) All five anti-E2 mAbs recognized both glycosylated and unglycosylated forms of E2 under unreduced 
conditions. 
 
3.4.3. Anti-E2 mAbs recognize reduction-sensitive conformational epitopes 
Crude lysates from CHIKVASIAN infected cells were either reduced with DTT and free 
sulfhydryl groups carboxymethylated to prevent reformation of disulphide bonds, or were left 
unreduced prior to SDS-PAGE. Subsequent immunoblotting illustrated that mAbs 1.3A2, 
4.6F5, 4.10C12, 5.2B2 and 5.2H8 all recognized rE2 in unreduced samples, but not in DTT-
reduced/carboxymethylated samples (Figure 3.3). These results show that the E2-specific 
mAbs recognized epitopes dependent on intact cysteine residues, suggesting a requirement for 
secondary structure provided by disulphide bonds for antibody binding. 
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Figure 3.3. Reaction of anti-E2 mAbs to DTT-reduced (+) and unreduced (-) CHIKV-infected cell lysates. 
DTT breaks disulphide bonds in proteins while the carboxymethylation process caps the free cysteine residues, 
preventing the reformation of disulphide bonds, and thus, proteins from refolding. All proteins were separated on 
4-12% Bis-Tris SDS-PAGE gels. 
 
3.4.4. Competitive binding assay reveals mAbs bind to three different epitopes of 
E2 
To determine the topology of the epitopes recognized by the mAbs on the E2 protein, each 
antibody was tested in competitive binding assays using ELISA. These assays showed that the 
five E2-specific mAbs collectively recognize at least three different epitopes on the protein 
(Figure 3.4). Monoclonal antibodies 1.3A2, 4.6F5 and 4.10C12 inhibited each another, 
suggesting the epitopes they recognize overlap. Meanwhile, mAbs 5.2B2 and 5.2H8 did not 
compete with each other, or with any of the other three mAbs, indicating that they bind to 
different epitopes within E2. 
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Figure 3.4. Competitive-binding profiles of E2-specific mAbs in ELISA. Antigens in lysates of CHIKVMAU-
infected Vero cells were adsorbed to 96-well plates at a 1/500 dilution prior to incubation with a saturating dilution 
of purified, unlabelled anti-E2 mAbs. Without washing, non-saturating dilutions of biotinylated mAbs were then 
added as ‘competitor’ antibodies to respective wells. The mean absorbance reading (OD405nm) of four replicates 
were plotted with bars showing standard error of mean (SEM). 4G2 is a control mAb specific to the E protein of 
flaviviruses. Assay was optimized to obtain complete inhibition of each biotinylated mAb by its homologous 
unlabelled competitor. 
 
3.4.5. Use of E2-specific mAbs in antigen-capture assay allows for sensitive 
detection of CHIKV E2 protein 
A double-antibody sandwich antigen-capture ELISA was performed to determine the ability of 
the anti-E2 mAbs to detect viral proteins in samples. After a series of empirical trials to 
determine the optimal antibody pairing, two mAbs that bound to different locations of the E2 
protein were selected for this assay – purified, unlabelled mAb 1.3A2 was utilized to capture 
the target antigen, sE2 protein, while a second biotinylated anti-E2 mAb, 5.2H8, was applied 
as the detecting antibody. Figure 3.5 shows that this assay is capable of detecting the sE2 
protein in the picogram range. 
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Figure 3.5. Detection of purified soluble E2 protein by anti-E2 mAb in an antigen-capture ELISA. 
Unlabelled mAb 1.3A2 was coated onto 96-well plates at 1 μg/well prior to incubation with target sE2 protein. 
The detecting antibody, biotinylated 5.2H8 mAb, was used at 400 ng per well. The mean absorbance reading 
(OD405nm) of eight replicates from two independent experiments were plotted with bars showing SEM. Dotted line 
represents the cut-off point, for a positive result, derived from the no antigen control plate (mean OD405nm reading 
x 2), while sE1 protein (n = 2) was utilized as a negative control for the assay. 
 
3.4.6. Anti-E2 mAbs exhibit virus neutralization in vitro 
Virus neutralization assays were undertaken to determine whether the CHIKV E2-specific 
mAbs were able to neutralize virus in vitro. Micro-neutralization tests were performed on Vero 
cells and revealed that mAbs 1.3A2, 4.6F5 and 4.10C12 were able to efficiently neutralize 
different CHIKV isolates (Table 3.2), with CHIKVMAU and CHIKVASIAN representing the 
East/South African and Asian phylogroups, respectively (Schuffenecker et al., 2006). 
Monoclonal antibody 5.2B2 showed some neutralization of CHIKVASIAN, but not with 
CHIKVMAU, while mAb 5.2H8 failed to neutralize either CHIKV isolate even at the highest 
antibody concentration. 
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Table 3.2. Neutralization activity of E2 mAbs against two CHIKV strains. 
  Amount of antibody (µg) required for 80% virus neutralizationa 
 CHIKV MAURITIUS CHIKV ASIAN 
Antibody 100 infectious units 100 infectious units 
CHIKV 1.3A2 2.5 2.5 
CHIKV 4.6F5 2.5 2.5 
CHIKV 4.10C12 2.5 2.5 
CHIKV 5.2B2 >5 5 
CHIKV 5.2H8 >5 >5 
   
Mouse Sera (CHIKVASIAN) b 1/100 1/100 
Isotype Control (2B2)c >5 >5 
   
a Determined microscopically as 80% reduction in CPE in four replicate wells per antibody dilution. 
b Dilution factor used instead of antibody concentration.  
c 2B2 is an IgG2A mAb that reacts to E protein of WNV.  
 
3.4.7. MAbs 1.3A2 and 4.6F5 protect against viraemia and arthritis 
A recent study described the use of an adult wild-type mouse model of CHIKV infection and 
disease, which mimics both the viraemia and rheumatic symptoms seen in humans (Gardner et 
al., 2010). This mouse model has, for instance, been used to test the efficacy of a number of 
CHIKV vaccines (Prow et al., 2010; Wang et al., 2011). The model was used to determine 
whether neutralizing mAbs produced to CHIKV E2 in this study could provide prophylactic 
protection from viraemia and disease after live CHIKV challenge. Based on their efficient 
neutralization of CHIKV strains in vitro, and the higher yields of purified monoclonal 
antibodies from their hybridoma cell lines, mAbs 1.3A2 and 4.6F5 were chosen for the in vivo 
study. Mice were inoculated with 400 μg of purified 1.3A2 or 4.6F5 mAb one day prior to 
challenge with CHIKV. Mice that received these antibodies showed no signs of arthritis as 
measured by foot swelling (Figure 3.6A) and showed a mean 7-8 log reduction in viraemia 
when compared with controls (Figure 3.6B). In contrast, control mice (that received PBS or a 
non-alphavirus reactive mAb) developed clear signs of arthritis that peaked day 6-7 post 
infection (Figure 3.6A), demonstrating the expected (Gardner et al., 2010) viraemia peaking at 
7-8 log10 CCID50 on day 2 (Figure 3.6B). These results show that mAbs 1.3A2 and 4.6F5 can 
provide complete protection against CHIKV arthritis and significantly suppress viraemia when 
administered prior to infection. 
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Figure 3.6. Foot swelling and virus replication in mice inoculated with CHIKV-specific mAbs. (A) Arthritis 
after CHIKV infection. Mice were given 400 µg of mAbs 1.3A2, 4.6F5, 2B2 (anti-flavivirus isotype control) or 
PBS subcutaneously, one day prior to infection with CHIKV. The data is presented as a group average of the 
percentage increase in foot height x width for each foot compared with the same foot on day 0 (n = 8 feet per 
group). PBS and 2B2 groups were significantly different from 1.3A2 and 4.6F5 groups on days 2-10; p ≤ 0.034, 
t-tests and Kolmogorov-Smirnov tests. (B) Serum viraemia. The same mice as in A were assessed for viraemia in 
serum collected at the indicated times (n = 4 mice per group). * indicates p ≤ 0.037, Kolmogorov-Smirnov tests. 
 
3.4.8. Detection of CHIKV antigens in tissue of infected mice by IHC 
To assess the use of the E2-specific mAbs to detect CHIKV in tissues samples, IHC was 
performed on formalin-fixed, paraffin-embedded samples previously prepared from foot pads 
of IRF3/7-/- mice infected with CHIKVREUNION (Rudd et al., 2012). Although staining of 
infected cells was observed with the use of all anti-CHIKV E2 mAbs when fixed with acetone, 
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4.10C12 was the only mAb that gave clear reactivity with formalin-fixed tissue sections (Figure 
3.7). The detection of CHIKV within keratinocytes in infected mice tissue shown here is 
consistent with previous studies (Rudd et al., 2012). These results indicate that the mAbs 
produced in this study can be applied to IHC to specifically recognize CHIKV antigens in 
formalin-fixed tissue sections. 
 
 
Figure 3.7. Immunohistochemical staining for CHIKV using E2-specific mAb 4.10C12. Five micron sections 
of formalin-fixed paraffin-embedded uninfected or CHIKV-infected feet tissue of IRF3/7-/- mice were stained 
using 4.10C12. One microgram of purified 4.10C12 was incubated with tissue sections overnight at 4 °C. 
Antibody binding was visualized using the anti-mouse IgG Envision kit, DAKO. Staining was observed in (A) 
epidermal keratinocytes (top arrow) and sweat glands (bottom arrow), and (B) skeletal striated muscle cells, while 
no staining was observed in the uninfected control (C); A and B were photographed at a magnification of 20x, 
while the uninfected control C is shown at 10x zoom.  
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3.5. DISCUSSION 
The persistent spread of CHIKV into new locations along with its high epidemic potential poses 
a serious global threat to areas where competent Aedes mosquito vectors are present. The social 
and economic impact of CHIKV epidemics underlines the demand for accurate diagnostics and 
effective anti-viral therapeutics, since vaccines are not yet available. This study describes the 
generation and characterization of five mAbs specific to the E2 glycoprotein of CHIKV. Their 
specific recognition of three strains of CHIKV (i.e. CHIKVMAU, CHIKVASIAN and CHIKVET) 
that represent the major global lineages of the virus (Schuffenecker et al., 2006), along with 
the lack of cross-reaction with other alphaviruses species examined, indicate these antibodies 
will be useful as specific research and diagnostic tools. 
The alphavirus E2 protein is thought to be involved in virus attachment to host cell receptors 
and contains critical binding sites for neutralizing antibodies as shown in SINV models (Davis 
et al., 1987; Strauss et al., 1991; Kielian et al., 2010).  This is consistent with in vitro virus 
neutralizing activity of mAbs 1.3A2, 4.6F5 and to a lesser extent 4.10C12. These mAbs 
potentially bind to either the receptor-binding site of the CHIKV E2 protein or an epitope 
capable of interfering with virus attachment. When we further assessed the ability of mAbs 
1.3A2 and 4.6F5 to provide in vivo protection in a previously established arthritis mouse model 
of CHIKV infection (Gardner et al., 2010), a single dose of either mAb gave complete 
protection against disease progression in all test animals (n = 8). Foot swelling was absent in 
mice inoculated with the anti-CHIKV mAbs, indicating that the virus had a significant 
reduction in its ability to proliferate in its primary site of injection. Moreover, the absence of 
viraemia indicated that the virus introduced was most likely neutralized and was less capable 
of spreading. The levels of in vivo protection provided by mAbs in this study were similar to 
that recently reported for human anti-CHIKV mAbs by Warter et al. (Warter et al., 2011; Fric 
et al., 2012). When inoculated into AGR.129 (IFN-α/β/γR-/-/- and RAG-2-) mice, they showed 
that at least 250 µg of mAb was required to achieve 80-100% protection from a lethal dose of 
CHIKV (Fric et al., 2012), as compared to complete protection obtained with 400 µg of mAb 
in the wild-type mouse model of CHIKV disease used in the current study. Although the 
practicality of utilizing such antibodies for therapeutic purposes is often questioned, these 
neutralizing antibodies might be useful to prevent mother-to-child infections (Suhrbier et al., 
2012). These results demonstrate the potential of these anti-E2 mAbs to be used 
prophylactically during an outbreak and warrant future investigation. 
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Our competitive binding studies indicated that the mAbs produced in this study recognized at 
least three spatially separated epitopes on E2. These data assisted in the design of a capture 
assay for CHIKV detection. By selecting two mAbs that bound to different epitopes on the E2 
protein, an antigen-capture ELISA was developed for the sensitive detection of CHIKV 
antigen. Using a purified recombinant CHIKV E2 protein as a standard, this assay was capable 
of detecting the antigen at picogram levels, demonstrating similar sensitivity to capture assays 
to detect West Nile virus (WNV) antigen in mosquitoes (Hunt et al., 2002). Further validation 
of the sensitivity and specificity of this assay is now required using clinical samples to assess 
its application as a diagnostic assay for the identification of CHIKV in acute infections. These 
mAbs could also be incorporated into an antigen-capture dip stick format for the detection of 
CHIKV in mosquito samples, as previously described for WNV (Nasci et al., 2003). Our 
demonstration that CHIKV E2 antigens can also be detected in infected mouse tissue samples 
by mAb 4.10C12 in IHC identifies a further application for these reagents as specific tools for 
the study of CHIKV pathogenesis. 
 
3.6. CONCLUSIONS 
In summary, we have produced a panel of mAbs capable of distinguishing CHIKV from other 
common alphaviruses that cause similar disease syndromes in Australia, representing 
potentially useful reagents to specifically detect CHIKV in mosquito vectors and/or acute 
patient samples. However, further studies are required to evaluate their specificity and 
sensitivity in various diagnostic formats. Successful employment of these antibodies, 
especially 4.10C12, to detect CHIKV antigen in tissues by IHC further reinforces their potential 
in a wide variety of diagnostic assays for clinical or research purposes. The evaluation of these 
anti-CHIKV mAbs against additional medically significant alphaviruses will also allow them 
to be utilized as diagnostic tools in other regions of the world. Furthermore, we have 
demonstrated that these E2-specific mAbs neutralize virus both in vitro and in vivo, 
highlighting their potential as prophylactic agents against CHIKV infection when genetically 
engineered into humanized forms. These mAbs will also be useful for studying the structure 
and function of E2 in viral assembly and virus-host interactions (Akahata and Nabel, 2012). 
Finally, Metz and colleagues have shown that the CHIKV E2 protein can be a good vaccine 
candidate and the mAbs developed in this study could prove extremely valuable in terms of 
monitoring the antigenic authenticity and production of such a vaccine for the disease (Metz et 
al., 2011).  
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CHAPTER 4: MONOCLONAL ANTIBODIES SPECIFIC FOR THE CAPSID PROTEIN OF 
CHIKUNGUNYA VIRUS SUITABLE FOR MULTIPLE APPLICATIONS 
 
This chapter has been published as Goh, L. Y., Hobson-Peters, J., Prow, N. A., Gardner, J., 
Bielefeldt-Ohmann, H., Suhrbier, A. and Hall, R. A. (2014). Monoclonal antibodies specific 
for the capsid protein of chikungunya virus suitable for multiple applications. J Gen Virol in 
press. as doi:10.1099/jgv.0.000002. 
 
4.1. SUMMARY 
Chikungunya virus (CHIKV) is a mosquito-borne pathogen responsible for epidemics of 
debilitating arthritic disease. The recent outbreak (2004-2014) resulted in an estimated 1.4-6.5 
million cases, with imported cases reported in nearly 40 countries. The development of 
CHIKV-specific diagnostics and research tools is thus highly desirable. Herein we describe the 
generation and characterization of the first monoclonal antibodies (mAbs) specific for the 
capsid protein (CP) of CHIKV. The antibodies recognized isolates representing the major 
genotypes of CHIKV, as well as several other alphaviruses, and were reactive in a range of 
assays including ELISA, Western blot, immunofluorescence (IFA) and immunohistochemistry 
(IHC). We have also used the anti-CP mAb, 5.5G9, in IHC studies to show that capsid antigen 
is persistently expressed 30 days post-infection in cells with macrophage morphology in a 
mouse model of chronic CHIKV disease. These antibodies may thus represent useful tools for 
further research including investigations on the structure and function of CHIKV CP, and as 
valuable reagents for CHIKV detection in a range of settings. 
4.2. BODY OF TEXT 
Chikungunya virus (CHIKV) is the etiological agent of CHIK fever first described in 1952 
during an epidemic in Tanzania, East Africa (Lumsden, 1955; Robinson, 1955). CHIKV 
belongs to the Alphavirus genus within the Togaviridae family and is an enveloped, single-
stranded positive-sense RNA virus (Strauss and Strauss, 1994b). The 11.5 kb alphavirus 
genome is capped at its 5ʹ end and polyadenylated at its 3ʹ end, and encodes for four non-
structural proteins (nsP1 to nsP4) and five structural proteins (capsid, E3, E2, 6K and E1) 
(Strauss and Strauss, 1994b). 
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CHIKV is transmitted to humans by Aedes aegypti, and recently also Aedes albopictus, 
mosquitoes.  Acute CHIKV disease is characterized by a rapid onset of fever, myalgia, and 
often a rash (usually maculopapular), with chronic disease characterised by episodic, often 
debilitating, polyarthralgia/polyarthritis (Robinson, 1955; Tesh, 1982; Borgherini et al., 2007; 
Staples et al., 2009; Suhrbier et al., 2012). The largest epidemic of CHIKV disease ever 
reported began in 2004 and has since been responsible for up to 6.5 million human cases 
primarily in Africa and Asia, with imported cases reported in over 40 countries (Munasinghe 
et al., 1966; Lam et al., 2001; Renault et al., 2007; Rezza et al., 2007; Grandadam et al., 2011; 
Suhrbier et al., 2012; Horwood et al., 2013; Van Bortel et al., 2014). The continued activity of 
the initial epidemic in conjunction with additional emerging events has led to independent 
outbreaks in other parts of the globe, such as in Australasia and the Caribbean (Horwood et al., 
2013; Viennet et al., 2013; Van Bortel et al., 2014). During the recent epidemic, CHIKV was 
also clearly associated with occasional severe disease manifestations and mortality, the latter 
primarily amongst elderly patients with co-morbidities and the very young (Mavalankar et al., 
2008; Economopoulou et al., 2009; Tandale et al., 2009; Jaffar-Bandjee et al., 2010). 
The alphavirus capsid protein (CP) is a multifunctional protein that has been shown to act as a 
serine protease for self-cleavage, bind viral genomic RNA and other CP molecules 
during nucleocapsid formation, and interact with viral spike proteins during virion formation 
and egress (Choi et al., 1991). The CP of CHIKV consists of 261 amino acids that form two 
major domains. The N-terminal domain has a high degree of positive charge implicated in non-
specific RNA binding, while the C-terminal domain harbours the globular protease and the 
binding site for the spike protein (Hong et al., 2006). 
The re-emergence of CHIKV, attributable in large part to a mutation allowing efficient 
transmission by Aedes albopictus, and the current risk it poses to human health, has prompted 
the demand for new diagnostic and research reagents. Herein we report the generation and 
characterization of the first monoclonal antibodies (mAbs) to the CP of CHIKV and describe 
their use in a variety of assays. 
CHIKV isolates obtained for these studies included CHIKV Mauritius strain (CHIKVMAU) 
(GenBank ID: EU404186); CHIKV Asian, Thailand strain (CHIKVTHAI) (GenBank ID: 
FJ457921) and CHIKV Asian, East Timor strain (CHIKVET). To generate mAbs against 
CHIKV viral proteins, BALB/c mice 6-8 weeks of age were immunized with purified 
inactivated antigen (CHIKVMAU), challenged with live virus (CHIKVTHAI), followed by a final 
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boost 20 months later with inactivated antigen (CHIKVTHAI) four days prior to fusions for 
hybridoma production as described previously (Goh et al., 2013). Hybridomas were screened 
for production of CHIKV-reactive antibodies using fixed-cell ELISA and positive hybridoma 
cultures were cloned twice by limit dilution as previously described (Hall et al., 1988; Clark et 
al., 2007). Eleven hybridomas secreting antibodies reactive to CHIKV proteins were expanded 
in Hybridoma SFM (Gibco, Life Technologies) with 20% FBS at 37 °C with 5% CO2, before 
being weaned off all FBS for the harvesting and clarification of mAbs as culture fluid. 
Reactivity of these mAbs (1.7B2, 4.1H11, 4.8E2, 4.10A11, 5.1B12, 5.2F8, 5.2H7, 5.4G8, 
5.5A11, 5.5D11 and 5.5G9) to various CHIKV strains and related alphaviruses were 
determined by fixed-cell ELISA (Table 4.1). 
Each mAb recognized the three CHIKV strains used in this study (CHIKVMAU, CHIKVTHAI and 
CHIKVET) with similar intensity in ELISA, suggesting the epitopes are highly conserved 
amongst these strains. However, the varying degree of reactivity between each mAb to the 
CHIKV antigens, as measured by optical density reading at 405nm (OD405nm), is likely due to 
their recognition of different binding sites on the CP and variation in the binding affinity 
between individual mAbs. To further assess their reactivity towards other closely-related 
alphaviruses, each mAb was also tested against Ross River virus (RRV) T48 strain (GenBank 
ID: GQ433359); Semliki Forest virus (SFV) (GenBank ID: NC_003215) and Sindbis virus 
(SINV) MRE16 strain (GenBank ID: AF492770). Three of the mAbs, 5.2H7, 5.5D11 and 
5.5G9, reacted with antigens of SFV, RRV and SINV in ELISA, while the remaining eight 
mAbs recognized SFV and/or RRV but not SINV (Table 4.1). The isotype of each mAb was 
also determined using the Mouse Typer isotyping kit (Bio-Rad) according to the 
manufacturer’s instructions and found to be either IgG1 or IgG2A (Table 4.1). When tested for 
viral neutralizing activity in a micro-neutralization assay (Goh et al., 2013), none of the mAbs 
neutralized any of the three CHIKV strains in vitro (data not shown). 
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Table 4.1. Reactivity of CHIKV CP-specific mAbs towards various CHIKV strains and other 
alphaviruses in ELISA. 
Monoclonal 
Antibody * 
Reactivity in fixed-plate ELISA 
CHIKV 
(MAU) 
CHIKV 
(THAI) 
CHIKV 
(ET) 
RRV 
(T48) 
SFV 
SINV 
(MRE16) 
5.2 H7 IgG1 + + + + + + + + + + + + + + + + + + + + + + + + + + + 
5.5 D11 IgG1 + + + + + + + + + + + + + + + + + + + + + + + + + + 
5.5 G9 IgG2A + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 
1.7 B2 IgG1 + + + + + + + + + + + + + + + + + - - 
4.1 H11 IgG1 + + + + + + + + + + + + + + + + + + - 
5.1 B12 IgG2A + + + + + + + + + + + + + + + + + + + + + - 
5.5 A11 IgG1 + + + + + + + + + + + + + + + + + + + + + - 
4.8 E2 IgG2A + + + + + + + + + + + + + + - 
4.10 A11 IgG1 + + + + + + + + + + + + + + - 
5.2 F8 IgG2A + + + + + + + + + + + + - 
5.4 G8 IgG1 + + + + + + + + + + + - 
G8 IgG2A † + + + + + + + + + + + + + - 
2F2 IgG1 ǂ - - - - - + + + + 
 
* The optimal mAb dilution producing the maximum mean OD405nm reading on CHIKVMAU antigen was determined 
empirically for each mAb and used for assessment for other virus strains. Scoring: +++++, OD > 1.0; ++++, OD = 
0.75 to 1.0; +++, OD = 0.5 to 0.75; ++, OD = 0.3 to 0.5; +, OD = 0.25 to 0.3. 
† MAb G8 was generated to the E1 protein of RRV and is cross-reactive with CHIKV and SFV (Oliveira et al., 2006). 
ǂ MAb 2F2, generously provided by Associate Professor Graham Burgess (TropBio Pty Ltd., Townsville, 
Queensland, Australia), was previously raised to the Australian prototype strain MRM39, and has been shown 
to be SINV-specific. 
 
To determine their viral protein specificity, each mAb was assessed for specificity 
against CHIKV antigens in infected Vero cell lysate by Western blot (Goh et al., 2013). 
CHIKVMAU antigens were prepared in 4 X NuPAGE LDS sample buffer (Invitrogen) and 
heated at 95 °C for 5 min. For reduced antigens, 10 mM dithiothreitol (DTT) was added prior 
to heating. The proteins were resolved on 4-12% Bis-Tris precast SDS-PAGE gels (Invitrogen), 
transferred onto Hybond C nitrocellulose membranes (GE Healthcare), immune-stained and 
developed as previously described (Clark et al., 2007). To assess the glycosylation status of 
the target antigen, lysates were treated with PNGase F (Sigma-Aldrich) according to the 
manufacturer’s instructions, prior to analysis by Western blot. All antibodies reacted to a 
protein band of ~36 kDa, in samples that were reduced or unreduced,  as well as PNGase F-
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treated and untreated material, consistent with recognition of the unglycosylated CHIKV CP 
(Fig. 4.1a). 
 
 
Fig. 4.1. Monoclonal antibody reactivity in Western blot and IFA. (a) Representative mAb 4.10A11 reactions 
against boiled, reduced (DTT+) or unreduced (DTT-) lysates of CHIKVMAU-infected C6/36 cells treated with (+) 
or without (-) PNGase F. (b) IFA staining of 4.10A11 against transfected/CHIKVMAU-infected cells. Cells were 
probed with mAb 4.10A11 before incubation with an anti-mouse Alexa Fluro 488 conjugate (green) and Hoechst 
33342 (blue) for nuclear staining. A cocktail of five mAbs generated in a previous study was used for the detection 
of CHIKV E2 (Goh et al., 2013). B10/G8 mAbs (anti-E1 cocktail) were generated to the E1 protein of RRV and 
are cross-reactive with the E1 protein of CHIKV (Oliveira et al., 2006). Successful expression of recombinant 
proteins was demonstrated using anti-V5 mAb. 
Specificity towards the CHIKV CP was confirmed by testing the mAbs for reactivity with 
recombinant CHIKVMAU CP (rCap) expressed in COS-7L cells via immunofluorescence assay 
(IFA). CHIKVMAU CP constructs were generated by amplifying the respective CP genes from 
cDNA synthesized by reverse-transcription PCR of genomic RNA of CHIKVMAU, with primer 
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set “CHIKV Capsid Forward pcDNA” 5ʹ- TATATA GCTAGC ATG 
GAGTTCATCCCAACCCAA -3ʹ, “CHIKV Capsid Reverse pcDNA” 5ʹ- TATATA GGATCC 
ACTCCACTCTTCGGCCCC -3ʹ, followed by ligation into a pcDNA3.1 (+) vector 
(Invitrogen) modified to express V5 and histidine tags at the C-terminus of the recombinant 
proteins. COS-7L cell transfection was performed using Lipofectamine 2000 (Invitrogen) 
according to manufacturer’s instructions. Expression of recombinant E1 (rE1) and E2 (rE2) of 
CHIKVMAU was also carried out for reference controls as previously described (Goh et al., 
2013). Transfected COS-7L cells were fixed onto glass coverslips with 100% ice-cold acetone 
and incubated with selected mAbs in hybridoma culture fluid for 1 h at 37 °C. In the case of 
live virus infection, Vero cells were allowed to grow overnight on glass coverslips before being 
infected with CHIKV at an M.O.I. of 0.1 for 1 h. Cell monolayers were then washed twice with 
PBS and incubated at 37 °C in complete growth medium. At 24 h post-infection, Vero cells 
were fixed and incubated with anti-CHIKV mAbs as described above. Coverslips were then 
stained, mounted and imaged as described by Goh et al. (2013). All 11 mAbs reacted with cells 
expressing rCap or cells infected with CHIKV, but not the mock-infected/transfected cells or 
those expressing CHIKV rE1 or rE2 (Fig. 4.1b & 4.S1). 
 
 
Fig. 4.S1. Monoclonal antibody reactivity by IFA with acetone-fixed monolayers of CHIKVMAU-infected 
Veros cells. Cells were probed with respective mAbs before incubation with an anti-mouse Alexa Fluro 488 
conjugate (green) and Hoechst 33342 (blue) for nuclear staining. 
 
To assess the use of the CHIKV CP-specific mAbs to detect CHIKV in tissues samples, IHC 
was performed, as previously described in details (Goh et al., 2013), on formalin-fixed, 
paraffin-embedded samples previously prepared from feet of IRF3/7-/- mice infected with 
CHIKVREUNION (Rudd et al., 2012) and from wild-type (WT) mice 30 days post-infection. 
Briefly, deparaffinized sections were subjected to antigen retrieval by heating at 95 °C in a 
citrate-buffer, pH 6 (Target Retrieval Solution, DAKO) for 25 min followed by a 20 min 
cooling period at room temperature. Following a series of blocking steps, the sections were 
incubated with undiluted hybridoma culture supernatant of mAb 5.5G9 at 4 °C overnight. 
Preliminary studies showed that this mAb gave the most intense signal in IHC (data not shown). 
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Antibody binding was visualized using the anti-mouse IgG Envision kit (DAKO). Sections 
were counterstained with Meyer’s hematoxylin, mounted and examined under a Nikon Eclipse 
51E microscope. Digital micro-photographs were captured using a Nikon DS-Fi1 camera with 
a DS-U2 unit and processed with the NIS-Elements F software. Clear staining of keratinocytes 
and skeletal muscle cells were observed in samples from acutely infected IRF3/7-/- mice with 
the use of mAb 5.5G9 (Fig. 4.2), consistent with previous in situ hybridisation studies in these 
interferon -response deficient mice (Rudd et al., 2012). 
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Fig. 4.2. Immunohistochemical labelling for CHIKV antigen using capsid-specific mAb 5.5G9. Labelling 
was observed in epidermal keratinocytes (a & b, top arrows), skeletal striated muscle cells (a & b, bottom arrows) 
and perineural cells (b, left arrow) in tissue sections of acutely-infected IRF3/7-/- mice. Macrophage-like cells 
within connective tissue of CHIKV-infected WT mouse feet 30 days post-infection also stained positive with 
5.5G9 (c). No reactivity was observed in the uninfected control (d). Digital micrographs were capture using a 
82 
 
Nikon DS-Fi1 camera with a DS-U2 unit and the NIS-Elements F software and are reproduced without further 
manipulation. 
 
An ongoing issue for the field of alphaviral arthritis is understanding the aetiology of chronic 
inflammatory disease. Persistence of CHIKV RNA and protein was reported in occasional 
macrophages (i) in a chronic CHIKV patient 18 months post-onset of disease in the face of a 
robust host immune response (Hoarau et al., 2010), and (ii) in cynomolgus macaques (Macaca 
fascicularis) 44 days post-CHIKV infection by in situ hybridization (Labadie et al., 2010), but 
has never been described in a mouse model, possibly due to the lack of sensitive reagents. 
Using the 5.5G9 mAb, we were able to detect CP antigen in scattered macrophage-like cells in 
connective tissue of the inoculated foot from WT mice 30 days post-infection (Fig. 4.2). This 
previously reported mouse model of acute infection and disease (Gardner et al., 2010) thus 
recapitulates a key feature of chronic disease seen in humans. CP expression on day 30 - well 
beyond the 4-6 day viraemic period - in this model further supports the view that CHIKV 
antigen expression persists long term and is the likely cause of chronic inflammatory disease 
(Robinson, 1955; Borgherini et al., 2007; Staples et al., 2009; Labadie et al., 2010; Suhrbier et 
al., 2012). In addition, the ability specifically to detect CHIKV CP positive cells in 
paraformaldehyde fixed, paraffin wax embedded and decalcified tissue further illustrates the 
utility of 5.5G9 for CHIKV research. The 5.5G9 mAb may also prove particularly useful for 
studies of viral persistence, as it allowed for the immune-labelling of rare cells with even low 
levels of CHIKV CP antigen in fixed tissue sections. CHIKV is a biosafety level 3 organism 
(thus tissue samples must be fixed prior to removal from the biosafety level 3 facility), with 
joints - necessitating decalcification - and associated tissues often the focus of research for this 
arthritogenic alphavirus. 
In this paper, we report the first mAbs generated to the CHIKV CP, and demonstrate their 
reactivity in ELISA, Western blot and IFA. Our findings suggest these mAbs represent useful 
research tools and have strong potential in a wide variety of applications. In addition, we have 
shown that CHIKV antigen can be detected in infected mouse tissue samples by mAb 5.5G9 
in IHC. This identifies a further application for these reagents as specific tools for the study of 
CHIKV pathogenesis. The mAbs generated in this study also recognized different strains of 
CHIKV (CHIKVMAU, CHIKVTHAI and CHIKVET) representing the two major global lineages 
of the virus (Asian and East/Central/South African) (Schuffenecker et al., 2006). Furthermore, 
the three mAbs (5.2H7, 5.5D11 and 5.5G9) that also reacted strongly with the non-CHIKV 
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alphaviruses tested here will also be useful research tools for studying CP in related 
alphaviruses. The mAbs described in this paper are available from the authors upon request. 
 
4.3. ACKNOWLEDGEMENTS 
We would like to acknowledge Dr. Sonja Hall-Mendelin and Dr. Alyssa Pyke from Queensland 
Health Forensic and Scientific Services for the provision of inactivated CHIKV antigens for 
ELISA and mouse inoculation, respectively, Dr. Penny Rudd and Jane Wilson for providing 
CHIKV-infected tissue samples for the IHC, Thisun Piyasena for his technical assistance in 
testing of mAbs in ELISA and Associate Professor Graham Burgess for the supplement of anti-
SINV mAbs as controls. Lucas Yuan Hao Goh was supported by the University of Queensland 
international research tuition award (UQIRTA) from the UQ Graduate School, The University 
of Queensland, and the ANZ Trustees scholarship for medical research, Queensland. 
  
84 
 
CHAPTER 5: THE CHIKUNGUNYA VIRUS CAPSID PROTEIN CONTAINS LINEAR B 
CELL EPITOPES IN THE N- AND C-TERMINAL REGIONS THAT ARE DEPENDENT ON 
AN INTACT C-TERMINUS FOR ANTIBODY RECOGNITION. 
 
This chapter has been submitted to Virology as Goh, L. Y., Hobson-Peters, J., Prow, N. A., 
Baker, K., Piyasena, T. B., Taylor, C. T., Rana, A., Hastie, M. L., Gorman, J. J. and Hall, 
R. A. (2014). The chikungunya virus capsid protein contains linear B cell epitopes in the N- 
and C-terminal regions that are dependent on an intact C-terminus for antibody recognition. 
Virology. 
 
5.1. ABSTRACT 
Chikungunya virus (CHIKV) is an arthropod-borne agent that causes severe arthritic disease 
in humans and is considered a serious health threat in areas where competent mosquito vectors 
are prevalent. CHIKV has recently been responsible for several millions of cases of disease, 
involving over 40 countries. The recent re-emergence of CHIKV and its potential threat to 
human health has stimulated interest in better understanding of the biology and pathogenesis 
of the virus, and requirement for improved treatment, prevention and control measures. In this 
study, we mapped the binding sites of a panel of eleven monoclonal antibodies (mAbs) 
previously generated towards the CP of CHIKV. Using N- and C-terminally truncated 
recombinant forms of the CHIKV CP, two putative binding regions, between residues 1 to 35 
and 140-210, were identified. Competitive binding also revealed that five of the CP-specific 
mAbs recognized a series of overlapping epitopes in the latter domain. We also identified a 
smaller, N-terminally truncated product of native CP that may represent an alternative 
translation product of the CHIKV 26S RNA and have potential functional significance during 
CHIKV replication. Our data also provides evidence that the C-terminus of CP is required for 
authentic antigenic structure of CP. This study shows that these anti-CP mAbs will be valuable 
research tools for further investigating the structure and function of the CHIKV CP. 
 
5.2. INTRODUCTION 
Alphaviruses are spherical, enveloped, positive-sense single-stranded RNA viruses responsible 
for several globally significant human and animal diseases. Alphavirus members include 
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Sindbis virus (SINV), Semliki Forest virus (SFV), Ross River virus (RRV), the Western, 
Eastern and Venezuelan equine encephalitis viruses, as well as Chikungunya virus (CHIKV), 
all of which are transmitted by mosquitoes. CHIKV infection is characterized by  onset of 
fever, headache, fatigue, nausea, myalgia and maculopapular rash, often followed by severe 
acute and/or chronic polyarthralgia (Tesh, 1982; Borgherini et al., 2007; Staples et al., 2009; 
Suhrbier et al., 2012). Since its re-emergence in the early 2000s, CHIKV has been responsible 
for a succession of unprecedented outbreaks causing up to 6.5 million human infections in over 
40 countries in East Africa, the Indian Ocean islands, several regions of South Asia, and most 
recently in Europe, Oceania and the Caribbean regions (Munasinghe et al., 1966; Lam et al., 
2001; Renault et al., 2007; Rezza et al., 2007; Grandadam et al., 2011; Suhrbier et al., 2012; 
Horwood et al., 2013; Van Bortel et al., 2014). It has also been recently associated with severe 
disease manifestations, and mortality in some cases, largely amongst elderly patients with co-
morbidities and the very young (Mavalankar et al., 2008; Economopoulou et al., 2009; Tandale 
et al., 2009; Jaffar-Bandjee et al., 2010). 
Similar to other alphaviruses, CHIKV has a ~11.5 kb RNA genome that is capped at its 5ʹ end 
and polyadenylated at its 3ʹ end. The genome encodes four non-structural proteins, nsP1 to 
nsP4, and five structural proteins: capsid, E3, E2, 6K and E1 (Strauss and Strauss, 1994b). 
Studies have shown that the alphavirus capsid protein (CP) is multifunctional and plays a 
crucial role in the assembly and budding of alphaviruses. It is capable of self-cleavage prior to 
the recognition and binding of genomic RNA (Choi et al., 1991). Apart from its primary role 
of forming the nucleocapsid, the CP has been shown to have inhibitive and/or regulative 
functions in regard to host cell transcription, viral replication, as well as host and viral protein 
synthesis (Elgizoli et al., 1989; Aguilar et al., 2007). The CP of alphaviruses, as described in a 
SINV model, is organized into three separate regions – I, II and III – each with their respective 
functions (Hong et al., 2006). As shown in Figure 5.1, the unconserved N-terminal domain of 
the alphavirus CP has a high degree of positive charge implicated in non-specific RNA binding, 
while the highly-conserved C-terminal region harbours a globular chemotrypsin-like serine 
protease and contains the binding site for the spike protein. A recent study by Thomas et al. 
(2013) has also identified functional nuclear localization and export signals (NLS/NES) within 
the CHIKV CP. Furthermore, previous reports on the discovery of nucleolar targeting signals 
in SFV CP suggest that these signals are responsible for the karyophilic properties of the protein 
(Nigg et al., 1991; Favre et al., 1994; Jakob, 1994). NLS sequences in forms of synthetic 
peptides have been used to demonstrate efficient transport of the CP into the nucleus of both 
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higher and lower eukaryotic target cells (Favre et al., 1994). Nonetheless, a functional role has 
yet to be attributed to this putative intracellular transport of the CP during infection. 
The CP is a critical component of the assembly of alphaviruses. To date, alphaviral CP research 
is mainly based on models of SINV and SFV, exact roles and/or functions of the CHIKV CP 
has largely been assumed to be similar to that of its closely-related viruses. However, the re-
emergence of CHIKV and its potential threat to human health has demanded for a more detailed 
understanding of the virus. Herein we report the use of a series of truncated recombinant 
proteins derived from the CHIKV CP, mass spec analysis of native CHIKV CP and competitive 
binding studies to map the binding sites of a panel of eleven monoclonal antibodies (mAbs) to 
antigenic domains at the N-terminal region and the C-terminal half of the protein. 
 
5.3. MATERIAL AND METHODS 
5.3.1. Cell and virus culture 
C6/36 (Aedes albopictus mosquito) cells were propagated in RPMI 1640 supplemented with 
2% fetal bovine serum. Cultures were passaged by dissociating the cell monolayer from the 
flask with trypsin/PBS and were incubated at 28 °C. Vero and COS-7L (African green monkey 
kidney) cell lines were cultured in DMEM and RPMI 1640, respectively, supplemented with 
5% fetal bovine serum (FBS) during proliferation and 2% FBS for maintenance. Mammalian 
cells were passaged by dissociating the surface monolayer from the flask with trypsin/EDTA 
and were cultured at 37 °C with 5% CO2. Hybridoma cells were expanded in Hybridoma SFM 
(Gibco, Life Technologies) with 20% FBS at 37 °C with 5% CO2, before being weaned off all 
FBS for the harvesting of mAbs in culture fluid. All cell cultures were supplemented with 50 
U penicillin mL-1, 50 μg streptomycin mL-1 and 2 mM L-Glutamine (Gibco, Life 
Technologies). 
Viruses used for the infection of C6/36 cells included CHIKV Mauritius strain (CHIKVMAU) 
(GenBank ID: EU404186) and RRV T48 strain (RRVT48) (GenBank ID: GQ433359). For 
harvesting of virus stocks, cells were infected at an M.O.I. of 0.1 for 1 h, washed thrice with 
PBS and incubated for a further 48-72 h before culture supernatants were clarified by 
centrifugation at 12,000 x g for 10 min at 4 °C and stored at -80 °C. To obtain crude cell lysates, 
mock and/or virus-infected C6/36 cell monolayers were incubated in a similar manner before 
cells were rinsed in PBS and disrupted by sonication in the presence of BS9 lysis buffer (120 
mM NaCl, 50 mM H3BO3, 1% Triton X-100 and 0.1% SDS, pH 9.0). Lysates were clarified as 
mentioned above and stored at -20 °C (Clark et al., 2007). 
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5.3.2. Cloning and expression of CHIKV CP truncations 
CHIKV CP truncation constructs (Figure 5.1, bottom) were generated by amplifying the 
respective CP genes from cDNA synthesized by reverse-transcription PCR of genomic RNA 
of CHIKVMAU, either by pairing the CHIKV Capsid Forward PCDNA primer with one of the 
CHIKV Capsid N1-6 Reverse PCDNA primers, or the CHIKV Capsid Reverse PCDNA primer 
with one of the CHIKV Capsid C1-6 Forward PCDNA primers (Table 5.1). Following that, 
inserts were ligated into a pcDNA3.1 (+) vector (Invitrogen) modified to express V5 and 
histidine tags at the C-terminus of the recombinant proteins. COS-7L cell transfection was 
performed using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. 
Cells were harvested 48 h post-transfection by addition of BS9 lysis buffer and clarified by 
centrifugation (Hobson-Peters et al., 2008). 
 
 
Figure 5.1. Schematic representation of the alphavirus CP within its RNA genome. The alphavirus CP is 
segmented into three separate regions, based on the prototype SINV CP model - adapted from Hong et al. (2006). 
Region I has a high degree of positive charge associated with non-specific binding of the genomic viral RNA. 
Located within the same region, Helix 1, a sequence of uncharged amino acids, is suggested to be involved in the 
interactions during nucleocapsid core formation and its stabilization. Region II contains the minimum sequence 
required for specific RNA binding, while the C-terminal protease domain (region III) forms capsomeres in the 
nucleocapsid core and interacts with the E2 glycoprotein. The bottom part of the figure depicts the locations of 
the C- or N-terminal truncations within the full-length CP. Truncations were made in 35-amino acid increments. 
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Table 5.1. Nucleotide sequences of CHIKV CP truncation primers. 
Primer code Sequence (5ʹ to 3ʹ) Tm (°C) 
Expected 
size (bp) 
CHIKV Capsid F PCDNA TATATAGCTAGCATGGAGTTCATCCCAACCCAA 76.7 - 
CHIKV Capsid N1 R PCDNA TATATAGGATCCGGCCACCACGCGTCCCT 72.3 678 
CHIKV Capsid N2 R PCDNA TATATAGGATCCGTGGTGCCAGTTGTAGTAC 55.3 573 
CHIKV Capsid N3 R PCDNA TATATAGGATCCCCGCTTAAAGGCCAGTTT 61.7 468 
CHIKV Capsid N4 R PCDNA TATATAGGATCCACCTTCGTGCTTGACTTC 57.8 363 
CHIKV Capsid N5 R PCDNA TATATAGGATCCCTGCTTCTTTTGATTTGTG 55.9 258 
CHIKV Capsid N6 R PCDNA TATATAGGATCCCAGTTTATTAACTGCTGAGATC 55.3 153 
CHIKV Capsid R PCDNA  TATATAGGATCCACTCCACTCTTCGGCCCC 74.8 - 
CHIKV Capsid C1 F PCDNA TATATAGCTAGCATGAGGCAAGCTGGGCAAC 67.6 678 
CHIKV Capsid C2 F PCDNA TATATAGCTAGCATGAAGCAAAAACAACAGGC 74.8 573 
CHIKV Capsid C3 F PCDNA TATATAGCTAGCATGTGCATGAAAATCGAAAAT 60.7 468 
CHIKV Capsid C4 F PCDNA TATATAGCTAGCATGAAGGGGACCATCGATAA 67.7 363 
CHIKV Capsid C5 F PCDNA TATATAGCTAGCATGTCGAAGTTCACCCATGA 65.6 258 
CHIKV Capsid C6 F PCDNA TATATAGCTAGCATGGGGGACAGCGGCAGA 71.6 153 
 
5.3.3. Immunofluorescence assay (IFA) 
Transfected COS-7L cells were fixed onto glass coverslips with 100% ice-cold acetone and 
incubated with selected mAbs in hybridoma culture fluid at a 1/20 dilution for 1 h at 37 °C. 
Coverslips were then washed and stained with Alexa Fluor 488-conjugated goat anti-mouse 
IgG (Invitrogen) diluted 1:500 in blocking buffer (5% BSA in PBS) for 1 h at 37 °C, followed 
by Hoechst 33342 stain (1:1,000 in PBS, Invitrogen) for 5 min. Coverslips were mounted with 
ProLong Gold Anti-Fade reagent (Invitrogen) and imaged using a Zeiss LSM 510 META 
confocal microscope. 
 
5.3.4. Western/dot blot 
CHIKV antigens were prepared as transfected COS-7L cell lysates as described by Setoh et al. 
(2011). Reduction and carboxymethylation of antigens were carried out as previously described 
(see section 3.3.7.). Briefly, lysates were diluted in Tris-HCl and reduced with 10 mM 
dithiothreitol. Samples were then degassed with streaming nitrogen and heated to 95 °C. The 
reduced lysates were cooled and iodoacetic acid was added before being subjected to a second 
round of degassing, followed by incubation at 37 °C in the dark. Antigens that were to be 
resolved on 4-12% Bis-Tris precast SDS-PAGE gels (Invitrogen), were prepared in 4 X 
NuPAGE LDS sample buffer (Invitrogen) and heated to 95 °C for 5 min prior to 
electrophoresis. The separated proteins were then transferred onto Hybond C nitrocellulose 
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membranes (Amersham) and immune-stained as previously described (Clark et al., 2007). For 
dot-blotting, treated or untreated antigen samples were carefully spotted directly onto Hybond 
C nitrocellulose membranes and allowed to dry for 5-10 min. Membranes were then blocked 
with TENTC blocking buffer (0.05 M Tris-HCl pH 8.0, 1 mM EDTA, 0.15 M NaCl, 0.05% 
(v/v) Tween 20, 0.2% (w/v) casein) for 1 h at room temperature prior to the addition of primary 
antibodies diluted 1/20, unless otherwise stated, in blocking buffer. After incubation for another 
hour, membranes were washed thrice with 0.1% Tween-20 in PBS (PBS/T wash buffer) and 
bound antibodies were detected with a HRP-conjugated goat anti-mouse IgG diluted 1:4,000 
in blocking buffer. The blots were incubated for a further 1 h before being washed three times 
with PBS/T wash buffer. Finally, blots were developed in DAB substrate solution (1.5 mM 
3,3ʹ-diaminobenzidine, 0.06% (v/v) H2O2 in PBS, pH 7.2) for 15 min before reactions were 
terminated by rinsing with PBS or ddH2O. 
 
5.3.5. Competitive binding ELISA 
Competitive binding between anti-CHIKV CP mAbs were assessed as described previously 
(Hall et al., 2009). Briefly, purified mAbs were biotinylated using the BiotinTag kit (Sigma), 
according to manufacturer’s instructions. Competitive binding ELISAs were performed in 96 
well plates coated with lysates of CHIKVMAU-infected C6/36 cells diluted 1/500 in coating 
buffer (0.05M sodium carbonate/bicarbonate, pH 9.6). After washing, a pre-defined optimal 
saturating concentration of each of the unlabelled mAbs was added for 1 h at 28 °C. Without 
washing, a pre-defined optimal non-saturating dilution of each biotin-labelled ‘competitor’ 
mAb (40 ng/mL) was added for 1 h at 28 °C. After washing six times with PBS/T, horseradish 
peroxidase (HRP)-conjugated streptavidin (Invitrogen) was added and incubated for 30 min. 
The wells were washed prior to incubation with ABTS substrate solution. Uninfected C6/36 
cell lysates were used as coating antigen to determine background cut-off values, while 4G2, a 
pan-reactive mAb targeting the flavivirus envelope protein, was used as the negative antibody 
control. 
 
5.3.6. Microsphere immunoassay 
A series of 20-mer peptides, with 10-residue overlaps, encompassing the entire CHIKV CP 
were designed (see Table 5.2) and commercially synthesized (Mocell Biotech). Each peptide 
was coupled to carboxylated polystyrene beads using the Bio-Plex amine coupling kit (Bio-
Rad) according to the manufacturer’s instructions. The coupled beads were then multiplexed 
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by diluting in microsphere immunoassay (MIA) buffer (1% BSA, 0.05% ProClin 300 (Supelco) 
in PBS) and distributed to give approximately 2,500 of each beadset (~100 µL) per well of a 
MultiScreen filter plate (Merck Millipore). Each anti-CHIKV CP mAb was then tested against 
the multiplexed beadsets by incubation for 45 min with shaking at room temperature. The wells 
were then washed three times with PBS/T wash buffer, prior to the addition of R-Phycoerythrin 
donkey anti-mouse IgG (Jackson ImmunoResearch). Following that, the wells were incubated 
and washed as previously, after which the beads were resuspended in MIA buffer. The Bio-
Plex 200 (Luminex, Bio-Rad) was then utilized to read the plate, measuring the mean 
fluorescence intensity for each beadset in their respective wells. 
 
5.3.7. Immunoprecipitation of CHIKV CP 
Protein pull-downs were performed on clarified lysates of CHIKVMAU-infected C6/36 cells 
using Dynabeads Protein G (Novex, Life Technologies) according to manufacturer’s 
instructions. Boiled and/or reduced samples were then resolved via SDS-PAGE as described 
above (see section 5.3.4.) prior to incubation of the gel in Coomassie blue stain (1% (w/v) 
Coomassie R250, 10% glacial acetic acid, 40% methanol in ddH2O) at room temperature for 
30 min before being rinsed twice with destaining solution (10% glacial acetic acid, 40% 
methanol in ddH2O). Gel was then incubated in destaining solution overnight with rocking. 
 
5.3.8. Mass spectrometry analysis 
Individually stained bands were excised reduced, alkylated and subjected to in-gel tryptic 
digestion as described in detail previously (Hastie et al., 2012). Acidified digests were 
subjected to NanoHPLC-MS/MS analysis using a nanoAcquity nanoHPLC system (Waters) 
interfaced with a linear ion-trap (LTQ)-Orbitrap Elite hybrid mass spectrometer (Thermo 
Fischer Scientific). Digests were loaded onto a 5 μ Symmetry 180 μm × 20 mm C18 trap 
column (Waters) at 15 μL/min in 98% solvent A (0.1% (v/v) aqueous formic acid) and 2% 
solvent B (0.1% (v/v) formic acid in 100% acetonitrile) for 3 min at 22 °C then switched in-
line with a pre-equilibrated analytical column (BEH130 C18 1.7 μm, 75 μm × 200 mm, Waters) 
at a flow rate of 0.3 μL/min and 98% solvent A, 2% solvent B. Peptides were separated at 35 
°C using a sequence of linear gradients: starting from 5% B over 1 min, to 40% B over 29 min, 
and finally, to 95% B over 4 min, before holding the column at 95% B for a further 4 min. 
Eluates from the analytical column were then introduced into the LTQ-Orbitrap Elite 
throughout the entire run via a Nanospray Flex Ion Source (Thermo Fisher Scientific) 
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containing a 10 μm P200P coated silica emitter (New Objective). Typical spray voltage was 
1.8 kV with no sheath, sweep or auxiliary gases; heated capillary temperature was set to 275 
°C. The LTQ- Orbitrap Elite was controlled using Xcalibur 2.2 SP1.48 software (Thermo 
Fisher Scientific) and operated in a data-dependent acquisition mode to automatically switch 
between Orbitrap-MS and ion trap-MS/MS. The survey full scan mass spectra (from m/z 380-
1700) were acquired in the Orbitrap with a resolving power of 120,000 after accumulating ions 
to an automatic gain control (AGC) target value of 1.0 x 106 charges in the LTQ. MS/MS 
spectra were concurrently acquired in the LTQ on the 20 most intense ions from the survey 
scan, using an AGC target value of 1.0 x 104. Charge state filtering, where unassigned 
precursors and singly charged ions were not selected for fragmentation, and dynamic exclusion 
(repeat count 1, repeat duration 30 sec, exclusion list size 500, exclusion duration 30 sec) were 
used. Fragmentation conditions in the LTQ were: 35% normalized collision energy, activation 
q of 0.25, 10 ms activation time, and minimum ion selection intensity of 500 counts. Maximum 
ion injection times were 250 ms and 100 ms for survey full scans and MS/MS scans, 
respectively. 
 
5.3.9. Data analysis 
Tandem mass spectra were processed using Proteome Discoverer (version 1.4, Thermo Fisher 
Scientific) and submitted to Mascot (version 2.5.1, Matrix Science). Fixed modification: 
carbamidomethyl-cysteine; variable modifications: deamidation (asparagine, glutamine) and 
oxidation (methionine). Enzyme: trypsin, 2 missed cleavages; MS tolerance 20 ppm; MSMS 
tolerance 0.6 Da using a database downloaded from UniprotKB on the 21 July 2014 consisting 
of the reference proteome for Aedes aegypti (UP000008820), Chikungunya virus (strain 
37997) (UP000008450), reference proteome Chikungunya virus (strain S27-African prototype) 
with the sequence of the capsid protein added as a separate entry. Scaffold (4.4.1.1, Proteome 
Software) was used to validate Mascot protein identifications (Searle, 2010). Scaffold 
probabilistically validates these peptide identifications using PeptideProphet (Keller et al., 
2002).  A cut-off of 99% +2, +3 and 5 ppm error was used to validate the peptides. 
 
5.4. RESULTS 
5.4.1. Anti-CHIKV CP mAbs recognize linear epitopes 
To determine whether a panel of eleven anti-CHIKV CP mAbs bound conformational or linear 
epitopes, antigens in the form of crude lysates derived from CHIKV-infected C6/36 cells were 
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subjected to reduction with DTT and carboxymethylation of their free sulfhydryl groups so as 
to prevent the reformation of disulphide bonds. These antigens were separated by SDS-PAGE 
alongside boiled, unreduced, or boiled, reduced, uncarboxymethylated lysates prior to 
immunoblotting. Probing with each of the CP-specific mAbs, including representative antibody 
1.7B2, revealed that all eleven antibodies recognized CP under both unreduced and reduced 
conditions, even after carboxymethylation (Figure 5.2), indicating that the anti-CHIKV CP 
mAbs recognized linear epitopes that are not dependent on disulphide bonds to provide 
secondary structure. 
 
 
Figure 5.2. Reactivity of anti-CHIKV CP mAbs against boiled, reduced and/or carboxymethylated CHIKV 
cell lysates. Boiled (B), boiled and reduced (B/R) or boiled, reduced and carboxymethylated (B/R/C) lysates of 
CHIKV (lanes 1-3), RRV (lanes 4-6) and West Nile virus (lanes 7-9) were probed against antibodies 1.7B2 (anti-
CP), RRG8 (anti-E1) and 17D7 (anti-E), respectively, in Western blot. Note that the increase in molecular weight 
with each treatment is an indication of successful chemical modification. 
 
Since the Western blot results indicated that all anti-CP mAbs recognized linear epitopes, we 
designed a series of 20-mer synthetic peptides, with 10-residue overlaps, spanning the entire 
CHIKV CP to fine-map the epitopes of the anti-CHIKV mAbs. However, none of the mAbs 
showed any reactivity towards the synthetic peptides in ELISA, dot blot or in MIA, despite the 
successful detection of all control peptides epitopes by their corresponding mAbs using these 
assays (Table 5.2). This surprising result suggested that the binding of the CP-specific mAbs 
may require additional structure provided by post-translational modifications not found in 
synthetic peptides. 
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Table 5.2. Reactivity of synthetic peptides in MIA, ELISA and dot blot. 
No. Sequence Length Protein* Position Luminex ELISA Dot Blot 
1. MEFIPTQTFYNRRYQPRPWT 20 CHIKV CP 1-20 - - - 
2. NRRYQPRPWTPRPTIQVIRP 20 CHIKV CP 11-30 - - - 
3. PRPTIQVIRPRPRPQRQAGQ 20 CHIKV CP 21-40 - - - 
4. RPRPQRQAGQLAQLISAVNK 20 CHIKV CP 31-50 - - - 
5. LAQLISAVNKLTMRAVPQQK 20 CHIKV CP 41-60 - - - 
6. LTMRAVPQQKPRRNRKNKKQ 20 CHIKV CP 51-70 - - - 
7. PRRNRKNKKQKQKQQAPQNN 20 CHIKV CP 61-80 - - - 
8. KQKQQAPQNNTNQKKQPPKK 20 CHIKV CP 71-90 - - - 
9. TNQKKQPPKKKPAQKKKKPG 20 CHIKV CP 81-100 - - - 
10. KPAQKKKKPGRRERMCMKIE 20 CHIKV CP 91-110 - - - 
11. RRERMCMKIENDCIFEVKHE 20 CHIKV CP 101-120 - - - 
12. NDCIFEVKHEGKVTGYACLV 20 CHIKV CP 111-130 - - - 
13. GKVTGYACLVGDKVMKPAHV 20 CHIKV CP 121-140 - - - 
14. GDKVMKPAHVKGTIDNADLA 20 CHIKV CP 131-150 - - - 
15. KGTIDNADLAKLAFKRSSKY 20 CHIKV CP 141-160 - - - 
16. KLAFKRSSKYDLECAQIPVH 20 CHIKV CP 151-170 - - - 
17. DLECAQIPVHMKSDASKFTH 20 CHIKV CP 161-180 - - - 
18. MKSDASKFTHEKPEGYYNWH 20 CHIKV CP 171-190 - - - 
19. EKPEGYYNWHHGAVQYSGGR 20 CHIKV CP 181-200 - - - 
20. HGAVQYSGGRFTIPTGAGKP 20 CHIKV CP 191-210 - - - 
21. FTIPTGAGKPGDSGRPIFDN 20 CHIKV CP 201-220 - - - 
22. GDSGRPIFDNKGRVVAIVLG 20 CHIKV CP 211-230 - - - 
23. KGRVVAIVLGGANEGARTAL 20 CHIKV CP 221-240 - - - 
24. GANEGARTALSVVTWNKDIV 20 CHIKV CP 231-250 - - - 
25. SVVTWNKDIVTKITPEGAEEW 21 CHIKV CP 241-261 - - - 
26. SAAKHARKERNITGGHPVSR ǂ 20 WNVKUN NS5 38-57 + + + 
27. CTTVESHGNYSTQVGATQAG ǂ 20 WNVNY99 E 146-165 + + + 
28. Full-length CHIKV CP # 261 CHIKV CP N/A ND + + 
        
* Each synthetic peptides was screened against all eleven anti-CHIKV CP mAbs, polyclonal anti-CHIKV 
antibodies, as well as 5H1 (anti-WNVKUNα3) and 17D7 (anti-WNYNY99 E). 
ǂ A "+" result represents reactivity with the peptide's respective control mAb. 
# ND = not determined. Full-length CHIKV CP was reactive towards all eleven anti-CHIKV CP mAbs and 
polyclonal anti-CHIKV antibodies in ELISA and dot blot. 
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We have previously shown that these mAbs react with CP treated with PNGase F (see Chapter 
4), indicating that N-linked glycosylation is not required, consistent with the absence of an N-
linked glycosylation site and the cytoplasmic location of the protein (Goh et al., 2014). Further 
analysis of the CHIKV CP sequence using a prediction software, NetPhos 2.0 
(http://www.cbs.dtu.dk/services/NetPhos/), revealed the presence of several potential 
phosphorylation sites that may participate in the structure of epitope(s) recognized by these 
mAbs (Figure 5.3). However, attempts to demonstrate this by dephosphorylation of CHIKV 
CP prior to analysis by Western blot were inconclusive. 
 
 
Figure 5.3. Capsid protein amino acid sequence alignment of closely-related alphaviruses. Asterisks (*), 
colons (:) and periods (.) indicate identical, conserved or semi-conserved substitutions, respectively. Residues 
highlighted in red represent potential phosphorylation sites predicted by NetPhos 2.0 
(http://www.cbs.dtu.dk/services/NetPhos/), while yellow residues mark the conserved catalytic triad residues 
involved in the auto-proteolytic function of the CP. The teal-coloured tryptophan (position 261) is where the auto-
cleavage occurs. Contributing amino acids of the predicted NLS and NES sequences are highlighted in green and 
blue, respectively. Red, bolded residues of the NES denote hydrophobic positions, indicating its similarity towards 
a non-classical NES sequence (Thomas et al., 2013). The methionine (position 105) highlighted in magenta 
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indicates the potential alternative translation initiation site of the N-terminally truncated form of CP. Putative 
mAb binding domains are in bold (group 1 mAbs: 157-175; group 2 mAbs: 1-35). 
 
5.4.2. Expression of N- and C-terminally truncated CHIKV CP 
In another approach to map the epitope(s) recognized by the anti-CP mAbs, recombinant full-
length and a series of N- and C-terminally truncated CP sequences were expressed in COS-7L 
cells. Successful expression of full length and truncated proteins C-terminally fused to a V5-
His tag, was confirmed by detection with anti-V5 mAb in IFA (Figure 5.4). Most of the 
truncations were also recognized by anti-V5 mAb in Western blot (Figure 5.5), although the 
smaller protein bands were not successfully transferred to the nitrocellulose membrane due to 
limitation of the membrane pore size. 
 
 
Figure 5.4. Monoclonal antibody reactivity by IFA with acetone-fixed monolayers of COS-7L cells 
transfected with full-length rCap or truncation constructs. Cells were probed with respective mAbs before 
incubation with an anti-mouse Alexa Fluro 488 conjugate (green) and Hoechst 33342 (blue) for nuclear staining. 
Two mAbs representing each group were chosen for this experiment: Group 1 - 1.7B2, 5.2H7, and Group 2 - 
4.10A11, 5.4G8. 
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Figure 5.5. Western blot of recombinant full-length and truncated CP in lysates of transfected cells. 
Clarified lysates of transfected COS-7L cells were boiled and reduced with DTT prior to immunoblotting with 
anti-V5 mAb. Lanes 1-6: C1-6; lanes 7: mock-transfected COS-7L lysate; lanes 8-13: N1-6; and lane 14: full-
length rCap. 
 
To identify the binding regions of these mAbs in CP, each antibody was subjected to Western 
blot analysis against each of the twelve truncated versions of CHIKV CP. Monoclonal 
antibodies 1.7B2, 4.1H11, 5.2H7, 5.5D11 and 5.5G9 (designated group 1), reacted with a series 
of the N-truncations (N1-4), as well as the full-length protein (rCap) (Table 5.3). This 
demonstrated that group 1 mAbs still recognized CP in the absence of the first 140 residues 
(see Figure 5.1) suggesting the epitope(s) they recognize resides in the C-terminal half of the 
protein. Failure of the group 1 mAbs to bind CP with larger truncations of between 175 (N5) 
and 210 residues (N6), conservatively placed their binding site between residues 140 and 210 
in CP.  Meanwhile, group 2 mAbs (4.8E2, 4.10A11, 5.1B2, 5.2F8, 5.4G8 and 5.5A11) were 
able to detect rCap but none of the N-terminally truncated proteins (Table 5.3). This suggested 
that all mAbs from group 2 bound the N-terminal region of the CP, since only the first 35 
residues were missing from the smallest N-truncation (N1). Similar results were observed when 
group 1 and 2 mAbs were tested against the N-terminally truncated recombinant proteins in 
acetone-fixed transfected cells by IFA (Figure 5.4). 
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Table 5.3. Reactivity of anti-CHIKV mAbs against full-length, C- or N-terminally truncated versions of 
rCap in Western blot. 
Monoclonal 
Antibody 
Group 
Reactivity in Western blot 
FL N1 N2 N3 N4 N5 N6 C1 C2 C3 C4 C5 C6 
1.7B2 1 + + + + + - - - - - - - - 
4.1H11 1 + + + + + - - - - - - - - 
5.2H7 1 + + + + + - - - - - - - - 
5.5D11 1 + + + + + - - - - - - - - 
5.5G9 1 + + + + + - - - - - - - - 
5.1B12 2 + - - - - - - - - - - - - 
5.5A11 2 + - - - - - - - - - - - - 
4.8E2 2 + - - - - - - - - - - - - 
4.10A11 2 + - - - - - - - - - - - - 
5.2F8 2 + - - - - - - - - - - - - 
5.4G8 2 + - - - - - - - - - - - - 
 
 
When all mAbs were tested against C-terminally truncated forms of CP, none of the antibodies 
from either group recognized any of the truncated proteins in IFA (Figure 5.4) or Western blot 
(Table 5.3) despite their recognition by the anti-V5 antibody, suggesting that the C-terminal 
region of CP might be required for authentic antigenic structure of CP. This was confirmed by 
the reactivity of mouse polyclonal anti-CHIKV antibody with rCap and N-terminally truncated 
proteins (N1-4) in Western blot but none of the C-terminally truncated proteins (results not 
shown). 
 
5.4.3. Group 1 mAbs bind native N-terminally truncated CP in CHIKV lysates 
IFA and Western blot analysis of N-terminally truncated recombinant CP indicated that group 
1 mAbs recognized a region in the C-terminal half of the CHIKV CP while group 2 mAbs 
bound the N-terminal region. We also observed that, in addition to detecting the rCap in lysates 
of CHIKV-infected cells (~35 kDa), group 1 mAbs also detected smaller, truncated versions 
of native CP (sCP) ranging from ~15-30 kDa (Figure 5.6A). In contrast, antibodies from group 
2 only recognized full-length CP in these lysates (Figure 5.6B). 
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Figure 5.6. Reactivity of anti-CP mAbs with full length and truncated versions of native and recombinant 
CP. Reactivity of mAbs 1.7B2 (lanes A1-3), 5.2H7 (lanes A4-6), cocktail of group 2 mAbs (lanes B1-3) and anti-
V5 mAb (lanes B4-6) in Western blot against boiled and reduced lysates of COS-7L cells expressing rCap (lanes 
1 & 4), mock-transfected COS-7L cells (lanes 2 & 5), and CHIKV-infected C6/36 cells (lanes 3 & 6). 
 
To determine the identity of the truncated native versions of CP, capsid proteins were immune-
precipitated from CHIKV-infected lysates with protein G beads coupled to mAb 1.7B2 (group 
1). Resulting pull-downs were resolved on SDS-PAGE and selected Coomassie-stained CPs 
were analysed by mass spectrometry. These analyses showed that all species of CP recognized 
by mAb 1.7B2, including the rCap, contained the same C-terminal peptide (Figure 5.7). 
However, as the CP molecules were truncated, detection of the N-terminus region was 
progressively lesser, with observations that peptides toward the N-terminal side of the protein, 
that were previously identified in larger-sized bands, were missing. No smaller molecules of 
CP were precipitated, which was consistent with the binding pattern of 1.7B2 and other group 
1 mAbs  to N-terminally-truncated recombinant CPs; binding to N1 to N4 (35 to 140 residues 
removed) but not N5 and N6 (175 and 210 residues removed). Together, these data confirm 
that the epitopes recognized by 1.7B2, and other group 1 mAbs, were located between residues 
140 and 210 in the C-terminal half of CP. Furthermore, the lack of recognition of native CP 
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truncated by 36 or more residues from the N-terminus also supports their binding to an N-
terminal domain - within the first 35 aa - of the protein. 
 
 
Figure 5.7.  Coverage of the CHIKV capsid protein by peptides identified via mass spectrometry analysis 
of different bands excised from SDS-PAGE of boiled and reduced proteins immunoprecipitated by a group 
1 mAb, 1.7B2. Sequences for peptides identified within each respective CHIKV CP band (1-7) are bolded and 
highlighted in yellow. 
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5.4.4. Group 1 mAbs target a series of overlapping epitopes on CP 
To further define the binding sites of the mAbs from group 1, and determine the topology of 
their epitopes in the C-terminal half of CP, representative group 1 antibodies were tested in a 
competitive binding assay against one another using ELISA. Three of the five mAbs in this 
group (1.7B2, 4.1H11 and 5.2H7) were successfully biotinylated and subsequently assessed 
for competition against saturating concentrations of each of the five unlabelled mAbs to 
establish the degree of inhibition exhibited for each pairing. MAbs 1.7B2 and 4.1H11 showed 
complete two-way inhibition with each other indicating they bind to the same or highly 
adjacent epitopes (Figure 5.8). Partial two-way inhibition of both these mAbs with mAb 5.2H7 
was also observed, suggesting that the epitope recognized by 5.2H7 is slightly different to the 
former pair but in the same spatial domain. The partial one-way inhibition of 5.2H7 by the 
unlabelled mAbs 5.5D11 and 5.5G9, but not by 1.7B2 and 4.1H11, suggests a continuum of 
overlapping epitopes (Figure 5.9). The competitive binding result also confirms that these 
antibodies bind to the same region of the CP. 
 
 
Figure 5.8. Competitive binding profiles of CHIKV CP-specific mAbs in ELISA. Antigens in lysates of 
CHIKVMAU-infected Vero cells were adsorbed to 96-well plates at a 1/500 dilution prior to incubation with a 
saturating dilution of purified, unlabelled anti-CP mAbs. Without washing, non-saturating dilutions of 
biotinylated mAbs were then added as ‘competitor’ antibodies to respective wells. The mean absorbance reading 
(OD405nm) of four replicates were plotted with bars showing standard error of mean (SEM). 4G2 is a control mAb 
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specific to the E protein of flaviviruses. Assay was optimized to obtain complete inhibition of each biotinylated 
mAb by its homologous unlabelled competitor. 
 
 
Figure 5.9. Schematic representation of proposed spatial relationship of epitopes recognized by group 1 
anti-CP mAbs. Antibodies in the same coloured circle illustrates two-way inhibition, with overlaps representing 
one-way inhibition amongst mAbs tested. While it is safe to assume that the sequence of overlapping should be 
fairly accurate since the group 1 mAbs do recognize linear epitopes, the order of epitopes might be inversed. 
Furthermore, it is highly likely that mAbs bind from residues 157 to 175, however, a more conservative estimate 
would be from position 140-210. 
 
5.5. DISCUSSION 
In this study, we used a series of truncated recombinant proteins to map the binding sites of a 
panel of CHIKV CP-specific mAbs produced in a previous study – see Chapter 4 (Goh et al., 
2014). The binding patterns of the mAbs in Western blot and IFA allowed us to deduce that 
these antibodies bound two regions of CP; one domain was located within the first 35 aa of the 
N-terminus of CP (group 2 mAbs), and a second domain in the C-terminal half of the protein 
between residues 140 and 210 (group 1 mAbs). This was supported by mass spectrometry 
analysis of naturally-truncated native CP species in CHIKV-infected cell lysates that were 
recognized by group 1 but not group 2 mAbs, which confirmed the location of the two binding 
domains of these mAbs. The binding of all group 1 mAbs to a defined region between residues 
140 and 210 in the C terminal half of CP was further supported by the competitive binding 
experiments. While the data demonstrated that these five mAbs recognized at least four 
different epitopes, there was significant overlap suggesting a continuum of binding sites in a 
defined region. The proposed spatial relationship of epitopes recognized by the group 1 mAbs 
is schematically presented in Figure 5.9. 
 
Truncated fragments of CHIKV CP displaying sizes similar to those observed in this study 
have been previously been identified in cells expressing recombinant CHIKV CP from a  
baculovirus vector, as well as cells infected with a recombinant measles vaccine expressing 
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CHIKV virus-like particles (Cho et al., 2008; Brandler et al., 2013). This uncharacterized 
minor product of CP has also been documented in other alphaviruses such as WEEV and SINV 
(Ishida and Simizu, 1981; Bell et al., 1983; Choi et al., 1996). Based on the observations made 
and data obtained in this study, a schematic of the different sized CP bands derived from 
molecular weight analysis of both CP from crude lysates of CHIKV-infected C6/36 cells and 
recombinantly expressed versions, was constructed (Figure 5.10). This suggests that sCP is 
approximately 10-11 kDa smaller than its full-sized counterpart and is truncated by ~100 
residues from the N-terminus. This was confirmed by successful retention of the C-terminally 
inserted V5-His tag and the mass spectrometry analysis that the N-terminal peptide identified 
in the major native species sCP in infected cells lysates began with the methionine at position 
105 in CHIKV CP. This also corresponds with a predicted alternate translation initiation site 
at the third AUG of the 26S RNA in the alphavirus structural polyprotein, previously observed 
in a SINV mutant (Ventoso et al., 2006). Irrespective of whether this minor form of CP is 
generated by alternate translation initiation, or protease cleavage,  the fact that this truncation 
has been consistently detected, along with the synthesis of full-sized CP, in naturally-infected 
vertebrate and mosquito cells implies that sCP may have functional significance. 
 
 
Figure 5.10. Schematic representation of different sizes of CP observed in Western blot. Stars represents the 
mAbs that are reactive toward that particular protein band. To obtain sizes of protein bands, a calibration curve 
was constructed by semi-logarithmically plotting the relative mobility values of the molecular weight standards 
against their known molecular weights. The relative mobility of each target protein was then utilized to estimate 
their molecular weight. 
 
Our initial findings that all the anti-CP mAbs included in this study recognized reduced and 
carboxymethylated antigens in Western blot, indicated they bound to linear or continuous 
epitopes independent of tertiary structure. Thus, it was surprising that attempts to further define 
the binding sites of these antibodies using a series of 20-mer synthetic peptides with 10-mer 
overlaps covering the entire CHIKV CP were unsuccessful. None of the mAbs showed any 
reactivity towards the peptides when adsorbed to the solid phase in ELISA, bound onto 
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nitrocellulose membranes in dot blot, or when presented on microspheres in a Luminex-based 
assay. The successful recognition of control peptides synthesized in the same batch by their 
corresponding mAbs in both assay formats indicated that incorrect synthesis was not likely to 
be the problem. This suggested that the epitopes on CHIKV CP required additional structures 
for mAb recognition, potentially post-translational modifications such as phosphorylation or 
glycosylation, as described in previous studies (Glenney et al., 1988; Kehoe et al., 2006). The 
CP of alphaviruses are known not to harbour any N-linked glycosylation, which was previously 
confirmed by endoglycosidase digestion – see Chapter 4 (Goh et al., 2014). However, eight 
potential sites of phosphorylation have been predicted in CHIKV CP based on its amino acid 
sequence, with two potentially phosphorylated residues at positions 8 and 20, both in the 
proposed binding region of group 2 mAbs, and one at residue 158 in the putative binding 
domain of group 1 mAbs (Figure 5.3).  
 
The lack of reaction of all mAbs and polyclonal antisera to C-terminally truncated recombinant 
CP, despite their clear detection by anti-V5 in Western bot and IFA, was also unexpected 
considering the apparent linear nature of their epitopes. This suggests that the C-terminal 
residues nay be crucial to the antigenic structure of CHIKV CP, either by facilitating 
phosphorylation of residues in the binding sites as referred to above, or by stabilizing the 
overall structure of CP and exposing these epitopes on the surface of the protein, allowing 
access for antibody binding. Both of these hypotheses fit well with the data obtained in this 
study, including the failure of the antibodies to recognize the synthetic peptides; the 20-mer 
peptides predicted to contain the putative binding sites (peptides no. 1-4 for group 2 mAbs; no. 
15-18 for group 1 mAbs) would also lack the C-terminal peptides of CP. Future studies to 
resolve this question and further define the binding sites of the anti-CP mAbs, could include 
the re-construction of rCap with variable internal deletions and the retention of the C-terminal 
residues. 
 
5.6. CONCLUSIONS 
In summary, we have mapped the binding sites of a panel of anti-CHIKV CP mAbs to two 
putative domains. Group 1 mAbs recognized an epitope(s) between residues 1-35, while group 
2 mAbs bound a region between residues 140-210; the latter targeting a series of overlapping 
epitopes. We also provided evidence that the C-terminus of CP is required for the authentic 
antigenic structure of the protein - and thus antibody binding - and have identified a smaller 
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species of CP in CHIKV-infected cells that may represent an alternative translation product of 
the viral 26S RNA. Our epitope mapping studies have identified novel structural properties of 
the CHIKV CP and characterized useful reagents for their further investigation. A better 
understanding of the structure of CP will provide valuable insight into the multifunctional role 
of this protein in CHIKV replication, as well as that of numerous other alphaviruses. 
 
5.7. ACKNOWLEDGEMENTS 
Access to proteomic infrastructure in the QIMR Berghofer Protein Discovery Centre was made 
possible by funding from Bioplatforms Australia and the Queensland State Government 
provided through the Australian Government National Collaborative Infrastructure Scheme 
(NCRIS) and Education Investment Fund (EIF). Lucas Yuan Hao Goh was supported by the 
University of Queensland international research tuition award (UQIRTA) from the UQ 
Graduate School, the University of Queensland, and the ANZ Trustees scholarship for medical 
research, Queensland. 
  
105 
 
CHAPTER 6: USING MASS SPECTROMETRY-GUIDED SPECIFIC PRIMER DESIGN 
FOR GENERATION OF CHIMERIC MOUSE-HUMAN ANTIBODIES FOR 
CHIKUNGUNYA DIAGNOSTICS 
 
This chapter has been submitted to Journal of Immunological Methods (recommended for 
publication following minor alterations) as Goh, L. Y., Jones, M. L., Hobson-Peters, J., 
Nouwens, A., Prow, N. A., Barnard, R. T. and Hall, R. A. (2014). Using mass spectrometry-
guided specific primer design for generation of chimeric mouse-human antibodies for 
Chikungunya diagnostics. J Immunol Methods. 
 
6.1. ABSTRACT 
Chikungunya virus (CHIKV) is an arbovirus that causes febrile illness with an incapacitating 
and prolonged arthralgic syndrome, and has recently caused a large epidemic involving 
millions of infections in over 40 countries. Several ELISA-based IgM/IgG diagnostic tests have 
been developed for the diagnosis of CHIKV infection. However, international standardization 
and validation of these assays are currently limited. Presently, the use of human sera collected 
from infected or uninfected individuals is required for the validation of diagnostic assays, and 
to determine cut-off values. Numerous drawbacks are associated with the routine usage of 
pooled reference sera from CHIKV-infected patients, including continuity of supply, ethical 
and safety concerns, and batch-to-batch variation. Herein we report the generation of a 
genetically engineered chimeric IgG, consisting of mouse hybridoma-derived variable chain 
regions and human constant regions. We also describe a novel approach utilising mass 
spectrometry and 5ʹ rapid amplification of cDNA ends (5ʹ RACE) to design gene-specific 
primers, whilst avoiding the amplification of aberrant immunoglobulin genes from the parent 
myeloma cell lines. The resulting recombinant, chimeric antibody retained the antigen 
specificity of the parent hybridoma antibody. 
6.2. INTRODUCTION 
Chikungunya virus (CHIKV) is a mosquito-transmitted arthritogenic alphavirus from the 
family Togaviridae, that includes other medically significant viruses such as Ross River virus, 
Barmah Forest virus, o’nyong-nyong virus, Mayaro virus and Sindbis virus (Suhrbier et al., 
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2012). Chikungunya disease in humans is characterized by acute and chronic 
polyarthralgia/polyarthritis (Hoarau et al., 2010; Suhrbier et al., 2012). The acute phase of 
disease is often also associated with an abrupt onset of fever, myalgia, and a rash that is usually 
maculopapular in appearance (Robinson, 1955; Tesh, 1982; Borgherini et al., 2007; Staples et 
al., 2009; Suhrbier et al., 2012). 
CHIKV was first isolated in 1952 in Tanzania and has caused sporadic epidemics of primarily 
rheumatic disease mainly in Africa and Asia (Suhrbier et al., 2012). In 2004-2011, CHIKV 
was responsible for up to 6.5 million infections reported in over 40 countries (Munasinghe et 
al., 1966; Lam et al., 2001; Renault et al., 2007; Rezza et al., 2007; Grandadam et al., 2011; 
Suhrbier et al., 2012; Horwood et al., 2013; Van Bortel et al., 2014). The recent epidemic has 
seen CHIKV associated with severe disease manifestations and mortality, primarily in elderly 
patients with co-morbidities, and in the young (Mavalankar et al., 2008; Economopoulou et 
al., 2009; Tandale et al., 2009; Jaffar-Bandjee et al., 2010). Mother-to-child transmission was 
also observed, with approximately half the infected neonates developing serious forms of 
CHIKV disease characterized by one or more of the following signs: haemorrhage, 
disseminated intravascular coagulation, cardiac and/or neurological manifestations; the latter 
often leading to permanent disabilities (Lenglet et al., 2006; Gerardin et al., 2008; Suhrbier et 
al., 2012). Treatment of CHIKV rheumatic disease currently involves the use of pain killers 
and/or non-steroidal anti-inflammatory drugs, with relief often inadequate. There is currently 
no licensed human vaccine available for CHIKV. 
The virus co-circulates with the causative agents of several other tropical diseases such as 
dengue fever and typhus. Although there are no specific antivirals or vaccines available for 
chikungunya, timely and accurate diagnosis of CHIKV is important. Undiagnosed patients 
presenting non-specific fever are commonly given antimicrobials empirically and 
unnecessarily (Joshi et al., 2008). This is a waste of resources which may contribute to 
antimicrobial resistance, preventable with a simple diagnostic test. Early diagnosis of CHIKV 
can also result in better interventions for vector control and disease management, in order to 
prevent further spread. Effective surveillance of emerging diseases, such as CHIKV, is crucial 
for alerting the local and global community to a potential threat. 
Serodiagnosis by detection of IgM and IgG via ELISA are used as a standard for laboratory-
based diagnoses of arthritogenic alphavirus diseases. “In-house” CHIKV ELISAs have been 
widely used in a number of countries due to their lower cost, rapidity and simplicity (Suhrbier 
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et al., 2012). However, kits utilized for the detection of antibodies against infectious agents 
commonly use human reference sera to establish cut-off values, concomitantly confirming the 
integrity of the tests (Jacobson, 1998). These sera, collected and pooled from infected 
individuals, are often included in commercial kits as positive controls and as cut-off calibrators. 
The routine use of these materials has several disadvantages. Firstly, a reliable supply of high-
titre serum from confirmed cases of CHIKV infections can be difficult to obtain. In addition, 
ethical problems may arise from the collection of blood from individuals who are unwell, from 
children, or in societies where acquiring blood is prohibited. Furthermore, there are safety 
concerns dealing with potentially infectious human sera, from both the manufacturer and 
consumer perspectives. Lastly, each finite batch of collected serum will require standardization 
due to the batch variation of antibody titre (Hackett et al., 1998). As an alternative, the 
generation of a non-serum-derived, recombinant positive control antibody that interacts 
specifically with a CHIKV protein and is recognized by an enzyme-conjugated anti-human 
antibody can be a solution to overcoming the disadvantages. Genetically engineered chimeric 
immunoglobulins consisting of mouse-derived variable chain regions and human antibody 
constant regions obtained from peripheral blood lymphocytes (PBL) satisfy these 
requirements. Chimeric antibodies have been previously shown to be useful controls in ELISA 
for the parasitic protozoan Toxoplasma gondii and the bacterium Orientia tsutsugamushi, 
responsible for scrub typhus (Hackett et al., 1998; Jones and Barnard, 2007). 
Primer sets are available for amplifying variable region genes from mouse hybridomas 
(Morrison, 2002), but these primers are not exhaustive and some hybridoma antibody genes 
can prove to be difficult to amplify (Carroll et al., 1988; Ding et al., 2010). In this study, we 
describe a novel method for generating the variable light chain (VL) region derived from an 
anti-CHIKV monoclonal antibody (mAb), 5.2H7. The method was based on designing specific 
primers complementary to nucleic acid sequences encoding the light chains of the target mAb, 
guided by mass spectrometry, combined with the 5ʹ rapid amplification of cDNA ends (5ʹ 
RACE). This method should facilitate the avoidance of a common problem regarding the 
amplification of an aberrant kappa chain variant encoded or expressed within certain 
commonly employed hybridoma cell lines. After isolation of the heavy and light chain variable 
regions, a splice-overlap extension PCR was performed to fuse the mouse variable regions of 
5.2H7 with the required human constant domains. Successfully fused genes were cloned and 
expressed in the mammalian cell line, COS-7L, then tested by ELISA. 
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6.3. MATERIALS AND METHODS 
6.3.1. Cell lines and virus culture 
C6/36 (Aedes albopictus mosquito) and COS-7L (African green monkey kidney) cell lines 
were propagated in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) during 
proliferation and 2% FBS for maintenance. Cultures were passaged by dissociating the cell 
surface monolayer from the flask with trypsin/PBS or trypsin/EDTA. C6/36 cells were 
incubated at 28 °C, and COS-7L cells at 37 °C, both in an atmosphere of 5% CO2. Hybridoma 
cell line 5.2H7, secreting mAbs against the CHIKV capsid protein (Goh et al., in press), was 
expanded in Hybridoma SFM (Gibco, Life Technologies) with 20% FBS at 37 °C with 5% 
CO2, before being weaned off all FBS for the harvesting of mAbs from culture supernatant. All 
cell cultures were supplemented with 50 U penicillin mL-1, 50 μg streptomycin mL-1 and 2 mM 
L-Glutamine (Gibco, Life Technologies). CHIKV Mauritius strain (CHIKVMAU) (GenBank 
ID: EU404186) was used to infect C6/36 cells for crude lysate preparation. Cell monolayers 
were infected with CHIKV at an M.O.I. of 0.1 and incubated for 3 days prior to the removal of 
culture supernatant and rinsing in PBS. Cells were then disrupted by sonication in the presence 
of lysis buffer (BS9 containing 1% Triton X-100 and 0.1% SDS) and the resulting lysate was 
clarified by centrifugation at 12,000 x g for 10 min at 4 °C and stored at -20 °C until use. 
6.3.2. RNA isolation and cDNA synthesis 
Total RNA was isolated from 5.2H7 hybridoma cells and the myeloma parent cell line 
P3X63Ag8.653 using TRIzol reagent (Invitrogen) according to the manufacturer’s 
instructions. cDNA was synthesized using SuperScript III Reverse Transcriptase (Invitrogen) 
following the manufacturer’s instructions. Primer JH_R was used to synthesize the VH chain 
cDNA, while the gene-specific 5.2H7_MS1-4_R primers were utilized to generate the VL chain 
cDNA after 5ʹ RACE (refer to section 6.3.8.). 
6.3.3. Generation of recombinant 5.2H7 heavy chain construct 
PCR amplification of the VH gene from 5.2H7 cells was performed by pairing a set of 
degenerate forward primers (Morrison, 2002), including the MVH_F primer (Table 6.1) that 
gave a product, with the JH_R primer. The PCR reaction consisted of 1 U Phusion polymerase 
(Finnzymes, Thermo Fisher Scientific), 1x Phusion HF buffer, 2 mM MgCl2, 0.4 mM dNTP, 
0.4 µM of each primer and approximately 100 ng of cDNA. PCR cycling conditions were as 
follows: initial denaturation for 30 sec (98 °C), 35 cycles of 10 sec denaturation (98 °C), 30 
sec annealing (65 °C) and 10 sec extension (72 °C) and a final extension of 5 min (72 °C). 
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Sizes of PCR products were verified by gel electrophoresis in a Tris-borate-EDTA, pH 8.3, 1% 
(w/v) agarose gel stained with Red Safe Nucleic Acid Staining Solution (ABC Scientific). 
Purified products were sub-cloned into pGEM-T Easy vector (Promega). Similarly, genes of 
the human IgG heavy chain constant (CH) region were amplified from cDNA generated from 
human peripheral blood leukocytes (PBL). Primer pair JH_F and CHG_R were utilized, with 
annealing at 60°C for 30 sec and extension at 72 °C for 30 sec. PCR products derived from the 
VH and CH region coding sequences were re-amplified from their respective pGEM-T Easy 
plasmids, electrophoresed and gel-extracted. The chimerization of the respective fragments 
was performed using a splice-overlap extension PCR (SOE-PCR) method as previously 
described (Jones and Barnard, 2005). Primers JH_R and JH_F are reverse complementary, 
therefore, equimolar amounts of mouse VH PCR product and CH region PCR product will 
hybridize and extend to produce a full length chimeric conditions in a reaction with 1 U Phusion 
polymerase (Finnzymes, Thermo Fisher Scientific), 1x Phusion HF buffer, 1 mM MgCl2, 0.25 
mM dNTP, with an initial denaturation for 3 min (98 °C), followed by 10 cycles of denaturing 
for 10 sec (98 °C), annealing and extension for 1 min (72 °C). Following that, the chimeric 
product was amplified by a subsequent PCR including the external primers (0.5 µM each of 
MVH_F and CHG_R) with annealing at 60°C for 30 sec and extension at 72 °C for 40 sec. The 
successfully chimerized product was then sub-cloned as previously described and sequenced 
by the Australian Genome Research Facility. After sequence confirmation, the chimeric gene 
was re-amplified using primers 5.2H7_V_F_NotI and CHG_R_XhoI to incorporate restriction 
enzyme sites, and cloned into the mammalian expression vector pcDNA3.1 (+) (Invitrogen). 
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Table 6.1. Nucleotide sequences of primers for generation of chimeric 5.2H7 mAb. 
  
Primer Name Primer Code Type/Species Sequence (5ʹ to 3ʹ) 
Tm 
(°C) 
5.2H7 Mass Spec Frag 1 Reverse 5.2H7_MS1_R Mouse RAANACRTARTGNGTRTTRAA 65.5 
5.2H7 Mass Spec Frag 2 Reverse 5.2H7_MS2_R Mouse NGTRTCNACNCCYTGNGT  47.9 
5.2H7 Mass Spec Frag 3 Reverse 5.2H7_MS3_R Mouse CCARTTNGCRTARTTRTG 55.1 
5.2H7 Mass Spec Frag 4 Reverse 5.2H7_MS4_R Mouse NCCNCCNCCRAANTGRAA 47.1 
5.2H7 Light Leader Seq Forward 5.2H7_LS_F Mouse CCACCATGGCCTGGACTTCACTTATACTCTCT 56.2 
5.2H7 Light Leader Seq Forward with HindIII 5.2H7_LS_F_HindIII Mouse ATATATAAGCTTCCACCATGGCCTGGACTTCACTTATACTCTCT 63.4 
Variable Heavy Forward # MVH_F Mouse CCACCATGGRATGSAGCTGKGTMATSCTCTT 64.2 
Variable Kappa Forward # MVK_F Mouse CCACCATGGAGACAGACACACTCCTGCTAT  
5.2H7 Heavy Variable Forward with NotI 5.2H7_V_F_NotI Mouse ATATATGCGGCCGCTCCACCATGGAATGGAGCTGGGTCTTTCTCTTC 70.2 
J-Light (Lambda) Forward JL_F Human/Mouse GGVACCAAGSTSACYGTCCTA 59.2 
J-Light (Lambda) Reverse JL_R Human/Mouse TAGGACRGTSASCTTGGTBCC 59.2 
J-Heavy Forward ǂ JH_F Human/Mouse GGGGCCAAGGGACCATGGTCACCGTCTCCTCAG 70.9 
J-Heavy Reverse ǂ JH_R Human/Mouse CTGAGGAGACGGTGACCATGGTCCCTTGGCCCC 70.9 
Igλ Light Constant Reverse CL_R Human CTATGAACATTCTGTAGGGGCCAC 57.3 
Igλ Light Constant Reverse with XhoI CL_R_XhoI Human ATATATCTCGAGCTATGAACATTCTGTAGGGGCCAC 62.5 
IgG Heavy Constant Reverse ǂ CHG_R Human TCATTTACCCGGAGACAGGGAG 58.2 
IgG Heavy Constant Reverse with XhoI CHG_R_XhoI Human ATATATCTCGAGTCATTTACCCGGAGACAGGGAG 62.2 
     
Bolded texts represent template-binding regions; red texts highlight restriction enzyme sites; underlined texts indicate start or stop codon in forward or reverse primers, 
respectively. 
# Primers adapted from Morrison (2002). 
ǂ Primers adapted from Jones and Barnard (2005). 
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6.3.4. SDS-PAGE and Coomassie blue staining 
Serum-free CHIKV CP-specific hybridoma 5.2H7 culture supernatant was clarified, and antibody 
was purified using a HiTrap Protein G HP column (GE Healthcare). The purified antibody was 
prepared in 1 X NuPAGE LDS sample buffer (Invitrogen) with 10 mM dithiothreitol and heated to 
95 °C for 5 min. The antibody was resolved on a NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen, 
Life Technologies) at 170 V for 30 min. Following that, the gel was incubated in Coomassie blue 
stain (1% (w/v) Coomassie R250, 10% glacial acetic acid, 40% methanol in ddH2O) at room 
temperature (RT) for 30 min before being rinsed twice with destaining solution (10% glacial acetic 
acid, 40% methanol in ddH2O). Gel was then incubated in destaining solution overnight with rocking. 
6.3.5. Sample preparation for LC-MS 
The band of interest, 5.2H7 mAb light chain, was excised from the SDS-PAGE gel and destained 
with 50 mM ammonium bicarbonate (pH 7.8)/50% (v/v) acetonitrile for 3 hr. Proteins were then 
subjected to reduction with 10 mM dithiothreitol at 60 °C for 30 min followed by the addition of 55 
mM iodoacetamide at RT for 30 min, in the dark, to alkylate proteins. Gel slices were washed twice 
with 50 mM ammonium bicarbonate (pH 7.8) by vortexing for 2 min, and dehydrated with 100% 
acetonitrile for 5 min. Rehydration was performed by incubating gel fragments in 8 µl enzyme 
solution (10 ng/uL in 50 mM ammonium bicarbonate, pH 7.8, of either trypsin, chymotrypsin or 
AspN) at 4 °C for 20 min. To prevent drying out, 12 µl of 50 mM ammonium bicarbonate was added 
to gel fragments before proteins were allowed to digest overnight at 37 °C. Digested peptides were 
extracted from the gel by sonication three times in 50% acetonitrile/0.1% trifluoroacetic acid for 10 
min. Peptide-containing supernatants were then lyophilized in a Savant SPD131DDA SpeedVac 
Concentrator (Thermo Scientific) at 45 °C. Samples were resuspended in 0.1% trifluoroacetic in 50% 
acetonitrile and cleaned up using C18 ZipTips (Merck Millipore) according to manufacturer’s 
instructions. 
6.3.6. Mass spectrometry 
LC-MS/MS analysis was performed similar to that described in Kappler & Nouwens (2013), with 
modifications. In brief, samples were separated on a Shimadzu Prominence nanoLC system.  Peptides 
were first desalted on an Agilent C18 trap (0.3 x 5mm, 5 µm) for 3 min, at a flow rate of 30 µL/min 
using buffer A, followed by separation on a Vydac Everest C18 column (300 A, 5 µm, 150 µm x 150 
mm) at a flow rate of 1 µL/ min.  Peptides were separated using a gradient of 10-40% buffer B over 
30 min, followed by 40-98% buffer B over 3 min, where buffer A = 1% acetonitrile/0 .1 % formic 
acid, and buffer B = 0.1% formic acid in acetonitrile.  A TripleTof 5600 (ABSciex) was used to 
directly analyze eluted peptides using a Nanospray III interface. A TOF MS scan was performed 
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across m/z 350 - 1800 for 0.5 sec, followed by data-dependent acquisition of up to 20 peptides across 
m/z 40 - 1800 (0.05 sec/spectrum) with intensity above 100 counts using rolling collision energy. Gas 
and voltage settings were adjusted as required. 
6.3.7. De novo peptide sequencing 
MS data was initially searched using MASCOT to filter out conserved antibody peptides (including 
the known myeloma-derived aberrant variable regions sequence), searching all species in the 
SwissProt database. Enzyme was set to trypsin, AspN or chymotrypsin, respectively, allowing for up 
to two mis-cleavages, using a mass tolerance of 50 ppm for MS and 0.1 Da for MS/MS. 
Carboxymethylation of cysteine (fixed) and oxidation of methionine (variable) were included as 
modifications. Unmatched spectra from MASCOT searches were then manually inspected and de 
novo sequenced to determine amino acid sequence. PEAKS Studio v6.0 was also used to facilitate de 
novo sequencing. De novo settings included 20 ppm error for MS and 0.1 Da for MS/MS, 
carboxymethylation of cysteine and oxidation of methionine, with up to three post-translational 
modifications per peptide, and five peptide sequences generated for each spectra. Computationally 
determined sequences were manually validated to confirm matches. 
6.3.8. Generation of recombinant 5.2H7 light chain construct 
Degenerate reverse primers were designed (5.2H7_MS1_R, 5.2H7_MS2_R, 5.2H7_MS3_R and 
5.2H7_MS4_R), with the help of a mouse codon usage table 
(http://www.kazusa.or.jp/java/codon_table_java/), based on four peptides that were considered to be 
unique towards the 5.2H7 VL sequence. These primers were used as gene-specific reverse primers for 
the 5ʹ Rapid Amplification of cDNA Ends (5ʹ RACE) system (Invitrogen), according to 
manufacturer’s instructions, on the 5.2H7 hybridoma RNA to obtain a PCR product extending from 
the front of the VL chain to the binding site of the mass-spectrometry derived reverse primers.  The 
5.2H7_MS1_R primer was able to efficiently amplify a distinct product and this product was 
subsequently cloned into a pGEM-T Easy vector (Promega) and sequenced. IMGT/V-QUEST 
analysis revealed that the sequence was a lambda light chain isotype, and Signal P 3.0 
(http://www.cbs.dtu.dk/services/SignalP-3.0/) analysis identified the presence of a functional 
antibody leader sequence. A gene-specific forward primer, 5.2H7_LS_F, and a lambda J-region 
reverse primer (JL_R) were thus created for the amplification of the 5.2H7 VL chain sequences. 
Additionally, lambda J-region forward (JL_F) and lambda light chain constant region reverse (CL_R) 
primers were designed with the help of IMGT’s Ig repertoire 
(http://www.imgt.org/IMGTrepertoire/Proteins/index.php). RT-PCR was carried out, as previously 
described, to obtain 5.2H7 VL and human Ig lambda CL gene segments. PCR products then underwent 
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SOE-PCR as described above before being re-amplified with 5.2H7_LS1_F_HindIII and 
CL_R_XhoI to include RE sites. The amplified product was cloned into pcDNA3.1 (+) mammalian 
expression vector. 
6.3.9. Recombinant mouse-human 5.2H7 mAb expression 
COS-7L cell transfection was performed using Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions. A 1:1 molar ratio of recombinant 5.2H7 heavy: light chain pcDNA3.1 
(+) construct was used for the transfection. Recombinant antibody-containing culture supernatant and 
cell lysates were harvested 2 days post-transfection. Supernatant was clarified by centrifugation at 
12,000 x g for 10 mins at 4 °C, while cell monolayers were detached using a cell scraper and subjected 
to sonication in PBS prior to clarification. 
6.3.10. Western blot 
CHIKVMAU antigen or recombinant mAb supernatant/cell lysate were heated in 1 X NuPAGE LDS 
sample buffer (Invitrogen), with or without 10 mM dithiothreitol, and resolved by SDS-PAGE as 
described above. Proteins were then transferred onto Hybond C nitrocellulose membranes 
(Amersham) and immune-stained as previously described in section 3.3.7., with slight modifications 
(Goh et al., 2013). After blocking, membranes were probed either with the recombinant 5.2H7 mAb 
at a 1:20 dilution, or a cocktail of anti-human Ig Lambda light chain mouse antibody (BioLegend) at 
a 1:2,000 dilution and anti-human IgG heavy chain rabbit antibody (DAKO) at 1:500, against the 
CHIKV antigens and recombinant 5.2H7 supernatant/cell lysate, respectively, for 1 h. CHIKV lysate 
samples probed with the recombinant mAb were then allowed to incubate with the anti-human mAbs 
for an additional hour. Thereafter, HRP-conjugated goat anti-mouse IgG (DAKO) and goat anti-rabbit 
IgG (DAKO) were used as detecting antibodies at dilutions of 1:4,000 and 1:2,000, respectively. 
Finally, the blots were developed in DAB substrate solution (1.5 mM 3,3ʹ-diaminobenzidine, 0.06% 
(v/v) H2O2 in PBS, pH 7.2) for 15 min at RT. 
6.3.11. ELISA 
Harvested recombinant mAbs were tested in ELISA as described previously (Hall et al., 1988; Clark 
et al., 2007). Briefly, CHIKVMAU lysate or uninfected C6/36 cell lysate were coated overnight onto 
96-well plates in coating buffer (0.05 M NaHCO3, 0.05 M Na2CO3, pH 9.6) at 4 °C, prior to blocking. 
Samples were then probed with 5.2H7 hybridoma supernatant or recombinant mAb supernatant/cell 
lysate, serially diluted 2-fold down the plate. Bound chimeric antibodies were then incubated with a 
cocktail of anti-human mAbs exactly as described in the Western blot section above. The appropriate 
HRP-conjugated goat anti-mouse and/or anti-rabbit IgG (DAKO) were used as detecting antibodies 
at dilutions of 1:4,000 and 1:2,000, respectively. ABTS substrate solution (0.02% (w/v) 2, 2’-azino-
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bis-3-ethylbenzthiazoline-6-sulphonic acid, 0.06% (w/v) H2O2 in 200 mM Na2HPO4 and 100 mM 
citric acid) was then added and allowed to develop for 30 min at RT in the dark prior to absorbance 
measurement at 405 nm optical density using a Labsystems Multiscan EX Type 355 UV plate reader 
(Pathtec). 
 
6.4. RESULTS 
6.4.1. Amplification of chimeric 5.2H7 heavy chain 
Murine VH and CH region genes were successfully amplified using cDNA synthesised from extracted 
5.2H7 hybridoma genomic RNA, with the primer sets MVH_F and JH_R, and JH_F and CHG_R, 
respectively. Agarose gel electrophoresis demonstrated that the PCR products were ~400 bp (VH) and 
~1 kb (CH), as expected (Figure 6.1A). SOE-PCR was used to hybridize the VH and CH genes, as 
shown in Figure 6.1B. The product was approximately 1.4 kb in size, confirming the successful 
chimerization of the heavy chain genes. 
 
 
Figure 6.1. Agarose gel electrophoresis of PCR products for generation of chimeric 5.2H7 heavy chain. A) Murine 
VH and human IgG CH region were amplified from 5.2H7 hybridoma RNA and human PBL mRNA via RT-PCR. Lane 
MW: DNA marker; lane 1: 5.2H7 VH PCR product; and lane 2: human IgG CH PCR product. B) SOE-PCR was utilized 
to hybridize the murine VH and human IgG CH genes prior to re-amplification with primers containing restriction enzyme 
sites for cloning into pcDNA3.1 (+). Lane MW: DNA marker; lane 1: chimeric 5.2H7 heavy chain product obtained from 
SOE-PCR; and lane 2: re-amplified chimeric 5.2H7 heavy chain with RE sites. 
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6.4.2. Amplification of chimeric 5.2H7 light chain 
Four mass spectrometry-derived peptides that were of unique amino acid sequences and showed no 
homology toward the MOPC-21 variable chain aberrant genes were used to design reverse primers 
to reverse-transcribe the 5.2H7 hybridoma RNA (Table 6.1). Utilizing these primers in the 5ʹ RACE 
system (Invitrogen), partial segments of the 5.2H7 VL gene were successfully amplified, sub-cloned 
and sequenced. Contrary to results of the Mouse Typer Isotyping Panel kit (Bio-Rad Laboratories), 
IMGT/V-QUEST analysis showed that mAb 5.2H7 harbored a lambda VL chain instead of a kappa 
one. Created from the 5ʹ sequence of the VL chain, gene-specific primer 5.2H7_LS_F, was used in 
combination with JL_R to re-amplify the VL gene, while the human lambda CL gene was successfully 
generated using JL_F and CL_R. Agarose gel electrophoresis revealed that the PCR products were 
~390 bp (VL) and ~360 bp (CL), as expected (Figure 6.2A). SOE-PCR was performed to hybridize 
the VL and CL genes, which were re-amplified prior to cloning into pcDNA3.1 (+). Figure 6.2B shows 
that the successfully chimerized light chain genes were approximately 700 bp in length. 
 
Figure 6.2. Agarose gel electrophoresis of PCR products for generation of chimeric 5.2H7 light chain. A) Murine 
VL and human Ig lambda CL region were amplified from 5.2H7 hybridoma RNA and human PBL mRNA via RT-PCR. 
Lane MW: DNA marker; lane 1: 5.2H7 VL PCR product; and lane 2: human Ig lambda CL PCR product. B) SOE-PCR 
was performed to hybridize the murine VL and human Ig lambda CL genes prior to re-amplification with primers 
containing RE sites for cloning into pcDNA3.1 (+). Lane MW: DNA marker; lane 1: chimeric 5.2H7 light chain SOE-
PCR product; and lane 2: re-amplified chimeric 5.2H7 light chain with RE sites. 
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6.4.3. Chimeric mouse-human 5.2H7 detects CHIKV in multiple assays 
Transfected COS-7L cells secreted fully-assembled, recombinant 5.2H7 mAb (Figure 6.3).  Clarified 
culture supernatants of transfected cells showed strong reactivity against CHIKV lysates in Western 
blot (Figure 6.4), detecting a capsid protein band of ~31 kDa. Both transfected COS-7L cell lysates 
and supernatant were able to bind to CHIKVMAU antigen in ELISA format (Figure 6.5).  These results 
confirm that the chimeric antibody retained the binding specificity of the parent hybridoma. 
 
Figure 6.3. Western blot analysis of chimeric 5.2H7 expressed in COS-7L cells. Boiled, DTT reduced (+) or unreduced 
(-) lysates/supernatant of chimeric 5.2H7 mAb harvested from transfected COS-7L cells were probed with cocktail of 
anti-human mAbs prior to detection using HRP-conjugated antibodies. Lanes 1 & 2: chimeric 5.2H7 cell lysate; lanes 3 
& 4: chimeric 5.2H7 supernatant; lanes 5 & 6: mock-transfected COS-7L cell lysate; and lanes 7 & 8: mock-transfected 
COS-7L supernatant. 
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Figure 6.4. Detection of CHIKV antigen by 5.2H7 hybridoma antibody and chimeric 5.2H7 antibody by Western 
blot. Boiled, reduced lysates of CHIKV-infected C6/36 cells were probed either with 5.2H7 hybridoma culture 
supernatant or supernatant from COS7 cells transfected with chimeric 5.2H7 mAb, prior to detection with anti-mouse or 
anti-human secondary antibodies, respectively. Uninfected C6/36 cells were used as negative controls. Lane MW: Protein 
standard; lanes 1 & 3: CHIKV-infected C6/36 cell lysate; and lanes 2 & 4: uninfected C6/36 cell lysate. 
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Figure 6.5. Detection of CHIKV by chimeric 5.2H7 mAb in ELISA. Crude, CHIKV-infected C6/36 cell lysates were 
coated onto 96-well plates prior to incubation with chimeric 5.2H7 mAb transfected COS-7L cell lysates or culture 
supernatant, or with 5.2H7 hybridoma supernatant. Bound antibodies were then probed with either anti-human or anti-
mouse secondary antibodies, respectively, followed by detection using HRP-conjugated antibodies. The mean absorbance 
reading (OD405nm) of duplicates from two independent experiments were plotted with error bars showing SEM. Uninfected 
C6/36 cell lysates were used as the negative control. 
 
6.5. DISCUSSION 
This aim of this study was to generate a fully-assembled human-mouse chimeric mAb as a positive 
control for use in CHIKV diagnosis. The first step in attempting to create a chimeric or humanized 
mAb is to clone the functional immunoglobulin variable genes via PCR amplification using 
degenerate primers and the cDNA of a hybridoma as template. However, the occurrence of 
transcribing non-functional genes from aberrant heavy and/or kappa light chain mRNA transcripts is 
relatively high (Carroll et al., 1988; Kutemeier et al., 1992; Ding et al., 2010).  The myeloma cell 
line P3X63Ag8.653 used for the creation of the 5.2H7 hybridomas was derived from MOPC-21 cells, 
which are known to express endogenous immunoglobulin heavy and light chain transcripts, as well 
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as harbor aberrant, non-functional genes (Strohal et al., 1987; Irani et al., 2008; Ding et al., 2010). 
Amounts of these unproductive transcripts can be extremely high in some hybridomas and have been 
shown to exceed levels of their functioning counterparts (Carroll et al., 1988; Irani et al., 2008). The 
construction of chimeric mAbs using these abnormal genes may produce immunoglobulin molecules 
that either exhibit a significant loss in antigenic affinity, or are completely defective. Although there 
are strategies that can reduce the amplification of these aberrant genes, the use of variable region 
gene-specific primers in a high-specificity PCR should be considered as one of the most accurate 
methods (Duan and Pomerantz, 1994; Ostermeier and Michel, 1996). This technique can furthermore 
ensure that the antibody’s natural leader sequence can be retained. 
In this study, a degenerate primer (Morrison, 2002) was successfully used to amplify a VH gene of 
mAb 5.2H7 which was determined to be functional by IMGT analysis, and was distinct from the 
known MOPC-21 non-functional heavy chain.  However, in contrast, the use of degenerate primers 
to amplify the VL gene of 5.2H7 was not successful. The Mouse Typer Isotyping Panel kit (Bio-Rad 
Laboratories) utilized in our study determined that the light chain of 5.2H7 was of the kappa isotype. 
Nonetheless, the degenerate kappa light chain-specific primers were only capable of amplifying genes 
of the aberrant transcript, requiring the design of a more specific primer for the 5.2H7 light chain. N-
terminal sequencing was performed on the light chain of mAb 5.2H7. However, we were unable to 
obtain any amino acid sequences, even after several attempts of unblocking procedures, due to the 
presence of an unknown N-terminal modification. Mass spectrometry was therefore utilized to obtain 
peptide fragments of the 5.2H7 VL region. Peptides with sequences homologous with regions of the 
MOPC-21 light chain (NCBI Accession No. M35669, GI: 197295) were discarded. Primers designed 
off the identified peptide sequences were used in conjunction with the 5ʹ RACE system to obtain 
partial 5.2H7 VL cDNA. Following further amplification and sub-cloning, the incomplete VL gene 
was sequenced and a functional leader sequence was identified, allowing a region for the design of a 
gene specific forward primer. The IMGT/V-QUEST analysis also revealed that the light chain of 
mAb 5.2H7 was of a lambda isotype, despite the results obtained with mAb isotyping kit that 
indicated a kappa chain. Therefore, lambda light chain J-region reverse and forward primers were 
designed for use in PCR amplification of the 5.2H7 VL region and human lambda CL region, 
respectively. 
Although the specific amplification method presented in this study was used for the generation of a 
VL gene, it can also be efficiently utilized for the generation of heavy chain genes. Few aberrant VH 
genes have been reported, yet, they are known to be far more complicated and diversified than the 
well-recognized aberrant VL gene. Moreover, more than one aberrant VH transcript may exist in a 
single hybridoma (Irani et al., 2008). Currently, the best strategy to avoid the non-functional VH genes 
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is by post-PCR screening via sequencing and comparative analyses in databases (Ding et al., 2010). 
By using the method described above for the generation of the 5.2H7 VL genes, it will be possible to 
eliminate the laborious task of screening numerous cloned products for the avoidance of aberrant 
heavy chain genes. 
We have demonstrated that culture supernatant from transiently-transfected COS-7L cells contains a 
functional chimeric form of 5.2H7 mAb that specifically detects the CHIKV CP antigen in Western 
blot and ELISA and maintains the reactivity of the parent hybridoma. This chimeric construct 
represents a good candidate for scale-up production by establishing stable cells lines for consistent 
and continuous secretion of the recombinant mAbs using well described procedures (Wong et al., 
1996; Jones and Barnard, 2007; By et al., 2009). The recombinant 5.2H7 antibody has potential 
application as a positive and cut-off calibrator control reagent in serology-based diagnostic assays for 
CHIKV, replacing the currently used human serum-derived reagents, eliminating problems associated 
with supply and batch-to-batch variation. 
We have previously shown that mAb 5.2H7 exhibits cross-reactivity to several other alphaviruses 
(e.g. Ross River virus, Sindbis virus, Semliki virus; see Chapter 4), and probably to additional 
alphaviruses not yet assessed, thus making it a prime candidate for use as a positive control in 
diagnostic tests for  these viruses as well (Goh et al., 2014). This antibody also performed well in IFA 
and recognized CHIKV CP in Western blot under reducing conditions – see Chapter 4 (Goh et al., 
2014). Thus, the chimeric version of 5.2H7 will potentially be a useful reference reagent in a variety 
of assay formats. 
 
6.6. CONCLUSIONS 
In summary, we have generated a chimeric human-mouse mAb to the CP of CHIKV that represents 
a candidate positive control reagent in human diagnostic assays. Additionally, we have described an 
efficient and simple method to specifically acquire sequences of immunoglobulin variable chain 
regions, while avoiding the unwanted amplification of the aberrant heavy and/or light chain RNA 
transcripts present in several myeloma cell lines commonly used in hybridoma fusion technology. 
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CHAPTER 7: A SENSITIVE EPITOPE-BLOCKING ELISA FOR THE DETECTION OF 
CHIKUNGUNYA VIRUS-SPECIFIC ANTIBODIES IN PATIENTS 
 
This chapter has been submitted to Journal of Virological Methods as Goh, L. Y., Kam, Y., Metz, 
S. W., Hobson-Peters, J., Prow, N. A., McCarthy, S., Smith, D. W., Pijlman, G. P. and Hall, R. 
A. (2014). A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific 
antibodies in patients. J Virol Methods. 
 
7.1. ABSTRACT 
Chikungunya fever (CHIKF) has re-emerged as an arboviral disease that mimics clinical symptoms 
of other diseases such as dengue, malaria, as well as other alphavirus-related illnesses leading to 
problems with definitive diagnosis of the infection. Herein we describe the development and 
evaluation of a sensitive epitope-blocking ELISA (EB-ELISA) capable of specifically detecting anti-
chikungunya virus (CHIKV) antibodies in clinical samples. The assay uses a monoclonal antibody 
(mAb) that binds an epitope on the E2 protein of CHIKV and does not exhibit cross-reactivity to 
other related alphaviruses. We also demonstrated the use of recombinant CHIK virus-like particles 
(VLPs) as a safe alternative antigen to infectious virions in the assay. Based on testing of 60 serum 
samples from patients in the acute or convalescent phase of CHIKV infection, the EB-ELISA 
provided us with 100% sensitivity, and exhibited 98.5% specificity when Ross River virus (RRV)- 
or Barmah Forest virus (BFV)-immune serum samples were included. This assay meets the public 
health demands of a rapid, robust, sensitive and specific, yet simple assay for specifically diagnosing 
CHIK-infections in humans. Lastly, we have also, for the first time, identified a CHIKV-positive 
serum sample within a pool of 29 patient serum samples using non-cross reactive, CHIKV-specific 
mAbs in an antigen-capture assay. This double-antibody assay was then transferred on a dipstick 
platform for the successful detection of CHIKV proteins. 
 
7.2. INTRODUCTION 
Chikungunya virus (CHIKV), the etiological agent of Chikungunya fever (CHIKF), belongs to the 
family Togaviridae and genus Alphavirus. CHIKV was first isolated in 1952 during an outbreak in 
Tanzania, East Africa (Robinson, 1955). Since then, CHIKV has caused sporadic epidemics of 
rheumatic disease though its prevalence has increased dramatically in recent years (Powers and 
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Logue, 2007). Between 2004 and 2011, CHIKV was responsible for a massive outbreak at an 
estimated 1.4-6.5 million infections, with imported cases reported in over 40 countries (Suhrbier et 
al., 2012). Geographical expansion of the Aedes albopictus mosquito’s distribution has allowed for 
the first autochthonous CHIKV infections in Italy and France, in 2007 and 2010, respectively (Rezza 
et al., 2007; Angelini et al., 2008; Grandadam et al., 2011). The increase in international travel has 
also seen the virus spread to previously unaffected countries such as the USA, the Caribbean and 
Australasia (Schwartz and Albert, 2010; Gibney et al., 2011; Viennet et al., 2013; Higgs, 2014; 
Mansuy et al., 2014). 
CHIKF is characterized by an abrupt onset of fever, headache, myalgia, fatigue, nausea, rashes 
(usually maculopapular) and severe polyarthralgia, which can persist from weeks to months 
(Robinson, 1955; Brighton et al., 1983; Hoarau et al., 2010). The re-emergence of CHIKV has seen 
it be associated with severe disease manifestations and mortality, primarily in elderly patients with 
co-morbidities and the very young (Mavalankar et al., 2008; Economopoulou et al., 2009; Tandale et 
al., 2009; Jaffar-Bandjee et al., 2010). Furthermore, mother-to-child transmission was also observed 
with about half the infected neonates developing serious disease outcomes such as haemorrhage, 
disseminated intravascular coagulation and/or cardiac and neurological complications, with the latter 
often leading to permanent disabilities (Rampal et al., 2007; Gerardin et al., 2008; Suhrbier et al., 
2012). The treatment of rheumatic disease caused by CHIKV currently involves the use of pain killers 
and/or non-steroidal anti-inflammatory drugs. Presently, there are no licensed human vaccines 
available although CHIKV vaccines are in development (Akahata et al., 2010; Wang et al., 2011; 
Brandler et al., 2013; Metz et al., 2013; Powers, 2014). 
The clinical profile of CHIKF is similar to that of several other infections such as dengue fever, 
malaria and a host of closely-related arthralgic alphaviral diseases (Carey, 1971; Sergon et al., 2007; 
Suhrbier et al., 2012; Roth et al., 2014). Co-infection of CHIKV with dengue virus and other tropical 
arboviruses that cause non-specific symptoms similar to CHIKF have also been reported, highlighting 
the requirement of definitive diagnostic tests to assist clinicians with treatment options as well as to 
inaugurate appropriate public health measures (Khai Ming et al., 1974; Vazeille et al., 2010; Kumar 
et al., 2012; Baba et al., 2013). 
During early stages of the infection when antibody responses have not been generated, virus culture 
and/or PCR-based techniques are typically utilized for the detection of CHIKV. However, blood 
samples must be taken during the viraemic period, which typically lasts only 5-7 days (Edwards et 
al., 2007; Laurent et al., 2007; Santhosh et al., 2007). Moreover, this narrow window of opportunity 
for nucleic acid detection often starts prior to the onset of symptoms, thus further limiting the 
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opportunity of obtaining viraemic patient samples for virus culture or PCR. Although the above-
mentioned techniques are still considered gold standards for diagnosing CHIKV, both techniques 
require specialized facilities or equipment, as well as technical expertise to perform, which are too 
costly and impractical for widespread use. 
In later phases of the illness (>1-2 weeks post-infection), ELISAs (indirect ELISAs and MAC-
ELISAs) are the most commonly used tests for laboratory-based diagnoses. Other serological tests 
available include hemagglutination inhibition (HI), indirect ELISAs and virus-neutralization assays 
(Adesina and Odelola, 1991; Tiwari et al., 2009; Sam et al., 2011). However, most existing MAC-
ELISA and HI tests are poorly established and lack credibility, in terms of specificity, due to the high 
possibility of false-positive results from cross-reactivity with other closely-related alphaviruses such 
as Ross river virus (RRV), Barmah Forest virus (BFV) and Sindbis virus (Niedrig et al., 2009; 
Rianthavorn et al., 2010; Blacksell et al., 2011; Kosasih et al., 2012; Reddy et al., 2012). Plaque-
reduction virus-neutralization tests (PRNTs) are currently recommended by the world health 
organisation (WHO) for serological detection of CHIKV antibodies in human. However, these assays 
are not only labour-intensive, but also require access to bio-containment facilities due to the handling 
of infectious virus, rendering them impractical for rapid and high-throughput diagnostics. 
According to the World Health Organisation, the ideal test should be rapid, specific, sensitive, cost-
effective, user-friendly for lesser skilled personnel, and robust in different climatic conditions. More 
importantly, the test should also be equipment-free (in terms of dependence on electricity) and easily 
accessible to those who need it (Urdea et al., 2006). Herein we report the use of a monoclonal 
antibody (mAb) to the viral E2 protein and recombinant virus-like particles (VLPs), produced in 
insect cells (Metz et al., 2013), in an epitope-blocking ELISA (EB-ELISA) for the sensitive and 
specific detection of anti-CHIKV antibodies in human sera. The use of a CHIKV-specific mAb in the 
assay has allowed for the development of a highly-specific diagnostic test for CHIKV that should not 
produce false-positive results with closely-related alphaviruses, as well as other co-circulating 
arboviruses such as dengue virus. Furthermore, the utilization of stably-expressed non-infectious 
recombinant VLPs as the coating antigen will enable the assay to be performed safely without 
requirements of biosafety containment. We have also illustrated the successful detection of CHIKV 
antigen from a human serum sample in ELISA using a combination of the CHIKV-specific mAbs. 
Finally, we have showed that these mAbs can be utilized in a dipstick assay for CHIKV protein 
detection as well. These assays offer highly-specific alternatives towards the diagnosis of CHIKV in 
the later stages without the issue of cross-reactivity with other closely-related alphaviruses, and can 
provide the basis for antigen detection in mosquito vectors as well as in the earlier phases of human 
CHIKV infections. 
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7.3. MATERIALS AND METHODS 
7.3.1. Cell and virus culture 
C6/36 (Aedes albopictus mosquito) cells were propagated in RPMI 1640 supplemented with 2% fetal 
bovine serum (FBS, Gibco, Life Technologies). Cultures were passaged by dissociating the cell 
monolayer from tissue culture flasks (Greiner Bio-One) with trypsin/PBS and were incubated at 28 
°C. African green monkey kidney epithelial-derived Vero-E6 cells were cultured in DMEM (Gibco, 
Life Technologies) supplemented with 10% FBS. The mammalian cells were passaged by 
dissociating the surface monolayer with trypsin/EDTA and were cultured at 37 °C with 5% CO2. 
Hybridoma cells were expanded in Hybridoma SFM (Gibco, Life Technologies) with 20% FBS at 37 
°C with 5% CO2, before being weaned off all FBS for the harvesting of mAbs in culture fluid. 
Spodoptera frugiperda (Sf21) insect cells (Invitrogen) were maintained as a monolayer culture in 
Grace’s insect medium (Invitrogen), supplemented with 10% FBS (Hyclone). Sf9-easy titer (ET) cells 
(Hopkins and Esposito, 2009) were maintained as a monolayer culture in Sf-900 II (Invitrogen) 
serum-free medium. All cell cultures were supplemented with 50 U penicillin mL-1, 50 μg 
streptomycin mL-1 and 2 mM L-Glutamine (Gibco, Life Technologies). 
CHIKV viruses used in this study included the CHIKV Mauritius strain (CHIKVMAU) (GenBank ID: 
EU404186) and the CHIKV La Reunion strain (CHIKVIMT) originally isolated from a French patient 
returning from Reunion Island during the 2006 CHIKV outbreak (Bessaud et al., 2006). CHIKV 
virion stocks were prepared by passaging CHIKVIMT twice in Vero-E6 cultures, washed with PBS, 
and clarified by sucrose-cushion ultra-centrifugation before storage at -80 °C. Viral plaque-forming 
unit assay and/or quantitative real-time PCR were utilized to evaluate the virus titres for both isolates. 
To obtain crude viral lysate, virus-infected C6/36 cell monolayers were incubated at 28 °C for 2-3 
days before cells were rinsed in PBS and disrupted by sonication in the presence of BS9 lysis buffer 
(120 mM NaCl, 50 mM H3BO3, 1% Triton X-100 and 0.1% SDS, pH 9.0). The lysate was clarified 
by centrifugation at 12,000 x g for 10 min at 4 °C and stored at -20 °C (Clark et al., 2007). 
 
7.3.2. Antigens and mAbs 
The CHIKV VLPs were expressed in insect cells using recombinant baculoviruses, and purified by 
affinity chromatography and sucrose gradient purification, respectively, as previously described 
(Metz et al., 2011; Metz et al., 2013). Concentrations of purified VLPs were determined by BCA 
Protein Assay Kit (Thermo Scientific Pierce) by the provider (Stefan Metz, personal communications) 
and confirmed in our laboratory with the Nanodrop 1000 Spectrophotometer (Thermo Fisher 
Scientific). CHIKV-specific anti-E2 mAbs were produced previously in Chapter 3 (Goh et al., 2013), 
125 
 
and purified using a HiTrap Protein G HP column (GE Healthcare Life Sciences) according to the 
manufacturer’s instructions. MAbs to be used as detecting antibodies were then biotinylated using 
the BiotinTag kit (Sigma), according to the manufacturer’s instructions. All purified mAbs were 
quantified using the BCA Protein Assay Kit (Thermo Scientific Pierce). 
 
7.3.3. Clinical samples 
A total of 109 human serum samples were used in this study. Obtained from PathWest (PW), 
Laboratory Medicine, Western Australia were 10 BFV-positive, 10 RRV-positive and 30 CHIKV-
positive serum samples previously collected from patients presenting with disease symptoms and 
infection between 6th December 1998 and 28th February 1999. These were confirmed by IgM 
detection via indirect immunofluorescence antibody assay, as well as HI assay (to screen for anti-IgG 
antibodies) (Lam et al., 2001). Of the 30 CHIKV-positive PW samples, 22 were collected during the 
acute phase of infection, while two (PW6 and PW28) were chronic samples. The remaining 6 samples 
(PW9, 11, 17, 18, 24 and 26) were not able to be classified. The study also included 30 plasma samples 
(CHIK001-030) of patients with CHIKF who were admitted to the Communicable Diseases Centre 
at the Tan Tock Seng Hospital (TTSH), Singapore, from 1st August through 23rd September 2008. All 
patients were confirmed to have CHIKF by reverse-transcriptase PCR (Chow et al., 2011).  Plasma 
samples were collected during the late convalescent phase 4-6 weeks post-illness onset (p.i.o.) for the 
EB-ELISA. Clinical samples obtained from TTSH, Singapore, were approved by the National 
Healthcare Group’s Domain-Specific Ethics Review Board (DSRB Reference No. B/08/026). 
 
7.3.4. Epitope-blocking ELISA (EB-ELISA) 
The optimal saturating concentrations of the coating antigens and detecting anti-CHIKV E2 mAb, 
1.3A2, were determined using a checkerboard titration via an indirect ELISA, as described previously 
with modifications (Hall et al., 1988; Clark et al., 2007). In brief, CHIKV virions or CHIKV VLPs 
were titrated across U-bottom PVC 96-well plates (BD Falcon) and incubated at 4 °C overnight in 
coating buffer (50 mM Na2CO3, 50 mM NaHCO3, pH 9.6) or PBS, respectively, prior to detection 
with biotinylated 1.3A2 titrated down the plates. Optimal sub-saturating concentrations were 
determined by the highest OD405nm value just before the absorbance reading starts to show a decrease. 
EB-ELISAs were performed on plates coated overnight at 4 °C with either CHIKV virions or VLPs. 
Coated wells were washed three times with PBS/T (0.05% (v/v) Tween-20 in PBS) and non-specific 
sites were blocked in TENTC blocking buffer (0.05 M Tris-HCl pH 8.0, 1 mM EDTA, 0.15 M NaCl, 
0.05% (v/v) Tween 20, 0.2% (w/v) casein) for 1 h at 37 °C. Test serum samples were diluted 1/1,000 
and 1/100 for the TTSH and PW samples, respectively, and added (50 µL/well) for 2 h at 37 ºC prior 
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to the introduction of the biotin-labelled, competing 1.3A2 at its optimal concentration, without 
removal of test sera, for an additional hour with gentle agitation. After rinsing six times with PBS/T, 
horseradish peroxidase (HRP)-conjugated streptavidin (Invitrogen) was added and the complexes 
were allowed to incubate for 30 min at 28 ºC. The wells were again washed before incubation with 
ABTS substrate solution (0.02% (w/v) 2, 2’-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid, 0.06% 
(w/v) H2O2 in 200 mM Na2HPO4 and 100 mM citric acid solution) for 1 h at 28 ºC. Optical density 
(OD) was measured at 405 nm using a multi-well plate reader. Results were considered valid only 
when the OD405mn value in negative control wells were at least 0.5. Cut-off value(s) were set at the PI 
(percentage inhibition) for negative controls plus 3 SD values; PI = 100 - [(OD unknown - OD background) 
/ (OD negative control - OD background) x 100], where the OD405mn of the negative control was the average 
absorbance reading of the healthy donor serum controls. PI value comparison between coating antigen 
used was determined by using the mean PI values of CHIKV samples, while specificity was 
calculated using this formula: [(No. of true positive samples + No. of true negative samples) / (Total 
no. of samples)] x 100%. 
 
7.3.5. Antigen-capture ELISA 
The double-antibody sandwich antigen-capture ELISA was carried out as described previously, with 
slight modifications – see section 3.3.9. (Goh et al., 2013). Briefly, U-bottom PVC 96-well plates 
(BD Falcon) were coated with 1 μg/well of an anti-E2 mAb at 4 °C overnight in coating buffer. 
Titrated human serum samples, at a starting dilution of 1:100, were then allowed to incubate for 1 h 
at room temperature, prior to an hour of blocking. A secondary biotinylated anti-E2 mAb that binds 
a different epitope from the capturing mAb was used as a detecting antibody. After incubating 1 h at 
28 °C, plates were washed and HRP-conjugated streptavidin (Invitrogen) was added. Following 
another hour of incubation, enzyme activity was visualized by the addition of ABTS substrate 
solution, and OD405mn was measured as described above. Serum from healthy donors were used as 
negatives, while 20 ng/well of the sE2 protein was utilized as positive control. Results were 
considered valid only when the OD405mn value of the positive control wells were at least 0.25 and 
doubled that of the negative wells. The criterion for specific recognition of antigen was defined as an 
OD405mn value of ≥0.2 and at least 2-fold greater than that of the negative wells. 
 
7.3.6. Dipstick antigen assay 
The dipstick assay is a rapid immune-chromatographic, lateral flow wicking assay, modified from 
the method previously developed by Ryan et al. (2003), for the qualitative detection of CHIKV 
antigens from infected mosquitoes. This assay is based on a dual antibody “sandwich” principle that 
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uses sensitive test strips (VecTOR Test Systems Inc.). E2-specific mAbs developed previously in 
Chapter 3 were screened for their sensitivity and specificity (Goh et al., 2013). Purified mAbs were 
either conjugated with colloidal gold, or immobilized as capture antibodies on the test strips 
(Fernandez et al., 1994; Wanja et al., 2014). Instead of utilizing mosquitoes grinds, CHIKVROSS 
(GenBank ID: AF490259.3) virus culture was used in this preliminary test. The virus was prepared 
using the VecTOR Test grinding solution as a diluent. Test strips were then incubated with samples 
in their respective tubes for 30 min, after which strips were removed and examined. If present, 
CHIKV antigens in the mosquito tissue suspension would bind to the CHIKV-specific colloidal gold-
conjugated mAb, and migrate along the test strip as a complex where it would be captured by the 
immobilized mAb. The development of a reddish-purple line within the “test zone” would indicate a 
positive result, while the appearance of an internal control line validates the performance of the assay. 
 
7.3.7. Statistical data analysis 
GraphPad Prism for Windows, version 6.00 (GraphPad Software, Inc.) was used to perform 2 or 3 
standard deviation to the mean negative control OD405nm to determine cut-off values for the ELISAs. 
Microsoft Office Excel 2013 was used to calculate the variance of PI from using whole CHIKV 
virions and recombinant CHIKV VLPs as coating antigens in the EB-ELISA. 
 
7.4. RESULTS 
7.4.1. Detection of CHIKV by E2-specific mAbs 
Preliminary testing was carried out to determine the affinities of five biotin-labelled CHIKV E2-
specific mAbs, designated 1.3A2, 4.6F5, 4.10C12, 5.2B2 and 5.2H8, against the two coating antigens 
used for this study - CHIKV VLPs and live, infectious virions - in an indirect ELISA. Biotinylated 
mAb 1.3A2, at its optimal sub-saturating concentration of 1.25 µg/mL, showed the strongest 
interaction with both the CHIKV VLPs and infectious virions, with OD405nm readings of >1.0 (results 
not shown). Furthermore, biotinylated 1.3A2, 4.6F5 and 4.10C12 were inhibited more efficiency than 
mAbs 5.2B2 and 5.2H8 in EB-ELISA in the presence of serially-diluted anti-CHIKV polyclonal 
mouse serum (results not shown). We have shown in Chapter 3 that mAbs 1.3A2, 4.6F5, and 4.10C12 
exhibit complete two-way inhibition of each other in competitive binding studies indicating that they 
bind the same or adjacent epitopes within the same region of the E2 protein (Goh et al., 2013). 
Considering these results, and our observation that the 1.3A2 hybridoma line was a superior producer 
of mAb, we selected this antibody for further analysis. 
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7.4.2. Development of an EB-ELISA 
Results from checkerboard titrations of CHIKV antigens and detecting mAb revealed that the optimal 
concentrations of recombinant VLP or purified CHIKV virion antigen were 200 ng or 106 infectious 
units per well, respectively (results not shown). Initially we compared the effectiveness of using 
CHIKV VLPs to that of using CHIKV virions as antigens in the EB-ELISA using serial dilutions of 
three reference samples; PW01 (CHIKV-immune); PW31 (RRV-immune) and PW41 (BFV-
immune). Using infectious virions at their optimal coating concentration, PI exhibited by the CHIKV-
immune sample declined significantly for each doubling dilution, with 1:400 diluted sera producing 
~50% inhibition (Figure 7.1). By comparison, using CHIKV VLP antigen in the EB-ELISA revealed 
>50% inhibition with the same CHIKV-positive sample diluted to 1:3,200. These results indicated 
that the VLP antigen was at least as sensitive as the native virion in this format. 
 
 
Figure 7.1. Epitope-blocking ELISA analyses of CHIKV, RRV and BFV-infected patient sera using (A) CHIKV 
virions, or (B) CHIKV VLPs. C6/36 cell lysate and baculovirus-expressed GFPs were used as negative control antigens, 
respectively (results not shown). 
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To determine a suitable cut-off value for PI in the EB-ELISA, a panel of four sera from healthy donors 
lacking antibodies to CHIKV - based on IFA for anti-CHIKV IgM - were tested for non-specific 
inhibition of mAb 1.3A2 binding to VLPs or virions. The mean non-specific PI of negative samples 
using virion antigen was 7.9% with a 3 x SD of 7.7%, while the PI by these samples on VLP antigen 
was 5.7% with a 3 x SD of 12.3%. Using a criteria of “mean PI of negative sera plus 3 x SD” this 
corresponds to cut-off values of 15.6% and 18%, respectively. A fixed cut-off point of 20% was set, 
with serum samples exhibiting PI of between 20% and 30% considered “positive with requirement 
of confirmation by RT-PCR, virus culture and/or neutralization”, which is a common practice for 
serological diagnostic assays. 
 
7.4.3. Evaluation of EB-ELISA using clinical serum samples 
The EB-ELISA demonstrated a sensitivity of 100% with all 60 CHIKV-immune serum, previously 
confirmed by IgM immunofluorescence and HI assays, also testing positive in the EB ELISA (Table 
7.1). The frequency distribution of percentage inhibition based on the use of CHIKV virions as 
coating antigen showed that more than two-thirds of the samples exhibited >60% inhibition (Figure 
7.2). The EB-ELISA also exhibited 98.5% specificity when CHIKV virions were used as antigen to 
assess inhibition by 10 RRV- and 10 BFV-immune sera, with a single RRV-positive sample 
exhibiting a PI of 22.7%. When VLPs were being used as the coated antigen, 100% specificity was 
obtained with the same samples (Figure 7.3). To further compare the efficiency of using CHIKV 
virion antigen with that of recombinant VLPs, mean PIs were recorded for 30 CHIKV-immune 
plasma samples tested in the EB-ELISA. The samples gave an average PI of 61.7% when virion 
antigen was used and 58.2% when VLPs were employed (Figure 7.3). These values indicated the two 
antigens provided similar efficacy in the EB-ELISA format. 
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Table 7.1. Comparison of the CHIKV-specific EB-ELISA against standard diagnostic techniques used for 
detection of antibodies to CHIKV in human sera. 
Human Serum 
Sample ⱡ 
Virus 
Type 
PI 
(Virions) 
PI 
(VLPs) 
HI 
Titre 
 
Human Serum 
Sample ⱡ 
Virus 
Type 
PI 
(Virions) 
PI 
(VLPs) 
HI 
Titre 
CHIK001 CHIKV 74.4 N.D. N.D.  PW11 CHIKV 52.0 54.5 320 
CHIK002 CHIKV 75.6 N.D. N.D.  PW12 CHIKV 44.9 59.6 160 
CHIK003 CHIKV 67.6 N.D. N.D.  PW13 CHIKV 43.2 64.2 160 
CHIK004 CHIKV 56.4 N.D. N.D.  PW14 CHIKV 36.8 59.2 <10 
CHIK005 CHIKV 78.3 N.D. N.D.  PW15 CHIKV 47.2 74.2 160 
CHIK006 CHIKV 85.4 N.D. N.D.  PW16 CHIKV 56.4 61.6 320 
CHIK007 CHIKV 77.3 N.D. N.D.  PW17 CHIKV 65.9 76.5 160 
CHIK008 CHIKV 82.0 N.D. N.D.  PW18 CHIKV 39.4 44.7 40 
CHIK009 CHIKV 84.2 N.D. N.D.  PW19 CHIKV 71.0 65.6 320 
CHIK010 CHIKV 78.9 N.D. N.D.  PW20 CHIKV 60.9 56.1 640 
CHIK011 CHIKV 79.4 N.D. N.D.  PW21 CHIKV 76.1 60.9 160 
CHIK012 CHIKV 88.8 N.D. N.D.  PW22 CHIKV 43.9 73.1 640 
CHIK013 CHIKV 70.7 N.D. N.D.  PW23 CHIKV 36.1 47.8 320 
CHIK014 CHIKV 79.8 N.D. N.D.  PW24 CHIKV 76.8 45.8 >640 
CHIK015 CHIKV 71.3 N.D. N.D.  PW25 CHIKV 41.8 64.3 80 
CHIK016 CHIKV 61.5 N.D. N.D.  PW26 CHIKV 78.6 54.5 320 
CHIK017 CHIKV 81.1 N.D. N.D.  PW27 CHIKV 72.7 54.8 160 
CHIK018 CHIKV 85.8 N.D. N.D.  PW28 CHIKV 83.3 80.7 320 
CHIK019 CHIKV 61.5 N.D. N.D.  PW29 CHIKV 73.9 57.3 80 
CHIK020 CHIKV 84.1 N.D. N.D.  PW30 CHIKV 77.1 47.8 40 
CHIK021 CHIKV 76.5 N.D. N.D.  PW31 RRV 0.0 6.2 40 
CHIK022 CHIKV 59.4 N.D. N.D.  PW32 RRV 0.0 11.2 20 
CHIK023 CHIKV 83.4 N.D. N.D.  PW33 RRV 0.0 16.0 160 
CHIK024 CHIKV 90.4 N.D. N.D.  PW34 RRV 0.0 7.8 160 
CHIK025 CHIKV 84.8 N.D. N.D.  PW35 RRV 0.0 10.3 <10 
CHIK026 CHIKV 86.9 N.D. N.D.  PW36 RRV 0.0 3.5 160 
CHIK027 CHIKV 77.3 N.D. N.D.  PW37 RRV 16.2 6.3 40 
CHIK028 CHIKV 83.3 N.D. N.D.  PW38 RRV 12.8 7.6 40 
CHIK029 CHIKV 81.5 N.D. N.D.  PW39 RRV 22.7 0.8 160 
CHIK030 CHIKV 80.9 N.D. N.D.  PW40 RRV 3.6 0.0 160 
PW01 CHIKV 78.5 46.5 320  PW41 BFV 0.0 0.0 40 
PW02 CHIKV 60.7 46.0 160  PW42 BFV 0.0 0.0 160 
PW03 CHIKV 64.0 45.9 80  PW43 BFV 0.0 3.6 >640 
PW04 CHIKV 87.5 50.1 20  PW44 BFV 17.3 7.5 160 
PW05 CHIKV 82.2 59.6 320  PW45 BFV 0.0 0.0 >640 
PW06 CHIKV 42.4 60.1 640  PW46 BFV 0.0 0.0 40 
PW07 CHIKV 75.8 58.3 640  PW47 BFV 0.0 6.7 80 
PW08 CHIKV 63.3 57.7 640  PW48 BFV 10.2 1.4 40 
PW09 CHIKV 69.8 65.4 80  PW49 BFV 9.2 0.0 160 
PW10 CHIKV 47.6 53.9 320  PW50 BFV 0.0 0.0 40 
           
ⱡ  Samples CHIK001-030 were tested CHIKV-positive by RT-PCR (Chow et al., 2011), while PW samples were confirmed 
to be CHIKV-positive by HI and IFA via IgM-detection. 
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Figure 7.2. Overall frequency distribution of PI values based on the EB-ELISA results from the 60 CHIKV-positive 
human samples tested with CHIKV virions used as coating antigen. Serum samples were considered positive for 
CHIKV antibodies when PI > 30%, and negative when PI < 20%. Serum samples exhibiting PI of between 20% and 30% 
were considered “positive with requirement of confirmation by virus culture and/or neutralization”. 
 
 
Figure 7.3. Comparison of PI values and specificity of using CHIKV virions vs. VLPs in EB-ELISA. Thirty CHIKV-
positive patient samples were utilized in the EB-ELISA for the comparison of A) sensitivity, in terms of PI, and B) 
specificity of using CHIKV virions vs. CHIKV VLPs as coating antigen. 
 
  
132 
 
7.4.4. Use of anti-E2 mAbs for detection of CHIKV antigens 
Our previous results (see Chapter 3) involving the generation of anti-CHIKV mAbs has shown the 
potential of utilizing a combination of two mAbs that map to different sites of the E2 protein in a 
double-antibody sandwich antigen-capture ELISA to detect for the presence of CHIKV in human 
blood samples (Goh et al., 2013). Monoclonal antibody 5.2B2 was coated onto 96-well plates for the 
capture of CHIKV E2 proteins, while a non-competing, biotinylated mAb 5.2H8 was used as the 
detecting antibody. Out of 29 RT-PCR positive patient samples tested, only one tested positive in the 
ELISA (Figure 7.4). The remaining 28 samples exhibited absorbance readings that were greater than 
that elicited by the negative controls at their respective dilutions. However, their OD405nm values were 
not at least twice that of the healthy donor samples and were thus deemed negative. 
 
 
Figure 7.4. Detection of CHIKV-specific protein in a human serum sample using an antigen-capture ELISA. 
Unlabelled mAb 5.2B2 was coated onto 96-well plates at 1 μg per well prior to incubation with diluted clinical samples. 
The detecting antibody, biotinylated mAb 5.2H8, was used at 400 ng per well. The mean OD405nm values of three replicates 
were plotted with bars showing SD. Protein sE2 (n = 20) was used as a positive control, while healthy donor serum sample 
(HD; n = 20) was utilized as a negative control for the assay. Solid line represents the mean negative OD405nm value, while 
the dotted line indicates the cut-off point, derived from 2 x the mean negative OD405nm reading. 
 
The mAbs were then incorporated into a dipstick assay, by our collaborators at VecTOR Test Systems 
Inc., to determine if the dipstick antigen-capture format could be used for the detection of viral 
proteins in diluted samples. Paired combinations (for capture and detection) of the five anti-E2 mAbs 
– labelled B1, B3, A2, A3, C1 and C2 – were kept confidential due to commercialization reasons.  
Nonetheless, results from testing indicated that some combinations performed better than the others 
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(Figure 7.5). From highest to lowest signal intensity: B3, B1, A2, C1, C2 and A3. Combination B3 
was then used to test a host of other closely-related alphaviruses (including CHIKV), as well as 
several unrelated flaviruses. Further testing also revealed that combination B3 managed to 
specifically detect CHIKV proteins, but not from any of the other 14 viruses tested (Figure 7.6). 
 
 
Figure 7.5. Detection of CHIKV antigens via dipstick assay. Six combinations of the anti-E2 mAbs as capture and 
detecting antibody were used for the detection of CHIKV proteins in diluted samples. Top control line (black arrow) acts 
as a positive control to indicate that the test strip is functioning properly, while bottom line (red arrow) is the test line. 
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Figure 7.6. Specificity of combination B3 in CHIKV dipstick assay. Fifteen different viruses were tested for their 
reactivity against the anti-E2 mAbs (B3 combo), with VecTOR Test Systems Inc. grinding solution as the negative 
control. Top control line (black arrow) acts as a positive control to indicate that the test strip is functioning properly, while 
bottom line (red arrow) is the test line. 
 
 
135 
 
7.5. DISCUSSION 
Epitope-blocking ELISAs have been successfully used for the sensitive and specific detection of 
serum antibodies to a variety of viral pathogens, including RRV, West Nile virus and influenza (Hall 
et al., 1995; Blitvich et al., 2003; Oliveira et al., 2006; Lorono-Pino et al., 2009; Prabakaran et al., 
2009; Sotelo et al., 2011). This study describes the use of a mAb that recognizes an epitope on the 
CHIKV E2 protein in an EB-ELISA to detect CHIKV-specific antibodies in clinical specimens.  
Sixty serum samples from individuals with known CHIKV exposure were utilized to evaluate the 
performance of the EB-ELISA. Using biotinylated 1.3A2 as the detecting antibody, the blocking 
ELISA detected CHIKV-specific antibodies in all convalescent human sera (100% sensitivity), with 
no false-positive results apart from a single RRV-positive sample, PW39, that exhibited low levels 
of inhibition (22.7%) of 1.3A2 binding, deeming it “positive with requirement of confirmation by 
virus culture and/or neutralization”. The RRV and BFV human serum samples were not previously 
tested for presence of antibodies to CHIKV. Therefore, although unlikely, the possibility that sample 
PW39 was obtained from a patient who had low levels of CHIKV antibodies from a prior 
asymptomatic exposure exists. Nonetheless, this still reflects a 98.5% specificity for the EB-ELISA 
using the 20% PI cut off. 
The anti-CHIKV mAb utilized in this study (1.3A2) was previously shown to have no cross-reactivity 
with other alphaviruses tested – see section 3.4.1. (Goh et al., 2013). This high level of specificity is 
consistent with the lack of inhibition of the mAb in the EB-ELISA in the presence of serum antibodies 
from patients with confirmed RRV or BFV infections. Thus the CHIKV-specific EB-ELISA 
developed in this study provides significant improvement in terms of specificity, allowing it to be 
used in regions of the world, such as Australia, Europe, Africa and Central/South America, where 
other alphaviral diseases of humans occur (Suhrbier et al., 2012; Knope et al., 2013). 
MAb 1.3A2 was also previously shown to recognise CHIKV isolates that represent the two major 
global lineages of the virus (Asian and East/Central/South African) – see section 3.4.1. The highly-
conserved nature of the E2 epitope recognized by this mAb is also predicted to provide similar 
detection sensitivity of antibodies to a range of CHIKV strains in the EB-ELISA. This is particularly 
relevant to patient samples from the Caribbean, where a CHIKV strain of the Asian genotype is 
suggested to be responsible for the ongoing outbreak (Lanciotti and Valadere, 2014). 
The recombinant CHIKV VLP antigen assessed in this study was previously generated in a well-
established baculovirus expression system as a safe and non-replicating vaccine candidate, and its 
production can be similarly scaled up for diagnostic use (Metz et al., 2013). More importantly, 
CHIKV VLPs exhibited a sensitivity comparable to that of infectious virions when used as the coating 
136 
 
antigen in the EB-ELISA. When 30 CHIKV-positive serum samples were used to compare the 
efficacy of the two antigens less than 3% variance was observed, with mean PIs of 61.7% and 58.2% 
for virions and VLPs respectively. This comparison demonstrated that apart from being safe, stable 
and easily mass-produced, the recombinantly-expressed CHIKV VLPs are suitable for replacing 
native CHIKV virions as antigens in this ELISA format. 
An antigen-capture ELISA was also developed for the detection of CHIKV proteins in human sera. 
By utilizing a pair of the anti-CHIKV E2 mAbs, a sandwich ELISA was designed to be used in 
conjunction with an antibody-detecting assay to significantly increase the window of diagnosis a 
CHIKV-infected patient. It is well understood that during the early stages of CHIK fever, where most 
patients seek medical advice, antibody responses might not be at sufficient levels required for 
detection due to the delayed activation of the humoral response (Suhrbier et al., 2012). This is when 
blood is taken to obtain a diagnosis, generally via virus culture and/or molecular techniques. The 
availability of an antigen-capture ELISA can be helpful in assisting clinicians obtain a preliminary 
diagnosis, prior to further testing. Safe, rapid and easy-to-perform, the antigen-capture assay could 
be used as a frontline test to screen for potential CHIKV-positive cases that will allow for more 
efficient quarantine and control measures, if required. The antigen-capture ELISA was previously 
tested for its ability to detect CHIKV antigens in the form of the sE2 protein (see section 3.4.5.), and 
was found to be capable of detecting antigen in the picogram range (Goh et al., 2013). Herein, clinical 
serum samples, collected at an average of 4 days p.i.o., were used to evaluate the assay. Results 
showed that only one out of 29 samples tested positive for the presence of CHIKV proteins. However, 
all samples exhibited reactivity above the healthy donor negative control. Due to the limited quantity 
of human samples available, samples were diluted 1:100, which might have been a crucial factor in 
the result, considering most antigen-capture assays require serum samples to be used neat or at a 
maximum dilution of 1:10 (Shukla et al., 2009; Yathi et al., 2013). Nonetheless, this result has 
illustrated the potential of these CHIKV E2-specific mAbs to detect minute quantities of viral protein, 
and as shown in the dipstick assay, may have potential as a vector surveillance tool pending further 
testing on mosquito samples. 
 
7.6. CONCLUSIONS 
The EB-ELISA for CHIKV diagnosis described here represents a rapid, simple, highly-sensitive and 
specific assay that is also cost-effective and safe. These attributes potentially meet the criteria set by 
the WHO for an ideal diagnostic test for CHIKV and may be utilized as a rapid front-line screening 
assay for the serodiagnosis of CHIKF. Furthermore, the platform’s robustness will enable it to be 
used in harsher environments as a point-of-care test. Lastly, the dipstick assay has suggested another 
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potential use for these mAbs as reagents for the specific detection of CHIKV protein, especially in 
mosquito vectors. 
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CHAPTER 8: GENERAL DISCUSSIONS AND CONCLUSION 
The primary objective of this project was to develop, characterise and evaluate a set of reagents, in 
the form of mAbs and recombinant antigens, that would be useful for CHIKV research, diagnostics 
and potentially as therapeutics to prevent disease. This thesis has described the generation of 
hybridomas secreting mAbs specific for the capsid and E2 protein of CHIKV. These mAbs were 
evaluated for their ability to detect CHIKV in various assays such as ELISA, Western blot, IFA and 
immunohistochemistry. The work presented in this study has shown that the anti-E2 mAbs have 
potential prophylactic properties while the CP-specific mAbs were capable of recognising multiple 
isolates of CHIKV as well as several other closely-related alphavirus such as RRV, BFV and SINV. 
In addition, these CHIKV E2-specific mAbs demonstrated their effectiveness, in the format of an EB-
ELISA, for the detection of anti-CHIKV antibodies in patients. Finally, the anti-E2 mAbs also showed 
their potential use in the capture of CHIKV antigen in both human and mosquito samples. 
Data obtained whilst attempting to determine the binding sites of the anti-CHIKV CP mAbs suggested 
that the C-terminus of CP is essential for antibody binding. Further analysis of native and recombinant 
CP also confirmed the presence of minor, N-terminally truncated versions of the protein, as seen in 
Figures 5.6 and 5.7. Lastly, using a novel technique to avoid the amplification of dominant non-
functional mRNA transcripts, a chimeric mouse/human mAb was engineered and transiently 
expressed to assess its potential use as an alternate positive control reagent in ELISA kits for the 
diagnosis of CHIKV. 
The re-emergence of CHIKV and its continued spread into previously unaffected regions has 
demonstrated that it is a serious public health problem on a global scale. Furthermore, the disease it 
causes can have a significant social and economic impact on affected communities. The high 
epidemic potential of CHIKV further accentuates the exigency for accurate diagnostics and effective 
anti-viral therapeutics (Akahata et al., 2010; Wang et al., 2011; Brandler et al., 2013; Metz et al., 
2013; Powers, 2014). 
 
8.1. GENERATION OF CHIKV-SPECIFIC MABS 
The generation of anti-CHIKV mAbs was carried out to meet the current shortage of research and 
diagnostic reagents for CHIKV. Following intensive screening of the antibody-producing 
hybridomas, mAbs harvested from selected and cloned parental cell lines were further characterised 
using multiple assays and were shown to bind either to the E2 or CP of CHIKV (Goh et al., 2013; 
Goh et al., 2014). The utility of these generated mAbs was highlighted when it was determined that 
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the anti-E2 mAbs were specific for CHIKV, but reacted equally well with isolates form different 
genotypes. In contrast, the anti-CP mAbs cross-reacted with related alphaviruses, including RRV, 
SINV and SFV. 
 
8.2. E2-SPECIFIC MABS 
A representative anti-E2 mAb, 1.3A2, was shown to prevent CHIK disease in mice administered with 
the mAb prior to challenge with the virus. Although its use in treating human disease may be 
impractical considering the large quantities that will probably be required for this antibody, this model 
may serve as a platform for the development of more potent mAb therapeutics/prophylactics against 
CHIKV and other medically important alphaviruses. For example, virus neutralising antibodies have 
been suggested for preventing vertical mother-to-child transmissions. MAbs are also currently being 
used in the prophylaxis of several infections, such as hepatitis A virus, hepatitis B virus, and 
respiratory synctial virus infections in the form of passive immunisation, prior to expected exposure, 
such as a forecasted epidemic or the entering of a region known to be endemic to certain infectious 
diseases (Sawyer, 2000; Both et al., 2013). Progress in the development of inexpensive production 
platforms will furthermore allow antiviral mAbs to be more widely available and affordable. Due to 
the non-conformational nature of the anti-E2 mAbs, we were unable to map their binding sites within 
the protein. However, it is probable that these mAbs recognises either the receptor-binding site(s) of 
E2 or an epitope capable of interfering with virus attachment onto the host cell membrane. 
Competitive binding of the E2-specific mAbs revealed that they recognised at least three spatially 
separated epitopes on the protein. This information was then used to design a capture assay capable 
of detecting CHIKV proteins in samples. Coupled with their high specificity towards the virus, the 
E2-specific mAbs were demonstrated to be extremely useful for the detection of CHIKV antigens in 
mosquito vectors. The rapid detection of CHIKV in mosquitoes via the use of a dipstick assay can 
provide a rapid and convenient surveillance tool for the prompt assessment of disease threat and 
timely implementation of vector control measures. These strategies are particularly useful during 
military deployments in high-risk areas (Nasci et al., 2003; Sattabongkot et al., 2004; Coleman et al., 
2009; Wanja et al., 2014). However, when clinical samples positive for CHIKV RNA by RT-PCR 
were tested in the antigen-capture assay, the efficiency of CHIKV antigen detection was relatively 
poor, with only one out of 29 early-phase human samples positive. Although all remaining samples 
exhibited reactivity above the healthy donor negative control, their OD405nm values did not reach the 
cut-off threshold (at least double that of the healthy donor samples) which was statistically determined 
to reduce the chance of false positives. The limited volume of human samples available, which 
required dilution to 1:100 for use in the assay, may have reduced our ability to detect viral antigen in 
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these samples. Indeed, most antigen-capture assays require serum samples to be used neat or at a 
maximum dilution of 1:10 (Shukla et al., 2009; Yathi et al., 2013). While the data has illustrated the 
potential of these CHIKV E2-specific mAbs to detect minute quantities of viral protein, further 
optimization of the antigen capture assay with lower dilutions of samples is required to fully assess 
the sensitivity and potential of the assay for clinical use. 
In this thesis we also demonstrated that one anti-E2 mAb, 1.3A2, exhibited exceptional sensitivity 
for the detection of CHIKV-specific antibodies in human serum samples in EB-ELISA. Both live 
CHIKV virions and recombinant CHIKV VLPs were assessed as coating antigens in the ELISA, and 
while no significant difference in the sensitivity or specificity were observed between the two 
antigens, we were unable to make a direct comparison as a result of the different dilutions of clinical 
samples used for each experiment, due to a lack of serum volume for the TTSH (Singapore) samples. 
Nevertheless, the ability of the EB-ELISA to retain its sensitivity and specificity even when the TTSH 
samples were diluted 1:1,000, instead of 1:100, further illustrates the high sensitivity of the detection 
assay using both antigens. More importantly, the successful use of the CHIKV VLPs as a non-
infectious antigen, that mimics the native structure of the virus and can be stably and continuously 
expressed on a large scale, has provided a safe and efficient alternative to using live virus in diagnostic 
assays. In conclusion, this use of an EB-ELISA for diagnosing CHIKF represents a safe, robust, 
simple-to-use and cost-effective alternative to currently available commercial kits (e.g. indirect and 
MAC-ELISAs). 
 
8.3. CP-SPECIFIC MABS 
We have shown with multiple assays such as ELISA, IFA, Western blot and IHC, that the anti-CP 
mAbs are capable of sensitive recognition of CHIKV antigen. The successful application of a 
representative mAb, 5.5G9, to detect CHIKV antigen in murine tissue samples in IHC further 
reinforces the potential use of these CP-specific mAbs for clinical diagnostics and research purposes, 
including the study of viral pathogenesis. Further evaluation of these mAbs against other medically 
significant alphaviruses will only increase their value as diagnostic tools in other regions of the world. 
Aside from their use in the identification of CHIKV, we believe that further characterising these CP-
reactive mAbs, in terms of their binding sites on the protein, will enable us to gain a better idea of 
how we can utilise these antibodies to obtain more information on this essential component of the 
nucleocapsid. Initial results indicated that anti-CP mAbs recognised linear epitopes by reacting with 
reduced and carboxymethylated antigens in Western blot. The use  of recombinant C- or N-terminally 
truncated versions of CP further suggested that the group 1 mAbs recognised a region spanning 
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approximately 105 aa (CP 105-210), while the group 2 mAbs bound within the first 35 aa of CP. 
These findings were supported by mass spec analysis of truncated native proteins in CHIKV-infected 
lysates that were bound by group 1 mAbs which further defined their binding region between residues 
157 and 210. 
To further narrow down the binding sites of these mAbs we designed synthetic peptides 
encompassing the entire CHIKV CP and assessed their recognition by the anti-CP mAbs in several 
assays, including ELISA and MIA. Unfortunately, none of the synthetic peptides were bound by CP-
specific mAbs or polyclonal anti-CHIKV mouse sera, despite all control peptides, that were 
synthesised in the same batch, being recognised by their respective mAbs in both assays. One 
conclusion from this result was that post-translational phosphorylation, which does not occur with 
synthetic peptides, was required for binding, consistent with the existence of potential 
phosphorylation sites in both of the predicted binding regions for these mAbs. However, the puzzling 
observation that none of the C-terminally truncated recombinant CP proteins were recognised by anti-
CP mAbs (even the group 2 mAbs predicted to bind to the N terminal region) or anti-CHIKV 
polyclonal serum, was inconsistent with this hypothesis. A second conclusion was that the C-terminus 
of CP is required for the protein to fold into an antigenically-authentic structure and allow antibody 
binding to occur. Based on the position of the smallest C-terminal truncation, this would suggest that 
the last 35 residues are required for recognition of the capsid by the mAbs or polyclonal antibodies 
used in this study. Without a doubt, this deduction would be compatible with the predicted binding 
sites of the 2 groups of mAbs and their failure to recognise the synthetic peptides. Future studies using 
rCap with internal deletions and various lengths of intact C-terminal sequences would confirm this 
hypothesis and identify the minimum C-terminal sequence required for mAb binding and elucidate 
the associated mechanism. 
In the process of mapping the epitopes of CP-specific mAbs, we also made an observation on the 
presence of a smaller, truncated version of CP in Western blots. Minor truncated products of the CP 
have previously been identified as unknown proteins or simply as “protein X” in CHIKV and some 
other alphaviruses (Bell et al., 1983; Choi et al., 1996; Cho et al., 2008; Brandler et al., 2013). While 
the presence of sCP has not been established in CHIKV, the discovery of a minor CP was recorded 
in WEEV and SINV (Ishida and Simizu, 1981; Choi et al., 1996), with Choi and colleagues 
suggesting a truncation of 113 N-terminal residues within the SINV CP. We have since confirmed by 
reactivity, with the help of the anti-CP mAbs, that the ~24 kDa protein is a part of the CP. Choi et 
al.’s (1996) prediction that the sCP was reduced by 100-110 aa also accurately reflects its size of ~24 
kDa on Western blot. The binding of the group 1 mAbs, but not the group 2 mAb, towards the sCP 
further supports this theory, while the missing residues also led us to propose that this product is 
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potentially a result of an alternate translation initiation codon, predicted to occur at position 105 in 
CHIKV CP. This is further supported by mass spectrometry analysis of CP molecules isolated from 
infected cell lysates by immune-precipitation with group 1 mAbs. While full-length and smaller 
versions of CP retained the same peptides at the C-terminal end of the protein, the smaller species of 
CP lacked peptides at the N-terminus. Indeed, the first six residues representing an N-terminal peptide 
of a major truncated species, MCMKIE (corresponding to CP 105-110), is predicted to be translated 
from the putative alternative translation initiation site. 
The fact that this minor product of the CP has been consistently detected in numerous alphaviruses, 
in both recombinant and native forms of the protein, implies that it may have functional significance 
during infection. Although we were unable to fully characterise this little-known sCP, the availability 
of these mAbs has allowed for further proteomic experimentations that were previously not possible. 
The anti-capsid mAbs have also been used to demonstrate nuclear staining within cells infected with 
CHIKV or transfected with rCap, supporting recent literature that the CHIKV CP contains nuclear 
import and export signals (Thomas et al., 2013). Reasons behind the transport of CP - and potentially 
sCP - to and from the host cell nucleus is unknown, and thus accentuates the requirement for further 
research into the role and function of the CHIKV CP. 
 
8.4. CHIMERIC MAB 5.2H7 
The versatility of the CP-specific mAbs led us to creation of a genetically re-engineered humanised 
version of the 5.2H7 mAb that could be utilised as a positive control reagent, providing diagnostic 
kits with a specific, consistent, cost-effective and ethical alternative to using human reference sera. 
Interestingly, through a minor but significant malfunction of a commercial antibody isotyping kit, we 
have managed to unveil a novel mass spectrometry-guided primer design and 5ʹ RACE approach to 
generate chimeric mAbs, while avoiding the amplification of non-functional antibody genes from 
aberrant mRNA transcripts of the parental myeloma cell line (Strohal et al., 1987; Irani et al., 2008; 
Ding et al., 2010). Although we eventually discovered that it was unnecessary to perform these 
techniques on a lambda light chain antibody, which is not known to harbour any non-functional genes, 
the method used should theoretically be applicable for immunoglobulin heavy and kappa light chain 
gene manipulations as well, and shall prove valuable for fuss-free generation of chimeric mouse-
human antibodies for diagnostic use. 
Although we have shown that the chimeric 5.2H7 mAb was successful in the detection of several 
CHIKV isolates, and can be stably and continuously expressed, there are concerns that the sensitivity 
of the COS-7L or CHO cell-expressed recombinant mAb was significantly lower than that of the 
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parental mAb, in the form of secreted hybridoma supernatant. However, it is worthwhile noting that 
due to the lack of optimisation of transfection efficiency and several other variables associated with 
recombinant mAb expression, the quantity of recombinantly-expressed chimeric 5.2H7 mAb cannot 
be compared to that of mAbs secreted by the original 5.2H7 parental hybridoma cell line. 
Theoretically, under optimised conditions, the production of the chimeric 5.2H7 mAb could be cost-
effectively up-scaled, with the option of further downsteam processing such as purification and 
concentration. This will allow for much improved performance of the antibody, and increased 
sensitivity towards CHIKV antigens. In summary, we have produced a reagent that has practical 
potential for use in commercial diagnostics. 
 
8.5. FINAL CONCLUSIONS 
In summary, we have developed and evaluated reagents that may prove valuable as reagents for the 
detection of CHIKV, and perhaps play significant roles in future research of the virus. Based on 
samples tested, the assessment of the anti-E2 mAbs and recombinant proteins, produced both in this 
project and by our collaborators, has led to the creation of a sensitive and specific diagnostic assay 
for the detection of anti-CHIKV antibodies in human sera. In addition, we have showed the potential 
of the anti-E2 mAbs to specifically detect minute quantities of CHIKV antigen, and their use in 
detecting CHIKV in mosquito vectors. Furthermore, the CP-specific mAbs were shown to be reactive 
towards several alphaviruses, including all strains of CHIKV tested in this study. These mAbs showed 
excellent sensitivity in numerous assays including IHC, where small quantities of CHIKV protein 
were detected in murine feet tissue weeks post-infection, highlighting the persistence of CHIKV in 
the mouse model. Through the process of mapping the binding sites of these CP-specific mAbs, we 
have also confirmed the presence of sCP and revealed that the C-terminus of the CP may be required 
for antibody recognition of the protein. Finally, we have successfully created a chimeric mouse-
human mAb for use in serological diagnostics and shown that the recombinant mAb retained the 
ability of the parent mAb to recognize different CHIKV genotypes. Future efforts to stably express 
the chimeric 5.2H7 antibody will provide a practical alternative to the use of human reference sera in 
commercial diagnostic test kits. 
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